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1. 1 BACKGROUND 
Safety issues remain the major cause of drug attrition during clinical 
development as well as of post-market drug withdrawals [1-5], accounting 
for 15-34% of all drug discontinuation [6, 7]. In the last decade 
cardiovascular safety, specifically drug-induced QT/QTc-interval 
prolongation, has been an increasing concern for both public health and in 
drug development [1]. Historically, however, the earliest well documented 
cases of QT-interval prolongation date back to 1943 regarding the use of 
quinidine [8, 9].  Quinidine was first introduced as an antiarrhythmic drug in 
1918 [10]. Its antiarrhythmic efficacy was attributed to its ability to prolong 
cardiac repolarisation duration.  On the other hand, its use was soon 
followed by reports of syncopal attacks and unexpected fatalities, and these 
adverse episodes were attributed to respiratory paralysis or ventricular 
irritability [11-13].  It was considered that QT-interval prolongation was an 
early significant indication of the onset of its activity.  In 1958, thioridazine 
was introduced to the market for the treatment of schizophrenia.  The 
observations that apparently, well-tested non-cardiac drugs could also have 
unintended adverse cardiac effects were made as early as 1963.  Following 
further reports, this effect was shown to be caused by electrophysiological 
changes that reflect on the surface electrocardiogram (ECG) as QT-interval 
prolongation [14-20].  Concern later extended to other drugs of its chemical 
class (phenothiazines) [21-27].  By early 1970s, the concern had extended to 
the entire therapeutic class of antipsychotic drugs. 
Given the potentially fatal consequences of this concentration-dependent 
adverse drug reaction, regulatory authorities have reacted to this relatively 
recent “pharmacoepidemic” by denying or delaying the approval of a number 
of new drugs and placing severe restrictions on the use of many old and 
some new drugs because of concerns arising from their potential to prolong 
the QT/QTc-interval. 
In the subsequent paragraphs of this chapter, we provide an overview of the 
physiological, clinical and epidemiological basis for the characterisation of 
drug-induced effects on cardiac conductivity, more specifically on QTc-
interval prolongation. A summary of the mainstream techniques used in in 
vitro and in vivo studies is presented, which provides insight into some of the 
challenges for the translation and prediction of drug effects in humans. This 
is followed by a discussion on the various methods used to establish 
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correlations between observations in clinical trials and in the target patient 
population under real-life conditions. Lastly, we introduce important 
methodological concepts pertinent to the evaluation of exposure-response 
relationships and the utility of these relations for the prediction of safety of 
compounds in drug development. 
1.2 ELECTROPHYSIOLOGY OF VENTRICULAR ARRHYTHMIAS 
QT-interval of in the surface electrocardiogram (ECG), typically expressed in 
milliseconds, represents the ventricular action potential time duration in the 
heart’s sinus rhythm (Figure 1).  It is determined by a balance between a 
number of inward and outward ionic currents, such as sodium (Na+), 
potassium (K+), calcium (Ca2+) and chloride (Cl¯).  The primary current is the 
rapid component of the outward repolarising current (Ikr) that is mediated 
primarily by the delayed rectifying potassium channels.   
 
Figure 1.  Sinus rhythm of a single heartbeat shown in a surface electrocardiogram (ECG).  There are 
typically six distinct waves (identified by the letters P, Q, R, S, T, and U) and they occur in a specific order, 
over specific periods of time, with specific relative sizes. While there is a significant range within which 
variations in rhythm are considered normal, anything that significantly deviates from sinus rhythm by 
more than a certain amount may be indicative of heart disease.   
http://en.wikipedia.org/wiki/File:SinusRhythmLabels.svg, as accessed on 27 March, 2012 at 15:44 EST. 
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Decreases in ionic currents leading to the prolongation of the QT-interval can 
be a result of electrolyte imbalance, endocrine dysfunction, autonomic 
imbalance, various disease states or following administration of drugs (as an 
intended effect or not).  Drug-induced prolongation is expected with class III 
antiarrhythmic drugs (potassium channel blockers) which are intended to 
produce their desired therapeutic benefit by blocking Ikr, delaying ventricular 
repolarisation and thereby increasing the myocardial refractory period.  
Some typical drugs in this category include d,l-sotalol, ibutilide, dofetilide, 
terikalant, azimilide and N-acetyl-procainamide. 
The QT-interval is also prolonged when the Ikr current is diminished as a 
result of genetic mutations, such as the Romano-Ward syndrome, a major 
variant of long-QT syndrome (LQTS) [28].  All forms of LQTS will involve an 
abnormal repolarisation of the heart causing differences in the refractory 
period of the heart muscle cells.  As a result of an increase in the frequency of 
the prolonged repolarisation, early after-depolarisations (EADs) can occur, 
which can degrade to various types of arrhythmias such as torsade de 
pointes (TdP), ventricular fibrillation and tachycardia that can eventually 
lead to sudden cardiac death (SCD) (Figure 2).  By contrast, the incidence of 
sudden death in young people without structural heart disease is 
approximately 1 in 2500 [29-31].   
 
 
Figure 2.  Electrocardiograms of patient in ventricular fibrillation (top) compared to one with normal 
heart rhythm (middle) and one with torsade de pointes (bottom).      
http://www.homeheart.co.uk/html/glossary.html, http://medlibes.com/entry/torsades-de-pointes, as 
accessed 19 April, 2012 at 9:03 EST. 
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1. 2. 1 TORSADE DE POINTES 
QT-intervals are very much related to heart rate, designated as the RR-
intervals (measured as the time interval between consecutive R peaks).  The 
relationship is that the faster the heart rate, the shorter the QT-interval.  
Thus QT-intervals are often adjusted / corrected for heart rate to describe 
the true action potential duration in an individual.   Typically population-
based correction factors are used in clinical practice. Bazett’s and Fridericia’s  
formula have become standard methods for routine ECG monitoring, even 
though individual correction factors have been shown to better account for 
individual differences. 
BAZETTs’ FORMULA:  QTcB=QT⁄√RR  [32] 
FRIDERICIA’s FORMULA:  QTcF=QT⁄ 3√RR   [33] 
Excessive RR-corrected QT (QTc)-interval prolongation can be 
proarrhythmic and degenerate into a potentially fatal ventricular 
tachyarrhythmia known as torsade de pointes (TdP), a unique polymorphic 
form of ventricular tachycardia which is associated with concomitant 
prolonged QTc-interval [34] (Figure 3).  The European regulatory guideline, 
based on the opinion of an ad-hoc expert group, used three gender-specific 
categories to differentiate QTc prolongation [35].  For women, normal is 
defined as < 450 msec, 451-470 msec as borderline and > 470 msec as 
prolonged.  For men, < 430 msec is normal, 431 to 450 msec is designated as 
borderline and prolonged is used when QTc-intervals are > 450 msec.    
Although QTc-interval prolongation is not necessarily harmful, it is at 
present the best and only surrogate marker for TdP, especially so because 
the definition of this particular arrhythmia requires prolongation of QT-
interval as a preceding event.  One review in 1993 concluded “at present, our 
knowledge base about the relation of the QT-interval and TdP is grossly 
incomplete” [34]. Unfortunately, despite extensive research since then, this 
still remains the case today.  To a large extent, the (near) theological reliance 
on QT-interval prolongation as a surrogate of TdP originates from the very 
definition of this unique polymorphic ventricular tachyarrhythmia [34].  
Ventricular tachyarrhythmias, even when meeting the morphological criteria 
of TdP are not labelled by many clinicians as TdP unless preceded by QTc- 
interval prolongation [37-39].   
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TdP is triggered by the appearance of early after-depolarisation (EADs), 
mediated by slow inward calcium current, during the late phase 2 of the 
prolonged cardiac action potential.  Therefore as an extension of their 
pharmacological effect, this iatrogenic proarrhythmia may be expected in 
some individuals following the use of antiarrhythmic drugs, which possess 
potassium channel blocking activity.  Critically, TdP is a potentially fatal 
adverse drug reaction.  That is because TdP subsequently degenerates into 
ventricular fibrillation in about 20% of cases [40] and not uncommonly, 
leads to cardiac arrest and even sudden death may be the outcome [41].  The 
overall mortality is of the order of 10-17% [40, 42]. 
 
 
Figure 3.  Electrocardiogram of torsade de pointes.                                                   
http://www.doctortipster.com/3748-ventricular-tachycardia-causes-diagnosis-and-treatment.html, as 
access on 19 April, 2012 at 9:12 EST. 
The balance between the risk of a fatal adverse event and therapeutic benefit 
is a very delicate one, depending not only on the drug concerned and its 
plasma concentration but also on a number of host modifying factors.  These 
risk factors include female gender, electrolyte imbalance (especially 
hypokalaemia), myocardial ischaemia, congestive heart failure, bradycardia 
and pre-existing prolongation (i.e. long-QT syndrome), which all result in 
inherently prolonged baseline QTc values.  Moreover, risk to an individual 
can vary from day to day.  An inter-current event or therapeutic intervention 
for an unrelated condition, such as interacting drugs, can easily increase or 
put risk on patient who was previously not at risk.   
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Unfortunately, the potential to prolong the QTc-interval and induce TdP is 
not confined to class III antiarrhythmia drugs.  A number of class I 
antiarrhythmia and anti-angina drugs as well as non-cardiovascular drugs 
also carry this liability.  In a survey of 2194 cases of TdP in the US Food and 
Drug Administration (FDA) database [42], the most common drugs 
implicated belong to the class of cardiac (26.2%), central nervous system 
(CNS) (21.9%), anti-infective (19.0%) and antihistamine (11.6%) 
compounds.  Of the 2194 cases, 61.1% were associated with hospitalisation, 
27.9% were life-threatening and 9.8% were associated with a fatal outcome.  
The regulatory focus on QTc-interval prolongation by drugs has therefore 
changed from one of a potentially desirable antiarrhythmia mechanism to 
one of potentially fatal proclivity.   
1. 2. 2 FREQUENCY OF TORSADE DE POINTES 
The frequency of TdP, or prolongation of the QTc-interval to proarrhythmic 
threshold, varies with the class of drugs.  It is, not unexpectedly, the highest 
with class III drugs.  For non-cardiac drugs, the frequency is unknown and 
can vary from approximately 1 in 100 (halofantrine) to 1 in 50 000 
(terfenadine), depending on clinical circumstances.  However, the true 
frequency of this effect with non-cardiac drugs is difficult to estimate 
because the diagnosis of this toxicity requires an ECG-monitoring facility, 
which is either not available in a general practitioner’s surgery or not readily 
utilised in local hospitals.  Due to the fact that TdP can be transient, its 
diagnosis in a patient presenting with dizziness or syncope requires an 
immediate access to cardiac rhythm recording facility.  Even in asymptomatic 
patients, despite the requirements included in prescribing information, there 
is a general lack of appropriate patient monitoring by ECG.  More 
importantly, however, the effect is often not recognised as iatrogenic and it is 
grossly under-reported (reporting rate in the order to 10-20%) even when 
recognised as drug-induced.  This was exemplified by the events preceding 
the withdrawal of terodiline [43].  In all likelihood, the frequency of these 
events is relatively low (<0.1%) and below what could be confidently 
detected by the size of the clinical trials database included in a regulatory 
submission. The frequency is sufficiently low, that the risk was uncovered 
only through spontaneous reports during the post-marketing use of the 
drugs concerned.  Although low, the risk is nonetheless unacceptable for 
many conditions which are relatively benign in nature.  Halofantrine and 
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arsenic trioxide best illustrate the careful need to balance the potential risk 
against potential benefits. 
Interestingly, not all drugs that prolong QT-interval to the same extent carry 
the same risk of causing TdP.  It is therefore important to appreciate that 
QTc-interval prolongation may not constitute a direct risk, as it could be 
inferred from some of the clinical findings.  Although QTc-interval 
prolongation is one of the major precursors of drug-induced TdP, this 
arrhythmia does not develop invariably in all individual with equivalent 
prolongation of the QTc-interval. Neither do all drugs that prolong the QT-
interval to an equivalent duration carry the same risk of inducing TdP [44, 
45].  The incidence of TdP is estimated to be 0.5-8.8% with quinidine [46] 
and 2.6 – 4.1% with d,l-sotalol [42, 47, 48] (Figure 4).  Since QT-interval 
prolongation is not an ideal surrogate for risk of TdP, withdrawals of drugs 
that simply prolong the QT-interval reflect a pragmatic and conservative 
approach to risk management.  When found to induce TdP frequently, drugs 
such as prenylamine, terodiline, terfenadine, astemizole, cisapride and 
levacetylmethadol were all withdrawn from the market when their 
benefit/risk ratio was determined to be adverse and safer alternatives were 
available.  On the other hand, arsenic trioxide was approved and is still on 
the market despite a known high frequency of TdP associated with its use.  
Likewise, pimozide and thioridazine continue to be available. The re-
introduction of sertindole has also been discussed because of its low 
potential for extra pyramidal adverse effects and lack of reports of TdP 
despite marked prolongation in QT-interval.  
1.3 IMPACT ON DRUG DEVELOPMENT 
Based on the aforementioned, regulatory and clinical expectations have 
evolved towards a pre-approval policy for new chemical entities (NCEs), 
which is aimed at assessing the potential risk of TdP for any new medicine, 
from early discovery throughout clinical development.   
Different actions have been taken to improve drug screening and selection of 
compounds. Non-clinical protocols have been introduced to support the 
selection of the most appropriate NCEs to bring them forward to human 
trials.  Experiments have been devised with the primary objective of 
eliminating torsadogenic compounds and assessing the propensity of QT-
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interval prolongation.  Although primary efforts have focused on class effects 
and other QSAR molecular structural relationships, the search for predictive 
and translational models for QTc-interval prolongation has remained 
empirical. The requirements for establishing in vitro, in vivo and ultimately 
clinical correlations in a quantitative manner are often ignored despite the 
relevance of concentration-effect relationships as basis for characterising 
drug properties in vivo.   
 
 
Figure 4.  Correlation showing the change in QTc-interval with sotalol dosages and incidence of torsade 
de pointes  [48]. 
Given the implications for public health, scientific efforts have faced a 
parallel movement driven by health authorities, which have imposed the 
introduction of supposedly effective measures for the approval of novel 
compounds. The EU Committee for Proprietary Medicinal Products (CPMP), 
known as the Committee for Medicinal Products for Human Use (CHMP) was 
the first scientific advisory body of a regulatory authority (European 
Medicines Agency) to issue, in December 1997, a formal guidance note on a 
strategy by which all NCEs should be investigated for their effect on the QTc- 
interval [35].  This guidance included recommendations on a set of non-
clinical as well as clinical investigations. All strategies devised subsequently 
are an elaboration of, or minor variations on, the broad pattern set by the 
CPMP.   
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In November 2002, the US FDA and Health Canada issued a joint document 
that focused exclusively on clinical strategies for evaluating the effects of 
NCEs on QT/QTc-interval prolongation (a preliminary concept paper for 
discussion) [49].  Following a number of amendments, it was entered into 
the International Conference on Harmonisation (ICH) process in February 
2003 for adoption as a topic that merited global harmonisation, topic E14. 
The ICH is composed of representatives from regulatory authorities and 
industry associations in the US, EU and Japan.  Representatives from the 
World Health Organisation (WHO), European Free Trade Area and Canada 
also attend as observers. In 2005, the guidance introduced the requirement 
to perform thorough-QT (TQT) studies as the basis for demonstrating a 
compound’s liability to cause QTc prolongation. In addition to outlining the 
assessment procedures for evaluating prolonged ventricular repolarisation, 
the ICH E14 document defines a 10 msec increase in QTc-interval as a critical 
threshold for cardiovascular safety and required the use of a positive control 
and supra-therapeutic doses of the investigational drug to ensure accuracy 
and sensitivity of the experimental protocol [50].   Suggestions are also given 
regarding the timing of the studies as well as the methodologies and 
interpretations used in the evaluation of QT measurements.   
In parallel, the ICH S7B guideline was also created to deal with specific 
aspects of the non-clinical evaluation of the potential for delayed ventricular 
repolarisation by human pharmaceuticals. In brief, it promotes integrated 
risk assessment, based on the chemical and pharmacological class of the drug 
together with data from two core tests – in vitro Ikr or hERG assays and in 
vivo studies in a suitable species.  Much progress has been made in the last 
10 years, but no single non-clinical assay has an absolute positive and/or 
negative predictive value nor any can be considered a gold standard.  
Therefore the use of several in vitro assays and/or in vivo models together, 
contributes to accurate decision-making and is recommended by most 
experts in the field.     
From a clinical development perspective, translational challenges still exist 
despite the aforementioned regulatory considerations.  Among other issues, 
insight is lacking into the impact of interacting factors, such as comorbidities, 
on the actual cardiovascular risk in the target population. Additionally an 
implicit assumption is made about the magnitude of the drug-induced effects 
in the population of interest and of the sensitivity of the patient population. 
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In the next sections, we will describe some key elements underpinning the 
efforts to translate, predict and bridge data across different phases of drug 
development.  We will show that the challenges to be overcome are partly 
due to the fact that each stage of the drug development process remains 
largely modular rather than integrative, with empirical evidence as the basis 
for developing criteria and decision making on safety matters.   
1.4 TRANSLATIONAL EFFORTS: NON-CLINICAL TO CLINICAL 
A summary of the mainstream techniques and experimental conditions used 
in in vitro and in vivo studies is presented below with the aim of highlighting 
the lack of a common strategy, i.e., the assessment of pharmacokinetic- 
pharmacodynamic relationships, which could be used as common 
denominator for the translation of non-clinical findings into clinically 
relevant measures.  This is followed by a discussion on the various methods 
used to establish correlations between non-clinical studies and human 
clinical trials.   A summary table (Table 1) is also provided at the end of the 
section highlighting the main points discussed. 
1. 4. 1 IN VITRO EXPERIMENTS 
hERG Assays 
Considered a pivotal step in the lead optimisation phase, the hERG assay is 
an in vitro assay designed to investigate the inhibition of the potassium 
current through a channel encoded by a human ether-a-go-go-related gene 
(hERG) [51].   An example of such analysis is shown in Figure 5 [52].  The 
hERG channel is the rapid component of the delayed rectifier potassium 
current (Ikr) which is the key determinant of the duration of cardiac 
repolarisation, also known as the QT-interval and thus used to assess the 
proarrhythmic potential of NCEs [53].  QT-interval prolongation, which can 
potentially, but not necessarily lead to a form of fatal arrhythmia, torsade de 
pointes (TdP), is found to be strongly linked with blockage of the hERG 
channel.  However, not all hERG-blockers will result in TdP [54, 55].  Several 
non-cardiovascular drugs have been withdrawn from the market because of 
their potential to induce QT-interval prolongation in the surface 
electrocardiogram (ECG) [56].  It has been reported that the ratio of the 
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hERG / Ikr assay IC50 (concentration that inhibits the hERG current by 50%) 
values to the free Cmax (maximal plasma concentration) observed in humans 
after administration of a therapeutic dose, is a useful marker of the potential 
QT-interval prolonging effect [55, 57].  In most cases, the ratio for drugs 
associated with QT prolongation has been less than 30-fold; however, there 
are isolated instances of TdP in humans reported for ratios greater than 30-
fold [55, 58].  Thus QT-interval prolongation is not always reliably correlated 
with hERG blockers or the occurrence of TdP [59].  Lack of confidence in the 
predictive value of the preclinical tests stems from the fact that each drug 
associated with TdP in human appears to tell a different story in terms of its 
electrophysiological profile.  There is a consensus about the importance of 
interactions with the hERG channel but experiments are still not consistently 
conducted in a quantitative manner and there is no agreement on what 
constitutes a safe margin [55, 60].     
 
Figure 5.  Concentration–response relationship for the inhibitory effects of quinidine, flecainide and d,l-
sotalol on hERG tail currents. The estimated IC50 and Hill slope values were, respectively, 0.33 μmol/L 
and 0.74 for quinidine, 1.03 μmol/L and 0.73 for flecainide and 68.99 μmol/L and 0.50 for d,l-sotalol. 
Each point with a vertical bar indicates the mean±SEM from six different experiments per compound. 
Although differences in potency are observed, this system is highly sensitive to experimental conditions.  
Differences in pH, buffer and voltage level produce differences in the potency and in the concentration-
response curve, irrespective of the drug [52].   
Action Potential Duration (APD) Assays 
The ICH topic S7B safety pharmacology guidance discusses the use of multi-
cellular system such as the Purkinje fibres and papillary muscle assay to 
assess drug-induced changes in repolarisation of action potentials (AP) [61].  
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Figure 6 summarises the potential mechanisms of APD [62].  These changes 
provide insight to the mechanisms underlying the genesis of arrhythmias 
from early after-depolarisation (EAD) making these assays theoretically 
useful in predicting clinical outcomes [63-65].  Cell preparations for in vitro 
assays are often obtained from different laboratory animal species including 
rabbit, ferret, guinea pig, dog, mini-pigs and occasionally from humans, given 
no real industry benchmark has been established [66].  Irrespective of the 
lack of gold standards, many have exposed the deficiencies in using Purkinje 
fibres where there is an obvious lack of correlation between the 
concentration required for hERG IC50 and 10% prolongation in APD90 (the 
duration at 90% of repolarisation), shown in Figure 7 [57, 67-70].   
 
Figure 6.  A summary of the potential mechanisms underlying the changes in the action potential 
duration (APD) [62]. 
Although the aforementioned non-clinical tests are adequate in predicting 
the risk of QT-interval prolongation, they are not necessarily sufficient in 
finding the propensity of pro-arrhythmic risks [59].  Figure 8 demonstrates 
the significant role of an individual's heart response to proarrhythmic 
activity as some hearts may develop arrhythmia and others may not in the 
presence of drug [71].  Thomsen et al. have shown that there is little 
relationship between the magnitude of the QT-interval and the incidence of 
TdP [72].  Furthermore, numerous publications have suggested better 
predictors of TdP in humans [54, 73-75].  Electrophysiological markers  
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 Figure 7.  Concentration-dependent effects of d,l-sotalol (top panels), cisapride (middle panels) and 
terfenadine (lower panels) on action potential duration in dog (Purkinje fibres) and guinea-pig 
(ventricular myocytes).  It is clear that some compounds are sensitive to AP like d,l-sotalol and cisapride 
when different frequency is used, but flat for terfenadine (insensitive).  The difference in the magnitude 
of effects may dependent on mechanism of action of the compound [70]. 
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associated with drug-induced TdP other than APD and QT-interval include 
but are not limited to: triangulation; reverse-use dependence; temporal, 
spatial and transmural dispersion of ventricular repolarisation; the 
difference in duration between the peak and end of the T wave; and 
incidence of overt pro-arrhythmias such as EADs and ectopic beats.  A 
version of the Langendorff-perfused female rabbit heart model, (the Screenit 
system) measures APD, conduction and the TRIaD parameters, namely 
triangulation, reverse-use dependence, instability and dispersion [76].   
 
Figure 8.  More triangulation of action potential configuration in hearts is associated with later torsade 
de pointes (TdP) as compared with hearts without developing TdP *P < 0.05 [71]. 
In fact, the Screenit system detects all changes in repolarisation indices and 
conduction velocity that might interfere with APD values. Changes in the 
TRIaD parameters have been found to be more predictive than changes in 
APD for an arrhythmic potential [76].  In several validation studies, Screenit 
was found to be highly predictive for the pro-arrhythmic potential in drugs.  
Other species used in the Langendorff heart model include the guinea pig 
[77-79]. 
The group of Antzelevitch developed another pro-arrhythmia model based 
on the transmural heterogeneity in the expression of cardiac ion channels 
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[73].  Using a left ventricular wedge preparation of the canine heart, trans-
membrane AP from epicardian and M-regions were simultaneously 
measured.  The data support the hypothesis that the risk for the 
development of TdP is related to the increase in transmural dispersion of 
repolarisation, rather than to prolongation of the QT-interval.  This model 
has been largely superseded by the use of arterially perfused rabbit 
ventricular wedge, which was found to be more sensitive than dog in terms 
of the torsadogenic potential when considering clinically relevant 
concentration ranges in human.  Validation with positive controls resulted in 
a successful translation between preclinical and clinical findings [80].  
1. 4. 2 IN VIVO STUDIES 
Anaesthetised Animals Models 
Anaesthetised animals are in general not as sensitive as conscious ones 
because anaesthetics often induce cardiovascular effects [81].  However, for 
certain compounds, it is necessary to sedate the animals to prevent 
unwanted events such as seizures.  Anaesthetised dogs and guinea pigs 
enable the measurement of cardiac contractility and the use of higher doses 
than in models with conscious animals.  Using this model, several 
cardiovascular parameters can be obtained simultaneously at a modest cost 
in terms of test compound and animals.  The goal of the experiments is often 
to determine the threshold at which cardiovascular events occur without 
further consideration of clinical applicability.  The lack of commonalities 
between clinical conditions and experimental settings make the translation 
of the outcome from these experiments rather challenging.   
Conscious Animal Models 
ICH S7A and S7B guidelines recommend the use of conscious animals for the 
assessment of non-clinical cardiovascular safety of a NCE before testing in 
humans [61, 82].  As a state-of-the-art model, the conscious dog, either sling 
trained or implanted for telemetry, is used [66, 67, 83].  Usually beagle dogs 
are used, which allow the model to be combined with complete 
haemodynamic and pharmacokinetic analysis.  However, side effects such as 
vomiting or CNS-mediated sedation or excitation, at higher doses may occur 
in conscious animals which may represent a limiting factor in the evaluation 
of supra-therapeutic doses [83, 84].  The results obtained from in vivo dog 
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studies have been proven to be a robust, sensitive predictor for clinical QT 
prolongation, but the incidence of TdP is rare [85]. Unfortunately, the current 
guidelines do not provide specific recommendations on study design, which 
lead to major inconsistencies among studies conducted by different 
investigators [86].  This in turn can result in difficulties in translating 
findings downstream to clinical studies.   
In addition to ICH S7A and S7B, other worldwide regulatory guidelines for 
drug safety evaluation recommend testing both in a rodent and a non-rodent 
species. Non-human primates, which are phylogenetically close to humans, 
are often thought of as the “ideal” non-rodent species [87].  Historically, 
because of ethical issues, ethics, three Rs (replacement, reduction, 
refinement), bio-safety concerns, price and supply issues, the use of non-
human primates in toxicology programmes has been restricted to special 
cases. Recently, however, biopharmaceutical scientists have turned to 
primates as the only non-human species in which the biological activities of 
some drugs are expressed. Even though attention should be paid to 
compounds for which the metabolites and/or metabolic rates differ between 
humans and monkeys and the HR changes are beyond the correctable range 
for the QTcBazett interval, in vivo QT assays using telemetry systems in 
conscious cynomolgus monkeys are considered to be a sensitive and useful 
model for assessing the potential for drug-induced QT prolongation in 
humans [88, 89].   
In contrast, the use of the mini-pig in pre-clinical research has been steadily 
growing in recent years, and is set to continue as experience accumulates. 
Studies performed on minipigs are fully acceptable by regulatory authorities. 
Mini-pigs offer several advantages as a second and even first non-rodent 
species in safety assessment. Furthermore, mini-pigs can be used for invasive 
and non-invasive cardiovascular safety pharmacology studies. Domestic pigs 
share many of their features with humans, including anatomy, physiology 
and biochemistry. In particular, the pigs’ cardiovascular system, skin and 
digestive tract are good models for humans, giving reliable predictions of the 
toxicity of drugs and chemicals.    The use of mini-pigs in regulatory safety 
testing is therefore not a new idea. Mini-pigs provide better prediction of 
drug safety than traditional rat or dog models, but have advantages that go 
beyond their biological similarity to humans [90]. Mini-pigs have a 
manageable size and are relatively sedentary. Furthermore, Markert et al. 
have demonstrated a dose-dependent QT prolongation when moxifloxacin 
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was administered orally at doses that produce clinically relevant plasma 
drug concentrations [91]. 
Smaller animals, such as rodents are also used in in vivo studies.  Rats are 
often selected for haemodynamic tests  while guinea pigs are used to study 
the monophasic action potential duration (MAPD) [92-94].  However, guinea 
pigs are unlikely to exhibit TdP because of their large repolarisation reserve, 
which makes this model not as sensitive as other species.   
1. 4. 3 ESTABLISHING TRANSLATIONAL CORRELATIONS 
Computational methods 
There has been increasing awareness in the importance of translating non- 
clinical findings to clinical situations.  Attempts are made to understand the 
construct validity of experimental settings and their implications for the 
interpretation of different study results.  While it is necessary to investigate 
the exposure at which adverse events occur, it is not sufficient to ensure 
accurate prediction of  the clinical outcome.  In real life conditions, many 
other factors contribute to the manifestation of cardiovascular safety issues 
such as underlying comorbidities and concomitant medications.  These 
conditions cannot be investigated extensively in a preclinical experiment or 
in a clinical trial.  Therefore, other methods need to be established to 
simulate a variety of situations or relevant scenarios.  One such technology is  
a computational model of cell electrophysiology for Purkinje fibres, in which 
information about the human genes responsible for individual ion currents is 
connected to whole cell behaviour [95].  Model simulations of selective ion 
channel blockade can reproduce results observed in pharmacological 
challenges characteristic of isolated Purkinje fibres in vitro, which has the 
potential to aid the translation between in vitro experiments and clinical 
response.  More recently, Bottino developed mathematical models that use 
hERG IC50 data and APD results measured from dog Purkinje fibres to 
predict drug interaction with other cardiac ion currents and dispersion of 
repolarisation in transmural ECG [96].  Furthermore, this in silico approach 
allows investigation of the influence of known clinical risk factors for 
arrhythmia (e.g. hypokalaemia) on the pro-arrhythmic risk in patients. 
Mathematical models have also been used to predict the clinical torsadogenic 
risk based on the pre-clinical data generated early on in the development 
process and explore the implications of multiple-ion-channel blockade [97].   
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While the aforementioned experimental and computational methods 
represent an advancement in translational research for cardiovascular 
safety, protocol design and data analysis techniques can affect the quality of 
the data produced and can therefore ultimately influence the interpretation 
of cardiovascular risk [98].  The discrepancy in results due to differences in 
measurement methods has been demonstrated by the work done by 
Ollerstam et al [99] (Figure 9).   
 
Figure 9.  Left panels - the drug-induced QT-interval prolongation  (mean±SE) during the initial 3.5 h of 
the experiments for dofetilide, moxifloxacin, and cisapride in dog models. Right panels: Plasma 
concentration (mean±SE) versus time for dofetilide, moxifloxacin, and cisapride in all dog models. The 
population pharmacokinetic prediction and the 95% prediction interval are shown superimposed on the 
data [95].  The various measurement methods used (in conscious, paced and anesthetised animals) 
render discrepancies of results. 
In contrast to empirical methods, the use of a model-based approach in 
which in vitro and in vivo concentration-effect (PKPD) relationships are 
characterised, could be the foundation for translational purposes, that is, the 
work done by Mittelstadt and Hart (Figure 10) [100].  However, the 
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implementation of a model-based approach does require further 
consideration about the generalisability and discrepancies in PKPD 
relationships between species. In particular, the identification of a species 
showing metabolic profile comparable to humans and understanding of the 
differences in baseline cardiovascular parameters are crucial for predicting 
clinical outcome.  Furthermore, having common PKPD parameters between 
species would facilitate the translation of results based on mechanism-based 
modelling techniques which allow discrimination between drug- and system-
specific properties.  These features reflect the inherent modularity of the 
method [101].  This gives rise to the significance of establishing harmonised 
experimental protocols so that only drug-specific parameters are evaluated 
while system-specific properties remain constant in the same species. 
 
Figure 10.  An example of the use of a model-based approach in which in vitro and in vivo concentration-
effect relationships are characterised and could be the foundation for translational purposes.  Right 
panel – Change in QT and QTc from predose.  Plots of mean and SEM (n = 4) QT-interval and QTc after a 
60 min infusion of vehicle and four doses of moxifloxacin.  *50 mg/kg significantly different (P < 0.05) 
than vehicle.  ^25 and 50 mg/kg significantly different (P < 0.05) than vehicle.  #10, 25, 50 mg/kg 
significantly different (P < 0.05) than vehicle.  Left panel – Plasma concentration vs. change in QTc. Plot 
of mean and SEM (n = 4) plasma levels vs. the change in QTc-interval at the end of infusion of vehicle 
and four doses of moxifloxacin [96].   
Pharmacokinetic-pharmacodynamic modelling 
Population pharmacokinetic (pop PK) and pharmacokinetic-
pharmacodynamic (pop PKPD) models basically comprise three main 
components: a structural model which describes pharmacokinetics or 
pharmacodynamic characteristics (e.g. 2-compartment disposition model or 
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sigmoid Emax pharmacodynamic model); a statistical model describing 
between-subject differences and an error model which accounts for the 
residual variability [102].  Population models also incorporate the effect of 
influential covariates, such as weight, age, and pharmacogenetics. Rather 
than correlating the effects of these factors directly to the observed variables, 
data analysis relies on the assessment of covariate effect on model 
parameters; for example, absorption and clearance. 
Empirical models have significant limitations when it comes to extrapolating 
PK and PD properties between species [103].  This is because the behaviour 
of drugs may change dramatically between different systems, be they normal 
or pathological.  Moreover, it is increasingly being recognised that, even 
across in vitro assays, compounds may display “pluridimentional efficacy” 
[104].  In the past, different PKPD models were required to describe pre-
clinical and clinical data [99].  In other cases, additional in vitro data was 
required to correlate findings across species [105].  Thus, the choice of 
parameterisation in these analysis is paramount in the success in translating 
results throughout drug development. 
The use of a model-based approach in the evaluation of safety has several 
advantages, one of which is the ability to update our knowledge of NCEs 
[106].  Logically, one should endeavour to apply the information learnt from 
one study in drug development to the next.  PKPD modelling has already 
proven to add considerable value for informed decision making regarding 
the safety profile of drug candidates [107].  It is a part of the pre-clinical 
integrated risk assessment where interspecies extrapolations are facilitated 
and clinical trial designs are optimised [108].  Another advantage is that the 
use of population methods allows for exploitation of sparse sampling of 
pharmacokinetic data, often collected during in vivo studies. This enables 
concurrent characterisation of the concentration versus time profile as well 
as the corresponding variability in the population [109].  Subsequently, it is 
possible to establish correlations between concentration-effect relationships 
across species. PKPD modelling can also take into consideration hysteresis 
and other time-dependent factors affecting the concentration-effect curve, 
which need to be accounted for to accurately assess the magnitude of drug-
induced ECG changes [110].  Publications on interspecies correlations for 
cardiovascular effects are limited and the relationship of exposure and 
response across species is not entirely understood [108].  However, recent 
examples suggest that allometric scaling of data obtained in preclinical 
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models may be applicable to predict not only pharmacokinetics, but also 
drug effects in humans [101, 111].  In addition to characterising inter-species 
differences, the use of PKPD modelling ultimately enables the assessment of 
in vitro-in vivo correlations. In fact, clinical QT prolongation has been 
predicted from hERG data [105]; however, this might be limited to selective 
hERG-blockers.  
With the introduction of mechanistic approaches and semi-mechanistic 
PKPD models, quantitative analysis of the dynamic interactions between 
drugs and biological system can be achieved [112-114].  By separating drug-
specific and biological system-specific parameters, a framework can be 
established for translational research that links the interactions between 
drug, pharmacological targets and integrated disease systems in a 
quantitative manner [101, 115, 116].  It can be anticipated that 
understanding of PKPD relationships will represent a strong platform from 
which to explore the wider question of which experimental protocol 
conditions, parameter(s) and species are most suitable for translating drug 
effects from animals to humans [117].  
The ability of the in vitro models to quantitatively predict drug effects at 
therapeutic concentrations is often limited.  The current non-clinical 
paradigm employs a one-dimensional decision making scheme where 
compounds are discontinued based solely on torsadogenicity without 
characterisation of the clinical relevance and concentration range at which 
the toxicities occur. The danger is that this represents a high rate of false- 
positive results and perfectly efficacious compounds are not further 
developed. Hence, in vitro experimental results should be considered 
together with in vivo study results before decisions are made. The ICH S7B 
suggests that in vivo assessment of the drug effects on QT-interval duration, 
performed in addition to a hERG channel assay, should form the minimal 
basis for the evaluation of pro-arrhythmic risk.  However, the utility of non-
clinical assays remains questionable. This is partly due to variability in 
methods, species, and lack of consistency in the experimental procedures 
reported in the literature [85].  The results of ongoing efforts have therefore 
led to great improvement in the sensitivity but not the predictability of 
screening protocols.  To establish in vitro-in vivo correlations, non-clinical 
studies must be calibrated against clinical data.  Furthermore, clinically 
relevant endpoints must be used as a benchmark.  
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  Technology Advantage Limitation 
1 In vitro experiments 
-  Able to detect the degree of 
QTc prolongation 
-  Assays give an insight into the 
mechanisms underlying the 
genesis of arrhythmias 
-  Measure action potential 
durations which are found to 
be more predictive of 
proarrhythmic potential 
drugs 
-   Not necessarily a good   
predictor to TdP 
-   Lack of correlation 
between the concentration 
required for hERG IC50 
and 10% prolongation in 
APD90 
2 In vivo studies 
-  Dogs are sensitive in 
predicting even small QT 
prolongation 
-  Guinea pigs possess specific 
ion channels similar to those 
in humans 
-  Monkeys are considered to be 
a sensitive and useful model 
for assessing the potential for 
drug-induced QT 
prolongation 
-  Mini-pigs share many of their 
features with humans, 
including anatomy, 
physiology and biochemistry 
-   Conscious animals can be 
constrained by the upper-
limit of dose 
-   Could have great 
repolarisation reserve so 
are not good for models of 
arrhythmia and not 
sensitive enough to detect 
known torsadogenic drugs 
-   Ethical and "three Rs" 
issues surrounding the use 
of monkeys 
-   Mini-pigs can remain in a 
state of excitement for 
several hours after feeding, 
which can lead to 






-  Creating models have the 
ability to update our 
knowledge of NCEs and add 
considerable value for 
informed decision making 
-   Population methods allow for 
exploitation of sparse 
sampling of PK data 
-  Simulations can be used to 
extensively test different real 
life scenarios from various 
phases of drug development 
-  Drug- and system-specific 
parameters can be derived 
across different species 
-   Requires thorough 
understanding of 
pharmacology and PKPD 
modelling concepts 
-   It can be challenging as 
routine technique due to 
the lack of integrated tools 
and methodologies 
Table 1.  Summary of current techniques and methodologies used for the assessment of cardiovascular 
safety 
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1.5 TRANSLATIONAL EFFORTS: CLINICAL TRIALS TO REAL-LIFE 
CONDITIONS 
A summary of the current techniques and experimental conditions used in 
clinical research is presented below, with emphasis on the lack of 
methodology that ensures the  assessment of pharmacokinetic- 
pharmacodynamic relationships as well as of other intrinsic and extrinsic 
factors known to affect heart conductivity.  This is followed by 1) a 
discussion on the importance of characterising the potential differences 
between well controlled clinical trials and real life patient populations as 
well as 2) a summary of the main methodological aspects. 
Both from a scientific and regulatory perspective, the crucial question 
remains  is “How efficient and reliable are the pre-approval clinical trials in 
identifying the clinical risk of TdP, given the patient population enrolled, 
background noise arising from spontaneous intra-individual variability in 
QTc-interval and the relatively low frequency of the clinically significant 
drug-induced effect” [118].  For a variety of reasons, clinical trials may or 
may not detect the frequency and intensity of QT-interval prolongation but 
they are most unlikely to detect the risk of TdP.  Firstly, the present approach 
to clinical trials is highly efficacy-orientated.  Secondly, the number of 
patients exposed to the drug in these pre-approval clinical trials is not large 
enough to detect a relatively rare but potentially fatal risk.  Thirdly, many 
subgroups of patients most at risk of TdP during the uncontrolled clinical use 
to the drug in question are usually excluded from these trials.  These 
subgroups include: females, the elderly, those with predisposing cardiac or 
non-cardiac diseases associated with diminished repolarisation reserve (and 
therefore greater susceptibility to prolongation of the QT-interval), those 
with pharmacogenetic defects of drug metabolising enzymes or 
pharmacological targets such as the potassium channels, those susceptible to 
bradycardia or electrolyte imbalance, or those receiving drugs with a 
potential for pharmacokinetic or pharmacodynamic interactions.   
1. 5. 1 THOROUGH-QT STUDY 
The primary analysis of a TQT study is based on the “double-delta” methods, 
which is an assessment of the upper bound of the 95% one-sided confidence 
interval for the largest time-matched mean effect of the drug on the QTc-
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interval.  The result of the assessment must exclude 10-msec increase in QTc-
interval if the drug is to be deemed safe, i.e. a negative study.  Requiring that 
the largest time-matched mean difference between the drug and placebo 
QTc-interval be ~5 msec or less implies that the one-sided 95% confidence 
interval should exclude an effect of > 10msec for every single measurement.  
Although this is thought to be the most suitable approach, it can lead to 
multiplicity issues and positive bias.   Another limitation of the proposed 
double-delta method is the absence of concentration-QT relationships.  From 
a scientific perspective, the evidence gathered to date means that any 
regulatory review of QT study is not complete without an assessment of 
concentration-QTc relationship.  
1. 5. 2 PHARMACOVIGILANCE 
Pharmacovigilance is the pharmacological science relating to the detection, 
assessment, understanding and prevention of adverse effects, particularly 
long term and short term side effects of medicines [119].  WHO established 
its Programme for International Drug Monitoring in response to the 
thalidomide disaster detected in 1961.  Often, epidemiological concepts are 
used to determine the distribution and patterns of health-events, health-
characteristics and their causes or influences in well-defined populations.  
The term epidemiology is widely applied to cover the description and 
causation of not only epidemic disease, but of disease in general, and even 
many non-disease health-related conditions, including QT/QTc-interval 
prolongation.   
1. 5. 3 EPIDEMIOLOGICAL COHORTS AS RISK ASSESSMENT TOOLS 
In 2005, the FDA published guidance for the industry on “Good 
Pharmacovigilance Practices and Pharmacoepidemiologic Assessment” 
[120].  The idea behind this stems from the fact that risk assessment during 
drug development on one hand should be conducted in a thorough and 
rigorous manner but it is also well understood that it is impossible to identify 
all safety concerns during clinical trials.  When a compound is marketed, the 
number of patients is dramatically increased including those with 
comorbidities and on concomitant medications.  Thus, it is useful and 
important to continue collecting post-marketing safety data and perform risk 
assessment based on observational data to characterise and amend the risk 
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profile of the product in Phase IV studies (Figure 11) .   In fact, many 
governments and academic institutions have set up formal observational 
databases to monitor drug adverse events and progression of health or 
disease in general or specific populations for public health and research 
purposes.  As a result, there exist several large population-based studies 
evaluating the association between the heart-rate corrected QT-interval and 
mortality [121-127].  
 
Figure 11.  The black cube represent a fraction of the general population that is enrolled into clinical 
trials.  Such population is tightly controlled by strict inclusion / exclusion criteria.  Setting and 
compliance of trials are also strictly controlled.  Due to the limitation in the trial population, it is 
important to continue collecting post-marketing safety data and perform risk assessment to amend the 
risk profile of the product in Phase IV studies.   
Various types of epidemiologic studies can be used to assess if there is an 
association between exposure of a drug and a particular outcome [128].  In 
cohort studies, the investigator defines two or more groups of people that 
are free of a particular condition/ disease and that differ according to the 
extent of their exposure to a potential cause of the condition.  The incidence 
times and rates of development are then measured and compared.  
Alternatively, case-control studies can be conducted to identify factors that 
may contribute to a medical condition / disease or treatment effect by 
comparing subjects who have the condition (cases) with those who do not 
have the condition (control) but are otherwise similar. Furthermore, medical 
condition / disease or treatment effect can be evaluated prospectively or 
retrospectively based on the timing relative to when the investigators begin 
to observe the development of condition / disease (Figure 12). 
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Figure 12. Case-control studies vs. Cohort studies on a timeline. http://www.wikipedia.org/wiki/Case-
control_stud, as accessed on 21 April, 2012 at 9:47 EST. 
Some epidemiologic studies have found results consistent with findings from 
the clinical trials.  For example, the Ziprasidone Observational Study of 
Cardiac Outcomes (ZODIAC) was a post-marketing study done to measure 
non-suicide mortality in the year after initiation of assigned treatments.  
Despite known risk of QTc prolongation with ziprasidone treatment, the 
findings from the study failed to show that the drug is associated with an 
elevated risk of non-suicidal mortality  in real-world use relative to 
olanzapine [129]. Conversely, some Phase IV studies have found 
inconsistencies between clinical trial outcomes and real life use.  Examples of 
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such discrepancies include tacrine, simvastatin and celecoxib [130]. From a 
clinical perspective, the hiatus between clinically relevant population and 
clinical trial population has been known to exist, but such differences are 
often assumed to have negligible impact on safety and efficacy. Many studies 
have highlighted that many subgroups of patient cardiovascular patients are 
under-represented in pre-registration Phase III trials [131, 132].   
1. 5. 4 ESTABLISHING TRANSLATIONAL CORRELATIONS 
The aforementioned hiatus between clinical trials and epidemiological 
cohorts has driven a series of efforts in pharmacoepidemiology and risk 
management, which are aimed at the generalisation of clinical findings into 
real life scenarios.  The assumption of generalisability is however violated 
when events are rare or occur at very low frequency. Specifically with regard 
to cardiovascular safety, the low incidence of TdP in clinical trials causes 
underestimation of this adverse event, which often are not identified until 
after the drug has been approved.  This is one of the reasons to establish 
Phase IV studies to monitor the safety issues of new drugs.  However, Phase 
IV studies are epidemiological in nature where the objective is to understand 
the risk, not necessarily to prevent or mitigate it. Most importantly, the 
findings are not necessarily as accurate given that exposure-response 
relationships are not taken into account.  Moreover, epidemiology studies 
often use dose as a proxy for drug exposure, irrespective of evidence of 
differences in pharmacokinetics (e.g. bio-availability and other possible 
drug-drug interactions). Assumptions are also made with regard to the 
effects of poor compliance or non-adherence to therapy.  
Bayesian hierarchical modelling 
In recent years, the use of Bayesian methods has increased considerably as a 
tool for the characterisation of exposure-response relationships and other 
medical applications. The key difference between classical and Bayesian 
statistics is the interpretation of probability. In the classical framework, 
probability is considered a surrogate for frequency, hence the term 
‘frequentist’ statistics. This means that a rigid statistician can only make 
probability statements about repeating events, such as coin tosses, but not 
about events that occur only once, such as the weather tomorrow or the 
outcome of a particular clinical trial. This is somewhat circumvented by 
applying statistical methods many times, so that the frequency is in the use of 
42        An Introduction to Mind the Gap 
the test rather than in the repetition of the experiment. For example: a 
confidence interval will contain the mean in 95% of the cases in which it is 
constructed (and not, as is commonly believed, contain the mean with 95% 
probability). In a Bayesian context, probability is considered to be a 
quantification of ‘degree of belief’. This means that Bayesian statisticians can 
make direct probability statements about any event, such as the probability 
that a treatment is superior to placebo. 
The statistical reasoning behind this is that frequentist statistics relies on the 
likelihood, i.e. the probability of observing the data given a range of 
parameter values. Bayesian statistics however relies on the posterior 
distribution, which is the distribution of the parameters (i.e., parameter 
space) given the observed data. To obtain the posterior distribution, both the 
likelihood and a prior distribution are required. The prior distribution can 
include all relevant information that is not captured by the actual 
experiment. Since the use of this prior means that no two analyses will be the 
same, it is important to be explicit about the prior distribution that has been 
used in any Bayesian analysis.  An advantage of the resulting posterior 
distributions is that the interpretation of the probability is more direct. 
Indeed, 95% credible intervals (as they are referred to in a Bayesian context) 
do have the interpretation that there is a 95% probability of an interval 
containing the true value. 
The increase in the use of Bayesian statistics in recent years is explained by 
developments in computational sciences and enhanced computing capacity 
of computer processors. For most Bayesian problems a closed-form 
analytical solution is not possible. However, using Markov Chain Monte Carlo 
(MCMC) methods, it is possible to sample directly from the posterior 
distribution. Typically, at least 10000 samples are required to characterise 
the posterior distribution. Increasing computer processor speeds have made 
this task feasible. It is important to emphasise that in the absence of an 
analytical solution, MCMC does yield very good, unbiased results, as opposed 
to many of the maximum-likelihood based algorithms that are currently 
used. The development of WinBUGS [133, 134] has removed many of the 
hurdles associated with the development of algorithms and paved the road 
for Bayesian statistics in many different areas. 
Another important aspect of the application of hierarchical (population) 
models is the focus on the population rather than the individual as the object 
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of the investigation.  The approach is particularly suitable when information 
on individual subjects is limited. Regardless of the density of the data, 
population models describing concentration-(adverse)effect relationships 
should be considered an ideal tool to translate between species (i.e., non-
clinical to clinical data) and between clinical trials and real life population.     
Lastly, it should be noted that the availability of hierarchical models offers an 
important opportunity as study optimisation tool (e.g., dose selection, 
sampling times, treatment duration and population size).  These models can 
also be used to support prediction and extrapolation of data across different 
age-groups, dosing regimens and formulations or delivery forms.  Moreover, 
population models may enable extrapolation of long-term efficacy and safety 
based on short-term pharmacokinetic and treatment response data.  
Clinical trial simulations 
In contrast to meta-analysis, clinical trial simulation (CTS) allows for the 
investigation of the impact of a range of design characteristics on the power 
to detect a treatment effect prior to exposing patients to an experimental 
drug (Figure 13).  In a field where most clinical trials have a conservative 
design, this methodology offers a unique opportunity to evaluate innovative 
designs. Rather than performing power calculations which only take sample 
size and endpoint variability into account, CTS allows calculation of power 
taking into account a multitude of other factors.  
 
Figure 13.  Major components of a clinical trial simulation (CTS).  In model-based drug development, a 
CTS can be used to characterise the behaviour of the compound in different population groups by 
utilising patient-specific covariate values [135]. 
In general, CTS in the context of translating results from clinical trial to real 
life population utilises two types of models [136].  First, a drug-action 
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(PKPD) model is considered, which comprises pharmacokinetic and 
pharmacodynamic factors. In chronic diseases the model also accounts for 
disease progression. Unfortunately, the lack of knowledge about the 
mechanisms underlying treatment response in many therapeutic indications 
has prevented the development of mechanistic models.  Hence, examples 
often refer to standard statistical models, such as e.g., the mixed model for 
repeated measures (MMRM).  Such statistical models have however a 
downside in that they often do not incorporate concentration-effect 
relationships.  Secondly, CTS requires a trial execution model. These models 
simulate other important aspects of the trial, such as dropout, compliance 
and protocol deviations. Therefore, one can determine all possible outcomes 
under candidate trial designs, allowing such trial designs to be compared in a 
strictly quantitative manner. Thus far, very few examples exist in which 
relevant design factors have been evaluated prospectively as part of the 
planning of a cardiovascular safety trial.   
It is also important to stress that CTS allows investigation of factors that 
cannot be scrutinised by meta-analysis or empirical design.  First, designs 
which have not been implemented cannot be included in a meta-analysis.  
Second, it is difficult to separate the influence of multiple design factors, 
whereas CTS allows evaluation of a single factor, one at a time. Although 
meta-analyses may provide valuable information about differences in patient 
populations and treatment response, it is unfortunate that many 
investigators consider overall publication review sufficient to gather 
evidence on the role of design factors, as often suggested in the discussion of 
meta-analysis results. 
If simulated data is to be exchangeable with actual patient data, it is 
imperative that not only model parameters are unbiased, but that estimates 
of variability are also accurate. Often interpretation of statistical model 
results focuses on the predicted values of the treatment effect. This does not 
necessarily mean that response distributions reflect what occurs in the true 
patient population. In fact, it is not infrequent to see model misspecifications 
being corrected by inflated estimates of variability. It is therefore critical for 
clinicians to understand that standard goodness-of-fit criteria do not take 
simulation characteristics into account and may therefore not be indicative 
of the best model. Such a comparison between simulated and original data 
can be performed using graphical and statistical tools. 
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CTS also relies on the availability of accurate model parameter and 
corresponding distributions to investigate “what if” scenarios across a 
different range of conditions or design features, such as population size, 
stratification levels, dose range,  sampling scheme, and even different 
endpoints.  One of the main advantages of such a virtual or statistical 
experiment is the possibility to predict ‘trial performance’ and so to identify 
potential limitations in a study and protocol design prior to its 
implementation and decide if the trial should be performed. In fact, some 
clinical trial simulations have been evaluated against outcomes from real 
trials.  
1.6 SUMMARY 
In this chapter, we have provided an overview of the concepts and 
underlying physiological and methodological aspects pertinent to the 
evaluation of chronotropic effects on cardiac conductivity and more 
specifically on QT-interval. Prolonged QT/QTc-intervals can degrade into 
ventricular arrhythmias and even sudden death. Due to its presence prior to 
incidences of fatal arrhythmias, QT/QTc-interval prolongation has been 
chosen as a safety biomarker.  Currently, a multitude of safety trials are done 
to test the propensity of drug-induced prolongation in different phases of the 
drug development process. 
Despite the numerous efforts to improve the detection of  QT/QTc-
prolonging effects, many limitations still exist in the current approaches. As 
described in the aforementioned paragraphs, a major hurdle remains the 
lack of an integrated approach in which exposure-response relationships are 
used as basis for translational purposes throughout the development and life 
cycle of a product.  Moreover, past attempts to introduce PKPD relationships 
have ignored the need to discriminate between drug- and system-specific 
parameter, making it challenging to assess risk in a quantitative manner.  
This limitation is accompanied by the discrepancy between the target patient 
population and healthy subjects currently used for the evaluation of drug-
induced effects.  The assumption of comparable drug response across 
population does not necessarily hold true. Tools are needed that enable the 
characterisation of drug properties, supporting the decision to progress or 
terminate the development a  compound. 
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2.1 BACKGROUND 
The evidence of dromotropic and arrhythmogenic properties of new 
chemical entities (NCEs) remains a major cause of attrition in drug 
development.  The pro-arrhythmic properties of a new chemical entity (NCE) 
are investigated throughout the drug development cycle, from the early in 
vitro screening phase all the way to clinical trials and post-launch 
surveillance. At the moment, each and every single study conducted 
pertaining to a compound is performed independently. Experimental 
evidence is not generated with the objective to characterise concentration-
effect relationships, nor to enable integration of the results from preceding 
stages as the basis for predicting or extrapolating findings in a subsequent 
stage of the development process. The lack of data integration and the 
absence of accurate markers and measures of drug effect, which provide 
direct evidence or support the use of inferential methods for the assessment 
of cardiovascular risk, represent additional contributing factors to the poor 
decision making and inadequate go/no go criteria [1]. 
On the other hand, drug developers and investigators are faced with a 
mandatory step in clinical development which imposes the implementation 
of a so-called thorough-QT (TQT) trial. The International Conference on 
Harmonisation (ICH) E14 guideline was meant to inform industry on how to 
collect, interpret and analyse QT data in a TQT trial and thereby promote a 
more systematic process for assessing the proarrhythmic risk of NCEs. The 
TQT trial is considered negative if the 95% upper interval of the largest time-
matched QTc measurements, does not include 10 msec after adjusting for 
baseline and placebo effects [2].  Among other issues, the approach neglects 
the underlying pharmacokinetic-pharmacodynamic relationships. 
Furthermore, a significant association or correlation between 10 msec 
prolongation and fatal arrhythmias has not been established so far.  Instead, 
it appears that prolonged QT/QTc-intervals, defined as an interval greater 
than 450 msec in males and 470 msec in females is indeed associated with 
cardiac mortality. Regulatory agencies and other stakeholders do not seem to 
have assessed the implications of such findings for drug development, nor 
their relevance for the evaluation of cardiovascular safety. 
In this thesis we will apply a model-based approach to the evaluation of 
cardiovascular safety of a NCE. More specifically, we will critically assess the 
requirements for data integration during development and life-cycle 
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management with the scope of facilitating the evidence synthesis for pro-
arrhythmic effects. To this purpose, focus will be given to the relevance of 
pharmacokinetic-pharmacodynamic relationships and to the accurate 
identification of drug- and system-specific parameters as basis for the 
translation of findings from early development stages into real-life 
conditions [3].  An important aspect of this translational investigation will be 
the identification of decision criteria and requirements for the progression of 
a compound into late-stage clinical development.  
Whilst data integration and the development of new technologies have been 
the subject of extensive discussion among stakeholders [4], little attention 
has been paid to the need for revised (model-based) criteria supporting the 
decision making process. Of particular relevance is the ability to derive 
quantitative information about drug effects in such a way that parameters, 
rather than experimental variables can be used to assess the implications of 
such effects for the target patient population. We envisage that if inherent 
physiological differences across species or experimental conditions can be 
parameterised independently from drug-specific effects, it will be possible to 
accurately assess and predict risk in humans.   
We aim therefore at evaluating how to optimally integrate data and explore 
model parameterisations that prove effective for the translation between 
species and experimental protocol conditions.  We will confront the current 
regulatory perspective that imposes formal evidence of safety based on the 
results of a thorough-QT study [5] and will demonstrate that accurate 
assessment of safety should rely on the evidence from pharmacokinetic-
pharmacodynamic relationships and on the quantification of other relevant 
intrinsic and extrinsic determinants of variability in drug response.  
Moreover, we will attempt to demonstrate the flaws in the assumption that 
evidence from clinical trials in healthy subjects using supra-therapeutic 
doses suffices in characterising safety. Clearly, one overlooks the 
implications of differences in demographics as well as the impact of inclusion 
and exclusion criteria which are applied to Phases I, II and III trials. We will 
assess how demographic factors, comorbidities and concomitant medications 
affect outcome and consequently risk.    
From a methodological perspective we will also show how modelling and 
simulation (M&S) techniques can be used for the evaluation of safety and 
risk, given the ethical constraints for human experimentation when dealing 
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with safety issues.  As a matter of fact, we will defend the views that M&S 
should be considered as the technology of choice for risk assessment and risk 
management. In order to predict how the treatment effects perform in the 
overall patient population, clinical trial simulations (CTS) will be used to 
evaluate drug effects in various populations with different characteristics.  
Furthermore, CTS can be critical for the optimisation of trial protocols, 
enabling increased signal-to-noise ratio and facilitating decision making at 
early stages of drug development. 
In summary, our hypothesis is that a model-based approach is required for 
accurate identification of pro-arrhythmic drugs and subsequently for the 
quantification of the dromotropic effect and its consequences on 
cardiovascular safety. We will demonstrate that model parameterisation is a 
critical component for effective decision making.  A model must discriminate 
between system- and drug-specific properties to allow prediction of drug 
performance in real-life population. Specifically, this thesis will evaluate 
existing data from compounds with known cardiovascular effects to address 
the following issues: 
1. How modelling and simulation (M&S) can facilitate the translation of 
studies across different phases of drug development, improving the 
predictive value of experiments. 
2. How historical data can be used to support model parameter estimation 
and subsequently applied as priors during the evaluation of drug safety.  
3. How concentration-effect (PKPD) relationships can be used as basis for 
the analysis of QTc-interval prolongation. 
4. How PKPD concepts can be used in conjunction with 
pharmacoepidemiological data to discriminate drug-induced effects from 
other confounders in the target patient population. 
5. How decision criteria can be optimised for the evaluation of novel 
compounds. 
64        Scope and Intent of Investigation 
Given the breadth and complexity of the subject, the focus of our 
investigation is split into three main sections. After a general introduction, 
we explore the technical requirements for model parameterisation and 
define the benchmark for the analysis and interpretation of risk during the 
evaluation of cardiovascular safety.  Subsequently, focus is given to a 
bridging strategy, which is proposed as basis for decision making and risk 
management. Lastly, different protocol optimisation scenarios are 
considered for prospective evaluation of novel compounds where one or 
more of the aforementioned issues are dealt with.   
2.2 GENERAL INTRODUCTION 
In Chapter 1, an overview of the current technologies available for assessing 
QT/QTc-interval prolongation is presented, which provides insight into some 
of challenges for translation and prediction of drug effects in humans. 
Limitations and flaws are highlighted and used as a foundation for this thesis. 
Furthermore, an overview is given of the physiological, clinical and 
epidemiological basis for the characterisation of drug-induced effects on 
cardiac conductivity, more specifically on QTc-interval, together with the 
theoretical basis for the measurement of  QT/QTc-interval and its association 
with  fatal arrhythmias. This is followed by a discussion on the various 
methods used to establish correlations between observations in clinical trials 
and in the target patient population under real-life conditions. We emphasise 
that not all drugs that prolong QT-interval to the same extent carry the same 
risk of causing TdP.  It is therefore important to appreciate that QTc-interval 
prolongation may not constitute a direct risk, as it could be inferred from 
some of the clinical findings.  Although QTc-interval prolongation is one of 
the major precursors of drug-induced TdP, this arrhythmia does not develop 
invariably in all individuals with equivalent prolongation of the QTc-interval 
[6]. Neither do all drugs that prolong the QT-interval to an equivalent 
duration carry the same risk of inducing TdP. Clearly, unwanted drug-
induced prolongation presents an important concern for drug development, 
thus the general progression of the publications of guidance for industry is 
also ensued. 
Lastly, we introduce important methodological concepts pertinent to the 
evaluation of exposure-response relationships and consequently useful for 
the prediction of safety.  In recent years, the use of Bayesian methods has 
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increased considerably as a tool for the characterisation of exposure-
response relationships and other medical applications [7]. The key difference 
between classical and Bayesian statistics is the interpretation of probability. 
In a Bayesian context, probability is considered to be a quantification of 
‘degree of belief’. We take advantage of this concept as the basis for the 
technical implementation of the model-based approach proposed throughout 
this thesis. In contrast to traditional statistical reasoning, which relies on the 
likelihood, i.e. the probability of observing the data given a range of 
parameter values, Bayesian statistics relies on the posterior distribution, 
which is the distribution of the parameters (i.e., parameter space) given the 
observed data. The prior distribution can include all relevant information 
that is not captured by the actual experiment.  
Based on a comprehensive review of the scientific rationale and of evidence 
from clinical and epidemiological data, specific issues have been identified in 
the current strategy for the assessment of pro-arrhythmic properties and 
QTc-interval prolongation which will underpin the scope of this thesis, as 
detailed here in Chapter 2. 
2.3 BAYESIAN HIERARCHICAL MODELS IN SAFETY ASSESSMENT 
As indicated previously, the lack of data integration and of integrative 
approaches for decision making contributes to the attrition rate in drug 
discovery and development. A streamlined approach is required which takes 
into account the concentration-response relationship across different phases 
of development, irrespective of the species, populations or experimental 
conditions. The evidence of risk of hazard or lack thereof must have 
predictive validity or value for the target population, both in qualitative and 
quantitative terms. Such considerations are not formally embedded in the 
requirements for evidence generation, and consequently lead to the 
implementation of experimental protocols which are not fully informative or 
eventually even biased.  Whilst model-based approaches have been used 
across numerous therapeutic areas to assess efficacy and safety, most 
attempts have been descriptive in nature, without clear focus on the 
prospective use of models as benchmark or strategy for drug screening and 
decision-making [8]. The possibility to dissect system from drug-specific 
features allows the introduction of modularity, which is essential for the 
assessment of drug-induced effects and risk management. Consequently, 
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here we propose a general but robust parameterisation which enables 
integration of historical data into decision making. Moreover, it allows a shift 
in the efforts usually required for model building into relatively simple 
parameter estimation procedures. These procedures also provide the basis 
for validation of screening tools in terms of sensitivity and specificity (i.e., 
false positive and false negative rates). We also show that decision making 
requires more than hypothesis testing, as currently assessed during a TQT 
trial. In fact, assessment of the liability of a compound to prolong QT/QTc- 
interval requires a well-defined, integrated set of assumptions and scenarios 
which together describe the observed findings not only in statistical terms 
(i.e., effect size), but ultimately are predictive of  yet-to-be observed events, 
providing insight into the mechanisms underlying the experimental data. 
This concept is introduced in Chapter 3, where a general model 
parameterisation is proposed in terms of drug-specific and system-specific 
properties. Using clinical data from Phase I trials in healthy volunteers, we 
demonstrate the feasibility of a Bayesian approach to characterise the 
exposure-effect relationship and the corresponding probability of QTc- 
interval prolongation of three compounds known to prolong the QT/QTc- 
interval (d,l-sotalol, moxifloxacin, grepafloxacin). The proposed model 
consists of an individual correction factor for heart rate, an oscillatory 
component describing the circadian variation and a truncated Emax model to 
account for drug effect. Probability curves for an increase in QTc-interval > 
10 msec are derived, which can be easily interpreted for clinical purposes.  
From a statistical perspective, in Chapter 3 we also draw attention to the 
implications of false-positive and false-negative results and emphasise the 
importance of a parametric approach to overcome high type I error rates, 
without the burden of traditional statistical methods that impose therefore 
large study populations. In addition, our approach readily allows for the 
incorporation of prior knowledge, which is abundant from historical data on 
system-related parameters describing e.g., QT/RR relationship and circadian 
variability. This approach also allows for the estimation of the posterior 
parameter distribution, which fully reflects all acknowledged sources of 
uncertainty.  
The advantages of model parameterisation based on drug- and system-
specific properties is further explored in Chapter 4, where we illustrate the 
suitability of the model to describe the pro-arrhythmic effects of d,l-sotalol, 
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cisapride and moxifloxacin. Data generated pre-clinically and clinically in 
dogs and in humans, respectively, is analysed using the same hierarchical 
model, enabling the assessment of correlations between species. We 
anticipate that the use of a common model during the course of drug 
development can facilitate the translation of data from pre-clinical to clinical 
conditions.  From a drug development perspective, these features are highly 
relevant, as they allow prospective evaluation of compounds.   
2.4 FROM PHARMACOLOGY TO EPIDEMIOLOGY: A BRIDGING 
STRATEGY FOR THE  EVALUATION OF CARDIOVASCULAR RISK. 
Translational efforts are required not only during the progression of a 
compound from preclinical to clinical phases of development. It is also 
critical to understand the safety profile of a drug in the overall target 
population, as observed during Phase IIb, III and IV trials. Although 
epidemiological evidence suggests a correlation between drug-induced QTc-
interval prolongation, the risk of fatal arrhythmias and consequently sudden 
cardiac death (SCD), little has been done to pro-actively evaluate whether the 
signal-to-noise ratio observed during a clinical trial changes under real-life 
conditions. In fact, trials in early- and late-phase clinical development are 
primarily designed to assess efficacy. The detection of safety signals and 
adverse events are limited by the duration of the study, by the 
inclusion/exclusion criteria as well as by the size of the study population. 
Furthermore, no formal procedures exist to mitigate the impact of such 
differences or support the management of cardiovascular risk in the target 
population.  Yet, many patient subgroups with higher risk factors are often 
excluded from the trials, but are ultimately part of the population receiving 
treatment after regulatory approval. It is, therefore, important to devise a 
strategy to anticipate the incidence of adverse events in these patients [9].  
Based on clinical trial simulation (CTS) concepts, in Chapters 5, 6 and 7 we 
explore innovative techniques to evaluate safety and cardiovascular risk in 
the overall population. 
In Chapter 5, focus is given to the characterisation of the differences between 
the expected magnitude of drug-induced QTc prolongation and the overall 
increase in QTc-interval in real-life conditions. In addition, we highlight some 
important practical and ethical hurdles associated with the generation of 
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safety data, particularly when safety concerns appear at low frequency or are 
rare events. Such information can only be derived from epidemiological 
studies, which are planned and performed only after drug approval.  
Instead, an integrated approach is proposed that enables data from clinical 
trials to be analysed parametrically to predict the overall treatment effect in 
the general population. Once more d,l-sotalol is used as paradigm compound 
to illustrate the potential clinical implications of differences in safety signal 
before and after marketing authorisation.  The Rotterdam Study cohort, an 
observational cohort established in a suburb area of Rotterdam, The 
Netherlands, is analysed in conjunction with the hierarchical model used 
previously to characterise QTc-interval in healthy subjects. From a statistical 
perspective, linear regression methods are combined with nonlinear mixed 
effects models. In contrast to using normalised daily dose, drug exposure in 
epidemiological cohorts is characterised by pharmacokinetic modelling. 
Inferences about individual exposure are based on the expected population 
parameter estimate and on covariate effects. 
Finally, the concept of Not-In-Trial Simulation as a way to predict QTc 
prolongation during the post-marketing phase is established in Chapter 6, 
where we attempt to reconcile the differences found between clinical trial 
population and real patients. Furthermore, we show that despite the 
widespread acceptance of model-based techniques in clinical pharmacology 
research and in drug development, the use of simulations remains limited, in 
particular for the evaluation of safety data.  Not-In-Trial Simulations are 
introduced as an inferential tool. This method offers the basis for improved 
risk management, dissecting drug-specific contribution to pre- or post-
approval safety findings. In fact, we anticipate that simulations can unravel 
the individual contribution of baseline QTc-interval, drug exposure, 
concomitant medications and comorbidity conditions to the overall effect in 
patients.  As such, Not-In-Trial Simulations offer an opportunity for pro-
active risk management. 
Given the relevance of the predictive validity of the proposed hierarchical 
model for QTc-interval prolongation, in Chapter 7 the advantages of Not-In-
Trial Simulations will be further assessed using cisapride as a reference 
compound. Model-predicted QTc-intervals are obtained taking into account 
differences in patient demographics, baseline QTc values, the exposure-effect 
relationship observed in a clinical trial population as well as the effects of 
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concomitant drugs and comorbidities. We endeavour to demonstrate that 
Not-In-Trial Simulations can provide a framework for the assessment of 
drug- versus disease-specific properties, facilitating the assessment of 
causality when describing or analysing safety data. The concept becomes 
increasingly important with less frequent or rare events, for which larger 
populations or longer trials are required. On the other hand, there are cases 
in which it is not the frequency of an adverse event, but its magnitude that 
cannot be accurately determined during the clinical development phase. In 
these circumstances the observed risk-benefit ratio may not reflect the actual 
implications of the therapeutic intervention in the target population. We 
consider QTc-interval prolongation as an example of such a case. 
After having addressed some of the issues associated with the lack of data 
and demonstrated the translational and predictive value of a hierarchical 
model to characterise QTc-interval prolongation, the next question to be 
considered in the evaluation of cardiovascular safety is the relevance of a 10 
msec increase and the meaning of such a threshold.  Currently, a TQT trial is 
mandated before drug approval to ensure accurate assessment of the risk of 
pro-arrhythmias. The underlying assumption is that QTc-interval 
prolongation >10 msec leads to an increase in the risk of torsade de pointes 
(TdP). However, the evidence for such a correlation remains debatable. In 
fact, several large population-based studies exploring the association 
between the heart-rate corrected QT-interval and mortality in apparently 
healthy persons did not find a consistent association between the length of 
the QTc-interval and total or cardiovascular mortality [10]. This very notion 
is challenged in Chapter 8, where we investigate whether TdP and sudden 
cardiac death (SCD) are indeed correlated with each other in a cause-and-
effect manner. Among other things, it is of interest to evaluate whether 
increases in QTc values, calculated as changes from baseline or absolute 
measured QTc values, are associated with SCD.  We envisage that any 
meaningful attempt to further implement QT-interval as a prognostic marker 
of cardiovascular risk must take into consideration the basic operating 
characteristics of working variables, i.e., its sensitivity and specificity to 
detect the signal of interest.  To this purpose, SCD data in the general 
population is obtained from the Rotterdam Study cohort. We apply trend-
analysis to describe the correlation between patients showing changes in 
QTc of <10 msec and >10 msec.  In addition, a sensitivity analysis is 
performed to explore the impact of the time span between death and last 
ECG measurement.  
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2.5 CLINICAL TRIAL SIMULATION AND STUDY DESIGN 
OPTIMISATION FOR THE EVALUATION OF CARDIOVASCULAR 
SAFETY 
In this section of the thesis, we consider the advantages of protocol design 
optimisation as the basis for improved statistical inference and accurate 
estimation of drug-induced effects (i.e., treatment effect size) in a clinical 
trial. Different protocol optimisation scenarios are explored under the 
assumption of treatment with drugs showing varying degrees of QTc-interval 
prolongation.  First, attention is paid to the confounding effects of heart rate, 
which also affects the QT-interval.  Correction for heart rate is required to 
ensure a single physiological value within the same subject under different 
conditions. In fact, the relationship between the QT-interval and heart rate 
can be modelled mathematically. However, despite the accuracy and 
precision of the parameters describing the so-called physiological 
relationship, the use of such functions in clinical trial simulations has been 
limited. In Chapter 9, rather than relying on data resampling using existing 
pairs of QT-RR values, a novel approach is proposed to describe the 
correlation between QT- and RR-intervals in healthy volunteers.   Based on 
simulations, a hypothetical population with physiological values of QT and 
RR values is used in Chapter 10 to explore and compare the sensitivity / 
specificity of the different methods currently available for the assessment of 
QTc-interval prolongation.  Of particular interest are the differences between 
the proposed parametric approach, based on a Bayesian hierarchical model 
and the double-delta method, which is the current gold standard for the 
analysis of QT-interval prolongation. In addition, the impact of different 
design factors on type I and type II errors  is considered for a variety of study 
scenarios in which hypothetical drugs with different effect sizes (namely, 10 
msec for a positive compound, 5 msec for a borderline compound and 2 msec 
for a negative compound) are evaluated [11].  Ultimately, the objective is to 
demonstrate whether the use of concentration-exposure relationships can 
facilitate the assessment of causality and overcome the statistical issues 
caused by the double-delta method. 
Given the statistical flaws, the ethical burden and financial consequences of 
the study design recommended by ICH E14, in Chapter 11 we also assess the 
feasibility of using first-time-in-human (FTIH) studies as the basis for 
evidence synthesis regarding the propensity for pro-arrhythmic effects.  
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FTIH studies are a mandatory step in the drug development process and 
include detailed information on drug exposure at therapeutic and supra-
therapeutic levels, enabling the characterisation of the concentration-effect 
curve.  It is hypothesised that FTIH trials can be modified and optimised to 
deliver the same information currently obtained from thorough-QT (TQT) 
studies by increasing the sampling frequency and by applying a parametric 
method for the analysis of the data. We also challenge the requirement for 
continuous assessment of the individual sensitivity to QTc-interval 
prolongation by the inclusion of a positive control arm.  In fact, historical 
studies with moxifloxacin can be used in a manner as priors during 
parameter estimation [12]. We anticipate that the possibility to modify 
traditional FTIH studies will provide invaluable safety information early in 
development [13]. Given that such modifications will consequently generate 
more informative data, it will facilitate and improve decision making. 
2.6 CONCLUSION AND PERSPECTIVES 
The final section of this thesis summarises the main findings and conclusions 
from the investigations presented throughout the various chapters.  In 
Chapter 12, we continue to advocate the need for data integration and on 
evidence synthesis based on pharmacokinetic-pharmacodynamic 
relationships. We provide recommendations for cardiovascular safety 
evaluation based on the assumption that accurate inferences can be made 
irrespective of the level of evidence obtained during the development phases. 
A new paradigm must emerge in which evidence generation does not replace 
or overshadows the need for evidence synthesis, which is by far more 
encompassing and comprehensive. We also reiterate the importance of 
revisiting current guidelines, in particular the ICH E14 document, which 
shows inconsistency with oncoming evidence from scientific research.  
Finally, we envisage that further advancements in the prediction of 
cardiovascular safety can be obtained by expanding the concepts of Not-In-
Trial Simulation to multiple endpoints as well as by incorporating 
mechanistic models to the pharmacometric framework proposed in this 
thesis. Given the increasing availability of pharmacovigilance cohorts, access 
to data will not be the limiting step any longer. In fact, the translational 
concepts developed here may be applied to a wider range of outcomes, 
enabling drug developers, clinical researchers and regulators to bridge the 
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gap between controlled clinical trial and real life conditions.  In any case, the 
ability to discriminate between drug- and system-specific parameters will 
remain critical for the success of a model-based approach.  
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ABSTRACT 
Early in the course of clinical development of new non-antiarrhythmic 
drugs, it is important to assess the propensity of these drugs to prolong 
the QT/QTc-interval. The current regulatory guidelines suggest using 
the largest time-matched mean difference between drug and placebo 
(baseline-adjusted) groups over the sampling interval, thereby 
neglecting any potential exposure-effect relationship and nonlinearity 
in the underlying physiological fluctuation in QT values. Thus far, most 
of the attempted models for characterising drug-induced QTc-interval 
prolongation have disregarded the possibility of model 
parameterisation in terms of drug-specific and system-specific 
properties. Using a database consisting of three compounds with 
known dromotropic activity, we built a Bayesian hierarchical 
pharmacodynamic (PD) model to describe QT-interval, encompassing 
an individual correction factor for heart rate, an oscillatory component 
describing the circadian variation, and a truncated maximum-effect 
model to account for drug effect. The explicit description of the 
exposure-effect relationship, incorporating various sources of 
variability, offers advantages over the standard regulatory approach.  
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3.1 INTRODUCTION 
The importance of evaluating possible effects of non-antiarrhythmic drugs 
on QT-interval has increased significantly in the past decade [1]. In fact, at 
present proarrhythmias due to drug-induced QTc prolongation are the 
second most common cause for withdrawal of a drug from the market [1, 2]. 
Such a cautionary measure derives from the notion that an increase in QTc-
interval is associated with the risk of developing a potentially fatal 
arrhythmia, i.e., torsades de pointes [3-5]. Therefore, the ability to assess 
QT/QTc prolongation effects as early as possible in the course of clinical 
development of a new drug is helpful not only in understanding the potential 
risk-benefit ratio of a molecule but also in deciding whether to progress with 
the development of the compound, thereby avoiding unnecessary costs. To 
address some of the main issues related to cardiovascular safety, the most 
current regulatory guideline - the International Conference on 
Harmonisation (ICH) E14 document, published in 2005 - introduced the 
requirement to perform thorough-QT (TQT) studies [1, 6] as the basis for 
demonstrating a compound’s liability to cause QTc prolongation. In addition 
to outlining the assessment procedures for evaluating prolonged ventricular 
repolarisation, the ICH E14 guidance defines a 10 msec increase in QTc- 
interval as a critical threshold for cardiovascular safety and requires the use 
of a positive control and supra-therapeutic doses of the investigational drug 
to ensure accuracy and sensitivity of the experimental protocol. Suggestions 
are also given regarding the timing of the studies as well as methodologies 
and interpretations used in the evaluation of QT measurements. 
The primary analysis of a TQT study is based on the “double-delta” method, 
which is an assessment of the upper bound of the 95% one-sided confidence 
interval for the largest time-matched mean effect of the drug on the QTc-
interval.  The result of the assessment must exclude a 10 msec increase in 
QTc-interval if the drug is to be deemed safe, i.e.,  a negative study [1].  
Requiring that the largest time-matched mean difference between the drug 
and placebo QTc-interval be ~5 msec or less implies that the one-sided 95% 
confidence interval should exclude an effect of >10msec for every single 
measurement. Although this is thought to be the most suitable approach, it 
can lead to multiplicity issues and positive bias [7, 8]. For instance, where 
electrocardiogram (ECG) measurements are taken at 10 post-dose sampling 
times, and in 9 of these, the one-sided 95% confidence intervals exclude a 10 
msec while the tenth measurement has an upper limit of 11 msec, can one 
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conclude with certainty that the drug causes QT/QTc prolongation? To 
minimise the multiplicity issues arising from having to establish non-
inferiority at each time point, investigators may choose to take 
measurements at only a bare minimum required number of time points. In 
other words, the more thorough approach of having ECG measurements 
taken at additional time points may itself carry a penalty; this is 
counterintuitive to the very purpose of TQTs. 
From a methodological perspective, it should be noted that assessment of 
drug-induced QT-interval prolongation by non-antiarrhythmic compounds 
involves quantification of a weak signal and is prone to generation of false-
positive and false-negative results. To overcome these issues and sustain 
enough power and acceptable Type I error rate, traditional statistical 
methods call for large study populations, representing considerable 
additional development costs. Another limitation of the proposed double-
delta method is the inability to detect concentration-QTc relationships. The 
ICH guidance suggests that “establishing the relationship of drug 
concentrations to changes in QT/QTc-interval may provide additional 
information"; however, "this concept is not embedded into the statistical 
method. The suggestion is limited to the planning and interpretation of 
studies assessing cardiac repolarisation” [5].  In fact, Garnett et al. and many 
other authors have examined the potential role of the assessment of the drug 
concentration-QTc relationship and provided examples that illustrate how 
this type of assessment has been useful during regulatory review [9].  
From a scientific perspective, the evidence gathered to date means that any 
"regulatory review of QT study is not complete without an assessment of 
concentration-QTc relationship” [10]. Assessing the relationship between the 
concentration of the drug and its effect on QT/QTc-interval can be achieved 
using alternative, yet equally powerful, quantitative methods; the latter 
would have a clear advantage over the standard E14 approach, namely the 
double-delta or any time point-based analysis.  In particular, nonlinear 
mixed-effects modelling of the concentration-QT relationship allows the 
integration of data across all time points as well as across all available 
treatment groups. Moreover, it relies on individual responses, instead of 
averaging the QT response across time points, thereby enabling a better 
understanding of the uncertainty in response as well as the impact of outliers 
[10].  Despite the many modelling efforts attempted in the area of 
cardiovascular safety assessment [11-16], none has yielded a summary of the 
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risks associated with increasing exposures in such a way as to enable an easy 
comparison of compounds and to facilitate translational research and 
decision making.  In addition, models often focus too much on drug-specific 
or experimental settings, overlooking the rationale underlying the 
assessment of causality in QTc prolongation. The model parameterisations 
proposed do not easily allow drug-specific properties to be distinguished 
from the biological or physiological system properties; nor do they facilitate 
translation from preclinical to clinical conditions. 
Interestingly, the use of Bayesian hierarchical models has been rather limited 
in the field, as opposed to the more commonly-used frequentist approach in 
which maximum-likelihood estimation methods are used [17]. The Bayesian 
approach readily allows for the incorporation of prior knowledge that can 
exist for the system-related parameters such as QT/RR relationship and 
circadian variability.  A wealth of knowledge has been generated throughout 
the history of cardiovascular safety assessment, and therefore the ability to 
incorporate prior information is invaluable.  Another advantage to using 
Bayesian methods is that there is no requirement for linearity or normality 
in the data and therefore inference is based directly on the desired model 
rather than an approximation of it.  Furthermore, the posterior distribution 
fully reflects all acknowledged sources of uncertainty and the fact that it is 
obtained in the form of a random sample means that numerous integrals of 
interest can be evaluated in a more straightforward manner.  As a 
consequence, Bayesian methods enable one to express uncertainty about a 
parameter in terms of probability. It should also be noted that probability 
can be interpreted in a much more natural and transparent manner than is 
possible in frequentist terms. This transparency helps stakeholders in 
making decisions regarding the safety profile of a compound without the 
need to decipher frequentist-generated results.  
Keeping in mind the aforementioned limitations with the current methods 
for the evaluation of QTc prolongation, the objective of this investigation was 
to demonstrate the feasibility of a Bayesian approach to characterise the 
exposure-effect relationship and the corresponding probability values of 
QTc-interval prolongation with respect to three compounds that are known 
to prolong the QT/QTc-interval (d,l-sotalol, moxifloxacin, and grepafloxacin), 
using clinical data from Phase I trials in healthy volunteers. Although any 
threshold values can be set, we have used a threshold of > 10 msec in 
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assessing the probability curves for increases in QTc-interval as an 
illustration of the concept.   
3.2 METHODS 
Clinical data source 
For this analysis d,l-sotalol, moxifloxacin and grepafloxacin - three 
compounds with known dromotropic activity - were selected from 
GlaxoSmithKline’s clinical data repository.  d,l-Sotalol treatment data were 
obtained from a three-way crossover, placebo-controlled (given twice), 
double-blinded, randomised trial design (study identifier EXP20001). Each 
subject was given a single oral dose of 160 mg d,l-sotalol or an equivalent  
dose of placebo.  Moxifloxacin data were extracted from a two-way 
crossover, placebo-controlled, single–blinded trial aimed at evaluating the 
effect of repeated oral doses of lamotrigine on cardiac conduction (study 
SCA104648). Only data from sessions with placebo and moxifloxacin (400 
mg), which was used as a positive control, was used for the purposes of our 
analysis [18]. Grepafloxacin data was obtained from a double-blind, placebo-
controlled, multiple-dose crossover study design in which healthy female 
volunteers received a 600 mg dose of grepafloxacin or placebo (study 
GFX10901).   
A summary of the relevant demographics, along with the time points for 
obtaining blood samples for pharmacokinetic and pharmacodynamic 
measurements pre- and post-dosing, pertaining to all three studies is shown 
in Table 1.   
PK Sampling and Bioanalysis 
For each of the compounds studied, whole blood (3 mL) was collected into 
plain tubes and left to clot at room temperature. After clot retraction 
occurred, the samples were centrifuged at 4°C at 1500 g – 2000 g for 10 
minutes with the minimum of delay. Serum (~1 mL) was carefully pipetted 
into pre-labelled Nunc (Roskilde, Denmark) 1.8 mL polypropylene tubes and 
frozen (with the tubes in upright position) at -20°C until assay. 
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 d, l-Sotalol Moxifloxacin Grepafloxacin 
Number of 
subjects 30 137 29 
Gender M: 18 (60%),  F: 12 (40%) 
M: 88 (64%), 
F: 49 (36%) F: 29 (100%) 
Age mean = 36           (19-53) 
mean = 27          
(18-50) 
mean = 24,2      
(18-47) 
Dose placebo, 160 mg placebo, 400 mg placebo, 600 mg 
PK sampling 
times 
-30, -15, 5, 15, 30, 
45 min, 
1, 2, 4, 8, 10, 18,    
24 h 
-0.8, 0.35, 0.6, 0.85, 
1, 1.3, 1.6, 2.1, 3.1, 
4.1,  
6.1, 12.1, 24.1 h 
-0, 0,5, 1, 1.5, 2, 
2,5, 3, 4, 6, 8, 12, 
16, 24,  
30, 36, 48 h 
PD sampling 
times 
-120, -105, -90, -75, 
-60, -45, -30, -15, 30 
min, 1, 1.25, 2, 4, 6, 
8, 10, 12, 18, 24 h 
-1, -0.5, -0.1, 0.25, 
0.5, 1, 1.5, 2, 2.5, 3, 
4, 6, 8, 10, 12, 24 h 
-25, -20, -15, -10, 
-5 min, 0.5, 1, 1.5, 
2, 2,5, 3, 4, 6, 8, 
12, 16, 24, 30,    
36 h 
Table 1.  Clinical protocol and demographic details of the studies used in the analysis. 
Concentrations of d,l-sotalol in serum were analysed using 96-well solid 
phase extraction/liquid chromatography-tandem mass spectrometry; the 
quantifiable range was 1.0 to 750 ng/mL with a coefficient of variation (CV) 
ranging from 5.86 – 13.29% and accuracy ranging from 93.95 – 109.9%. 
Both moxifloxacin and grepafloxacin were analysed by means of high-
performance liquid chromatography/tandem mass spectrometry, using a 
TurboIonspray interface (ABSCIEX, Foster City, CA) and multiple-reaction 
monitoring. Drugs were extracted from human plasma by solid-phase 
extraction using Oasis HLB cartridges (Waters, Milford, MA) with 
moxifloxacin-d4 as an internal standard. This method had a lower limit of 
quantification (LLQ) of 25.0 ng/mL and an upper limit of 5000 ng/mL.  
Quality-controlled results were deemed to be acceptable if they deviated by 
no more than 15% from the actual concentration. For the analytical run to be 
approved, no more than 33% of the results from quality control samples 
could be beyond ±15% of the actual concentration and at least 50% of the 
results for each concentration needed to be valid (not more than ±15% of the 
actual concentration). 
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ECG measurements 
All subjects were required to stay overnight at the study location before 
receiving the relevant study drug. The drug was administered with 200 mL of 
water.  The consumption of all foods and beverages was restricted in 
accordance with the respective protocols so as to minimise random 
variability in ECG measurements. The subjects were also asked to refrain 
from strenuous physical activity before and during the trial period so that 
ECG measurements would not be altered by external factors. 
Twelve-lead ECG machines (Marquette™, GE Healthcare, Bucks, UK) were 
used for the assessment of QT, QTc[Bazett], QTc[Fridericia], RR, and HR.   
Strict procedures were followed to ensure that subjects remained in the 
supine position at least 5 min before ECG recordings commenced and 
throughout the duration of the recordings. Triplicate ECG printouts were 
obtained at each sampling time. QT-intervals were measured manually from 
lead II by a cardiographist who was blinded with regard to the treatment 
randomisation.  Subsequently, the average was taken from the available 
replicates at each sampling time.  Pre-dose ECG measurements were used as 
baseline values for each study.  PK and PD sampling time points for each 
study are shown separately in Table 1 since the sampling schedules in each 
trial were very different.  
Pharmacokinetics (PK) modelling 
Population pharmacokinetic models were built for each compound using 
nonlinear mixed-effects modelling techniques as implemented in NONMEM 
VI (v 1.0, ICON Development Solutions, Ellicott City, MD, USA) [19].  Model 
selection was based on the likelihood ratio test, parameter point estimates 
and their respective confidence intervals as well as parameter correlations 
and goodness-of-fit plots.  For the likelihood ratio test, the significance level 
was set at p=0.05, after the inclusion of one parameter; this corresponds to a 
decrease of 3.84 points in the minimum value of the objective function 
(MVOF) under the assumption that the difference in MVOF between two 
nested models is chi-square distributed. Fixed and random effects were 
introduced into the model in a step-wise fashion.  Inter-individual variability 
in PK parameters was assumed to be log-normally distributed.  Different 
residual variability models describing measurement and model errors were 
tested to achieve the best fit.  The final model was used to generate 
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individual plasma concentrations at each of the sampling times associated 
with ECG measurements.   
Pharmacodynamic-pharmacodynamic (PKPD) modelling 
The pharmacodynamic (PD) model describing QTc-interval was developed in 
a modular way that allowed a distinction to be made between physiological 
(QT and RR) and drug-specific (concentration) parameters; an individual 
correction factor for RR-interval (heart rate), an oscillatory component 
describing the circadian variation and a truncated Emax model to capture 




where, QT0 [msec] is the intercept of the QT-RR relationship. The sex of the 
patient was included as a covariate for this parameter whenever applicable. 
RR [sec] is the interval between successive R waves, α is the individual heart 
rate correction factor, A [msec] is the amplitude of circadian rhythm, t is the 
clock time, φ is the phase, slope [msec/concentration] is the linear 
pharmacodynamic relationship, and C is the predicted concentration of drug 
at the time points of QT-interval measurements.  
Instead of applying traditional maximum likelihood methods to model QTc-
interval, a Bayesian adaptation of the model is proposed using WinBUGS 1.4 
[22, 23]. The model was implemented in a hierarchical manner, in which 
subject-specific levels (between-subject variability) were considered for all 
parameters (i.e., α , A , φ  and slope). On the basis of physiological 
considerations, these parameters can be assumed to be independent and 
uncorrelated. Furthermore, given that each drug relates to a different drug, 
study was not included as a term in the analysis.  
The use of a Bayesian approach ensures systematic translation of the 
concentration-effect relationship and interpretation of the risk associated 
with drug-specific effects.  Each parameter is estimated as a mean value, with 
its precision and random effects describing the between-subject variability.  
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advantages, Monte-Carlo Markov-Chain (MCMC) methods allow in-
corporation of prior information during parameter estimation. In addition, 
they yield full posterior distributions from which 95% credible intervals can 
be derived, thereby facilitating understanding of the model and parameter 
uncertainty. Detailed information on Bayesian analyses of PKPD models may 
be found elsewhere [24, 25]. 
Priors 
The kth observed QT measurement for the jth occasion for the ith (QTijk) 
individual was assumed to be normally distributed around the individual 




Non-informative priors were specified as:  
 
where θ is a vector of population mean parameter estimates, is the prior of 
the population means, Σ-1 is the precision of the prior for the population 
mean parameter values and I is the identity matrix.  The inverse of the 
between-subject variance, Ω-1, arises from a Wishart distribution: Ω-1 ~W(ρΩ, 
ρ), with ρ=5 degrees of freedom, where Ω represents our prior guess at the 
order of magnitude of the covariance matrix.  Finally, non-informative 
Gamma (0.0001, 0.0001) priors were assumed for measurement precision 





ττ =   ),,(~ ijkijk fNQT
    Chapter 3      87 
Goodness- of- fit and modelling diagnostics 
Two MCMC chains were run in parallel for 25,000 samples and pooled 
together to provide final parameter estimates. The posterior distributions 
provided by WinBUGS enabled the model-predicted outcomes to be 
compared with the observed values.  Appropriateness of parametric 
distributions as well as the drug model was assessed using the deviance 
information criterion (DIC) as a measure of the goodness-of-fit [26, 27].  The 
number of iterations was deliberately chosen to exclude any residual 
correlation.  Convergence was determined using the Gelman-Rubin test 
statistic [28-30] and also visually, using history and autocorrelation plots.   
Probability of QTc-interval prolongation ≥ 10 msec  
In conjunction with model parameter estimation, a step function was set to 
calculate the probability of observing QTc-interval prolongation > 10 msec at 
peak concentrations (Cmax). The procedure consisted in obtaining the 
cumulative distribution of values in the posterior samples of the product of 
Slope and Cmax which were >10 msec. 
3.3  RESULTS 
Pharmacokinetic modelling 
Each compound was modelled separately; the details are shown in Table 2. 
Despite the use of different parameterisations for volume of distribution, we 
found that a two compartment pharmacokinetic model best described the 
time course of concentrations in plasma for all three QTc-prolonging drugs. 
For d,l-sotalol and grepafloxacin, the absorption phase was characterised by 
a lag time, whereas for moxifloxacin, a combination of zero- and first-order 
absorption processes was required.  In the case of d,l-sotalol, it was found 
that body weight had a significant effect on the volume of distribution and 
that creatinine clearance affected clearance. None of the covariates was 
found to affect the pharmacokinetics of moxifloxacin and grepafloxacin.  In 
addition to standard statistical criteria, goodness-of-fit plots were created so 
as to visually inspect the fit for each of the models (Figure 1). The maximum 
population-predicted concentration (Cmax) were 932 ng/mL for d,l-sotalol, 
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1771 ng/mL for moxifloxacin and 2515 ng/mL for grepafloxacin. A summary 
of the estimated model parameters is shown in Table 2.  
Given that sample collection for the drug concentration quantifications was 
carried out at time points different from those for ECG measurements, the 
purpose of the pharmacokinetic models was to allow imputation of drug 
concentrations at the time point of each ECG measurement so that pair-wise 
concentration-effect data would be available for pharmacodynamic (PD) 
modelling.  
Compound d,l-Sotalol Moxifloxacin Grepafloxacin 
Number of 
compartments 2 2 2 
Parameter 
estimates Mean IIV Mean IIV Mean IIV 
Ka [/h] 1.27 1.39 2.21 0.786 1.32 0.779 
D1 [/h] - - 0.629 0.725 - - 
CL [L/h] 9.39 1.03 13.4 0.0161 0.0823 0.0065 
Vss [L] 147 1.02 - - 0.217 0.776 
V2 [L] - - 122 0.0828 - - 
V3 [L] - - 55.4 0.196 - - 
ALAG [h] 0.45 1.16 - - 0.413 - 
Q [/h] 5.58 0 78.4 - - - 
Error model 
used proportional proportional Proportional 
Covariates 
Creatine on CL 
N/A N/A 
Weight on Vss 
Table 2. Summary of pharmacokinetic parameter estimates for d,l-sotalol, moxifloxacin, and 
grepafloxacin. 
Pharmacokinetic-pharmacodynamic modelling 
The pharmacokinetic-pharmacodynamic (PKPD) model allowed the system-
specific parameters (i.e., those related to the individual correction for the QT-
RR relationship and circadian rhythm) to be estimated separately from the 
drug-specific parameters (i.e., drug-induced QTc-interval prolongation). 
Accordingly, it was found that QT0, the exponent of the individual QT-RR 
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correction factor (α), the amplitude (A) and the phase (φ) of the 24-hour 
circadian rhythm were in the same range of values for all three compounds. 
The one parameter that is noticeably different between the compounds was 
the slope value describing the relationship between drug concentration and 
QTc-interval.  As expected, this effect is drug-specific. Estimates for all 
parameters used in the PKPD model are presented in Table 3, including the 
between-subject variability (BSV) and inter-occasion variability (IOV).  
 
Figure 1. Predicted (solid line) and observed (dots) concentration time profiles for (a) d,l-sotalol, (b) 
moxifloxacin and (c) grepafloxacin. The lower panel shows the goodness-of-fit plots for the individual 
predicted vs. observed drug concentrations. 
In addition to the statistical criteria, accuracy of model predictions was 
assessed graphically by superimposing population-predicted QT-interval for 
each compound onto observed QT values. A direct comparison between 
model predictions and the observed QTc-intervals was not possible because 
Bazett’s correction factor was applied to the original data. Goodness-of-fit 
plots showing individual predictions vs. observed values confirm the absence 
of bias (Figure 2). Likewise, diagnostic plots show that the model accurately 
described the PKPD relationship between QTc-interval and predicted 
concentrations of d,l-sotalol, moxifloxacin and grepafloxacin (Figure 3). 
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Using Bayesian inference, the probability of QTc-interval prolongation >10 
msec was calculated based on the cumulative distribution of values in the 
posterior samples of the difference between the QTc–interval values at 
baseline and after drug administration.  This procedure enables the 
characterisation of drug effect on QTc-interval throughout the observed 
concentration range and beyond, providing a systematic translation of model 
findings into clinically relevant measures.  Figure 4 shows the mean drug 
effect along with the 95% credible intervals throughout a wide range of 
concentration values for d,l-sotalol, moxifloxacin and grepafloxacin.  The 
95% credible intervals, which are analogous to confidence intervals in 
frequentist statistics, provide a measure of uncertainty in the PKPD 
relationship. With therapeutic doses (160 mg for d,l-sotalol, 400 mg for 
moxifloxacin, and 600 mg for grepafloxacin), the probability of having a QT 
prolongation >10 msec at observed maximum predicted concentration range 
was 100% for all three compounds.  
 
Figure 2.  Predicted (solid line) and observed (dots) QT-interval vs. time following administration of (a) 
d,l-sotalol, (b) moxifloxacin and (c) grepafloxacin. The lower panel shows the goodness-of-fit plots for 
the individual predicted vs. observed QT-interval. 
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Figure 3. Pharmacokinetic-pharmacodynamic relationship between QTc-interval and plasma 
concentrations of (left) d,l-sotalol, (middle) moxifloxacin and (right) grepafloxacin.  The solid line 
represents the regression for the population predicted slope and intercept. Dots show the observed QTc-
interval and the corresponding (predicted) individual concentration data 
 
Figure 4.  Pharmacokinetic-pharmacodynamic relationships (mean and 95% CI) and corresponding 
probability curves for QTc-interval prolongation > 10 msec vs. the predicted plasma concentrations of 
d,l-sotalol (left), moxifloxacin (middle) and  grepafloxacin (right). 
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Sex Effect [msec] 17  (7-27) 
8  
(5-12) - 
























































 > 10 msec at Cmax 1.00 1.00 1.00 
*Mean values with (95% confidence interval) 
Table 3. Mean parameter estimates of the Bayesian pharmacokinetic-pharmacodynamic model for d,l-
sotalol and moxifloxacin, and grepafloxacin with 95% confidence intervals. 
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3.4 DISCUSSION 
The E14 document recommends that almost all drugs, especially non-
antiarrhythmic compounds, undergo careful clinical testing in TQT study.  
The underlying concept is that a study in healthy volunteers using supra-
therapeutic doses of a drug is sufficient to detect small increases in QTc-
interval.  This finding can unveil potentially larger prodromic effects in 
patients, who are more prone to develop pro-arrhythmias [31, 32].  However, 
one of the main limitations of this approach is that it does not explicitly 
account for individual plasma drug concentration levels and the 
corresponding PKPD relationships when assessing treatment effect, yielding 
biased estimates of the true drug effect [33].  Antiarrhythmic and non-
antiarrhythmic drugs that prolong the QTc-interval have been shown to do 
so in an exposure- or concentration-dependent manner [34-37].  Moreover, 
other physiological and protocol design factors contribute to changes in QTc-
interval, and these might not be mitigated by randomisation methods and 
other statistical techniques.  
To address this limitation, we aimed in this study to show how a Bayesian 
hierarchical model can be used to describe the relationship between drug 
concentration and QTc-interval prolongation with respect to d,l-sotalol, 
moxifloxacin and grepafloxacin.  The use of an integrated modelling 
approach has also allowed explicit identification of drug-induced component 
of QTc prolongation, discriminating it from other components such as 
variation in heart rate and circadian rhythm. It should be noted that the 
drug-specific parameter in this model (slope) does not independently 
indicate whether there are risks associated with the use of the compound, 
nor does it indicate whether the development of the drug should be stopped.  
Rather, it provides an unambiguous description of the PKPD relationship, 
taking into account various sources of variability. Furthermore, the use of a 
linear or log-linear relationship to describe drug-specific effects offers 
advantages as compared with the standard regulatory approach in that it 
yields estimates of the exposure required to reach clinically relevant increase 
in QT-interval without the requirement for parameterisation of maximum 
effect (Emax) [38].  The resulting PKPD relationships are also similar to values 
that have been previously reported using other methodologies. For example, 
Dixon et al. found an increase in QTc of ~6 msec per 1000 ng/mL QTc [18], 
and Bloomfield reported 3.9 msec/1000 ng/mL [39]; our finding was 4 msec 
per 1000 ng/mL. 
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From a drug development perspective, this approach is highly relevant 
because it allows prospective evaluation of compounds. Given the distinction 
between drug- and system-specific parameters, drug effects can be 
characterised even if hysteresis occurs, as in the case of indirect mechanisms 
or metabolite-induced QTc-interval prolongation. A link model can be 
introduced to infer effect-site concentrations without the burden of 
subsequent drug-specific model adaptations. The proposed Bayesian analysis 
provides clearly interpretable clinical measurements which may aid in the 
decision-making  process throughout the development of new compounds. In 
fact, the posterior (predictive) distribution can be used directly to translate 
liability to QTc-interval prolongation across varying doses or concentration 
ranges.  These concepts contrast with the current recommendations by the 
ICH E14, which suggest the use of supra-therapeutic doses in TQT studies, 
without the incorporation of pharmacokinetic information. Unfortunately, 
many investigators do not realise that, as a consequence of such 
recommendations, the effect size observed under these conditions cannot 
properly be deduced for therapeutic doses.  Similar arguments may also be 
applicable to situations to which exposure could potentially be altered 
because of other factors that are relevant for the assessment of the 
benefit:risk ratio, such as drug-drug interactions or comorbidity conditions.   
The ability to extrapolate the effect size across different dose ranges and to 
estimate the associated risk levels can greatly enhance the decision making 
process for regulators, clinicians and drug developers. In this investigation, 
we have shown the probability values associated with increases in QTc-
interval >10 msec, over a given range of concentrations.  However, this 
threshold can easily be changed to higher or lower values to accommodate 
other types of assessments, rendering this model useful for different types of 
analysis or scenarios, including the comparison of drug effects across species. 
From a statistical perspective, whether our proposed methodology 
overcomes the high rate of type I error observed with the traditional 
approach remains to be further investigated. Nevertheless, we expect that 
the use of model-based approaches will be a requirement for the assessment 
of drug safety. Accurate judgement of the risk and liability associated with a 
novel chemical or biological entity cannot be performed without 
distinguishing between drug-specific parameters and the so-called system-
specific parameters. This concept has been elegantly illustrated by Danhof et 
al. and proposed as the basis for translational pharmacology research, 
particularly at the interface between drug discovery and early drug 
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development [40]. In this sense, we envisage the use of our model as a 
framework for clinical trial simulations and optimisation of clinical protocol 
design.     
The high attrition rates in drug discovery and development are largely 
attributable to issues of efficacy and/or safety. Regulatory guidelines should 
ensure that the appropriate level of evidence is available for better decision-
making before the approval process. This requirement does not seem to be 
warranted by the current ICH E14. Concerted efforts are needed to ensure 
that patients are granted access to drugs on the basis of scientific evidence of 
safety. The bias imposed by traditional methods should not continue to be 
ignored.  
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APPENDIX  - EXAMPLE OF THE WINBUGS CODE REQUIRED FOR 
MODELLING QTC-INTERVAL PROLONGATION 
model{ 
for(i in 1:N) { 
    for(k in 1:P){ 
        for(j in offset[P*(i-1)+k]:(offset[P*(i-1)+k + 1] - 
1)){ 
QT[j] ~ dnorm(mu[j],tau.pop) 
mu[j]<-(1+exp(theta[i,2])*cos((2*3.1416/24)*(CTIME[j]-                
exp(theta[i,3])))+(0.00001*theta[i,4])* 





P.res[j]<-phi(res[j])    #p-value for res 
Y.pred[j] ~ dnorm(mu[j],tau.pop) #predicted response 
P.pred[j]<-step(QT[j]-Y.pred[j]) #indicator of whether 
      #observed >predicted              
}#data 
 














fixed.effect[1:6] ~ dmnorm(mean[1:6], prec[1:6 ,1:6 ]) 
R[1:5,1:5] ~ dwish(omega[,],5) 
tau.pop ~ dgamma(1.0E-3,1.0E-3) 
sigma2<-1.0/sqrt(tau.pop)    
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ABSTRACT 
Aims: Given the similarities in QTc response between canines and 
humans, dogs are often used in preclinical cardiovascular safety 
studies.  The objective of our investigation was to characterise the 
PKPD relationships and translational gaps across species following the 
administration of three compounds known to cause QTc-interval 
prolongation, namely cisapride, d,l-sotolol and moxifloxacin.  
 
Methods: Pharmacokinetic and pharmacodynamic data from 
experiments in conscious dogs and clinical trials following 
administration of the drugs were used. First, pharmacokinetic 
modelling and deconvolution methods were applied to derive drug 
concentrations at the time of each QT measurement. A Bayesian PKPD 
model was then used to describe QT prolongation, allowing 
discrimination of drug-specific effects from other physiological factors 
known to alter QT-interval duration.  A threshold of > 10 msec was 
used to explore the probability of prolongation following drug 
administration.  
 
Results:  A linear correlation was found between the PKPD 
relationships in dogs and humans. The drug-specific parameter (slope) 
in dogs and humans were  respectively, 0.0045 vs. 0.009, 0.002 vs. 
0.021, 0.00056 vs. 0.0039 msec/nM for cisapride, d,l-sotalol and 
moxifloxacin. Despite the statistically significant differences between 
species, QTc prolongation > 10 msec  at therapeutic exposure range in 
humans could be predicted from data in conscious dogs. 
 
Conclusions:  Our findings indicate that the slope of PKPD relationship 
in conscious dogs may be used as basis for the prediction of drug-
induced QTc prolongation in humans. Furthermore, the risk for QTc 
prolongation can be expressed in terms of the probability associated 
with an increase > 10 msec, allowing direct inferences about the 
clinical relevance of the pro-arrhythmic potential of a molecule.  
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4.1 INTRODUCTION 
Cardiovascular safety issues are one of the main causes of failure and 
attrition in drug discovery and development [1, 2]. One challenge has been 
the possibility to translate pre-clinical findings and anticipate the 
implications for further clinical development. A major pre-requisite in 
translational research remains however, the characterisation of 
concentration-effect relationships, which can be used as basis for 
extrapolation of pharmacokinetic and pharmacodynamic data across species 
[3].  The aforementioned pre-requisite has been overlooked by the focus on 
compliance to regulatory guidelines, which currently do not endorse the 
need for the generation of safety data in an integrated manner, in which drug 
exposure and/or relevant biomarkers of drug effect are analysed using a 
model-based approach [2, 4, 5].  
One area which can benefit substantially from such an approach is the 
evaluation of the propensity of non-antiarrhythmic drugs in prolonging 
QT/QTc-interval [2, 6].  Prolongation of the QT-interval has been associated 
with the development of polymorphic ventricular tachycardia or torsade de 
pointes (TdP), one of the major reasons for post-market withdrawal [1, 7].  
Despite the fact that QT-interval can easily be measured as part of  routine 
electrocardiogram (ECG) monitoring, assessment of drug-induced QTc-
interval prolongation relies on empirical criteria, preventing the accurate 
scaling of drug effects across species [8].   
Currently, various in vitro and in vivo systems are available for assessing QT 
prolongation [9-11], which support decision-making for the progression of 
assets into clinical development.  These assays provide in most cases 
qualitative measures of drug effect and must therefore be complemented by 
safety data in a thorough-QT (TQT) trial [2, 12-14].  In contrast, the use of a 
model-based approach offers a strictly quantitative basis for translational 
research, which can enhance the integration and extrapolation of preclinical 
data, eventually dismissing the need for additional evidence from a TQT trial.  
Recently, we have proposed a Bayesian pharmacokinetic-pharmacodynamic 
model to assess the probability of QTc-interval prolongation of three 
compounds known to prolong the QT/QTc-interval (d,l-sotalol, moxifloxacin, 
grepafloxacin) using data from Phase I trials in healthy volunteers [15]. Our 
method relies on model parameterisation that allows drug-specific 
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properties to be distinguished from the biological or physiological system 
properties, facilitating the translation of data from preclinical to clinical 
conditions.  In addition, the approach readily allows for the incorporation of 
prior knowledge, which is abundant from historical data on system-related 
parameters describing e.g., QT/RR relationship and circadian variability.  It 
also offers the possibility to estimate posterior parameter distributions, 
which fully reflect all acknowledged sources of uncertainty.  From a drug 
development perspective, this approach can be highly relevant, as it allows 
prospective evaluation of compounds.  Given the distinction between drug- 
and system-specific parameters, drug effects can be characterised even if 
hysteresis occurs, as in the case of indirect mechanisms or metabolite-
induced QTc-interval prolongation. 
The objective of this investigation was therefore to demonstrate its value for 
predicting the clinical effects of cisapride, d,l-sotalol and moxifloxacin based 
on the exposure-effect relationships and the corresponding probability of 
QTc-interval prolongation from in vivo dog data. Even though any threshold 
values can be defined for probability curves, our analysis assumes 
comparable effect size for the increase in QTc-interval in dogs and in humans 
(i.e. > 10 msec). 
4.2 METHODS  
4.2.1.  EXPERIMENTAL DATA 
Preclinical protocols  
A four-way crossover design was used for the evaluation of QTc-interval in 
conscious, freely moving beagle dogs. All dogs were chronically instrumented 
with radio telemetry probes measuring blood pressure (BP), ECG and body 
temperature (T). The ECG electrodes were placed in a lead II position. 
Animals were administered vehicle, a sub-therapeutic, a therapeutic and a 
supra-therapeutic oral dose of each compound.   
Blood sampling scheme for pharmacokinetics was based on preliminary 
pharmacokinetic data to ensure accurate characterisation of absorption, 
distribution and elimination phases.  ECG was monitored continuously over 
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the period of 24 hours, with samples collected every 30 sec.  Further details 
on the experimental design and data acquisition are summarised in Table 1a. 
 Cisapride d,l-Sotalol Moxifloxacin 
Number of animals 8 6 8 
Dose [mg/kg] Vehicle, 0.6, 2, 6 Vehicle, 4, 8 
Prestudy, 
vehicle, 3, 10, 30 
PK sampling times [h] 
0, 0.5, 1, 1.5, 2, 
2.5, 3, 3.5, 4, 5, 
6, 8, 24 
0, 0.5, 1, 1.5, 2, 
2.5, 3, 3.5, 4, 6, 8, 
24 
0, 0.5, 1, 2, 4, 8, 
24, 36, 48 
PD sampling times 
Every 30 sec, 
averages over 
24 h 
Every 5 min, 
averages over  
24 h 
Every 1 min, 
averages over  
24 h 




Plasma drug concentration, clock time,  
Heart rate, Blood pressure, 
Weight, Sex, 
LvPr, QT, RR, QRS 
Table 1a. Treatment, measurement variables and sampling scheme details for the pre-clinical 
experiments in conscious dogs. 
Clinical protocols  
All three protocols were Phase I studies in healthy volunteers.  For cisapride, 
a randomised, placebo-controlled, dose-escalating design was used in which 
subjects received up to five doses.  Due to safety issues, the study was not 
continued after the fourth dose. d,l-Sotalol data was extracted from a double-
blind, randomised, placebo-controlled, three-way crossover design in which 
each subject received one active treatment and two placebo doses.  Data for 
moxifloxacin was available from the positive control arm of a two-way 
crossover, single-blind, randomised, placebo-controlled trial aimed at 
evaluating the effect of repeated oral doses of lamotrigine on cardiac 
conduction.  Further details on the experimental design and data acquisition 
are summarised in Table 1b.   
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 Cisapride d, l-sotalol Moxifloxacin 
Number of subjects 24 30 137 
Gender M: 14 (58%) F: 10 (42%) 
M: 18 (60%) 
F: 12 (40%) 
M: 88 (64%) 
F: 49 (36%) 
Age [yr] mean = 40             (19-54) 
mean = 36    
(19-53) 
mean = 27   
(18-50) 
Dose [mg] placebo, 10, 20, 40, 80 placebo, 160 placebo, 400 
PK sampling  times [h] 0, 1, 1.5, 2, 3, 4, 6, 12, 24 
-0.5, -25, 0.83, 
0.25, 0.5, 0.75, 
1, 2, 4, 8,  
10, 18, 24 
-1, -0.5, -0.83, 
0.25, 0.5, 1, 1.5, 
2, 2.5, 3, 
 4, 6, 8, 10, 12, 
24 
PD sampling  times [h] 
-24, -23, -22.5, -21, -
20, -18, -12, 0, 1, 1.5, 
2, 3, 4, 6, 12, 24 
-2, -1.75, -1.5, -
1, -0.75, -0.5, -
0.25, 0.5, 1, 
1.25, 2, 4, 6, 8, 
10, 12, 18, 24 
-1, -0.5, -0.83, 
0.25, 0.5, 1, 1.5, 
2, 2.5, 3, 
 4, 6, 8, 10, 12, 
24 




Plasma drug concentration, clock time,  
Heart rate, 
Weight, Sex, 
QT, QTcb, QTcf, RR 
Table 1b.  Treatment, measurement variables and sampling scheme details for the clinical studies in 
healthy volunteers. 
4.2.2. PHARMACOKINETIC SAMPLING PROCEDURES AND BIO-ANALYSIS 
Preclinical experiments 
Cisapride - Approximately 0.5 mL samples were obtained from the jugular 
vein and transferred into uniquely labeled EDTA tubes.  All samples were 
mixed gently and placed on crushed water-ice until centrifugation at 3000 g 
for 5 minutes, which was carried out at approximately 4 ˚C. The resultant 
plasma was separated, transferred to uniquely labeled clear matrix tubes, 
frozen immediately over solid carbon dioxide and stored at approximately    
–80 ˚C or below until analysis.  Cisapride concentrations were analysed using 
a method based upon protein precipitation followed by LC-MS/MS analysis.  
The lower limit of quantification (LLQ) was 0.5 ng/mL for a 25 µL aliquot of 
dog plasma.  
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Sotalol - Approximately 0.6mL blood samples were obtained from the jugular 
vein and transferred to BD-microtainers K2E with K2EDTA, and centrifuged 
at 8000 rcf for 3 min in a cooled centrifuge.  The resultant plasma was 
separated, transferred to uniquely labeled clear matrix tubes and stored at 
approximately –18 ˚C or below until analysis.  Racemic d,l-sotalol was 
analysed using a LC–MS/MS method (Waters UPLC) and an API 4000 mass 
spectrometer. An Acquity UPLC® BEH hilic, 1.7 µm: 2.1x100mm column was 
used for the separation by the LC method (with A = 0.1% Formic Acid  and B 
= CH3OH). The lower limit of quantification (LLQ) was 1 ng/mL. 
Moxifloxacin - Approximately 1.0 mL whole blood samples were obtained 
from the jugular vein and transferred into uniquely labelled potassium EDTA 
tubes where plasma was separated by centrifugation. Serum concentrations 
of moxifloxacin (Ryan Scientific, Mt. Pleasant, SC) were determined by 
acetonitrile precipitation, followed by analysis using the LC–MS/MS method. 
Samples were prepared by an addition of 600 μL of acetonitrile containing 
500 ng/mL of lomefloxacin (Sigma Chemical Co. Ltd., St. Louis, MO) as an 
internal standard to 25 μL of serum. Moxifloxacin serum concentrations were 
determined by an Applied Biosystems API4000 triple quadrupole mass 
spectrometer (Applied Biosystems, Foster City, CA, USA) equipped with a 
TurboV™ source.  Spectra was acquired by multiple reaction monitoring 
(MRM) in the positive ionisation mode. A calibration curve was constructed 
using peak area ratios of moxifloxacin and the internal standard calibration 
samples of lomefloxacin, with a weighted (1/x2) linear least squares 
regression analysis.   
The lower limit of quantification (LLQ) was 1ng/mL and the upper limit was 
5000 ng/mL.  The same procedure was used for two separate analysis days. 
Clinical protocols 
For all bio-analysis pertaining to the clinical studies, 3 mL blood samples 
were collected into vacutainers for the determination of serum 
concentrations of the specific compound.  Blood samples were left to clot at 
room temperature. After clot retraction occurred, samples were centrifuged 
at 4°C at 1500 g for 10 minutes with the minimum of delay. Serum 
(approximately 1 mL) was carefully pipetted into pre-labelled Nunc 1.8 mL 
polypropylene tubes, then frozen in an upright position at -20°C until assay.  
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All samples were kept frozen in Cardice pellets during transit and transport 
to various analysis facilities.   
Cisapride - Plasma concentrations of cisapride were determined by a 
validated high performance liquid chromatography (HPLC) method.  The 
analytical range was between 5.00 and 500 ng/mL.  Each analytical batch of 
cisapride assays consisted of a set of 8 calibrators, freshly prepared in blank 
heparinised plasma.  The lowest calibrator was at the level of the lower limit 
of quantification and the highest calibrator was at the level of the upper limit 
of quantification.  Back-calculated values of the calibration standards had to 
be within 15% validation-criterion (20% at LLOQ).  The coefficent of 
variance (CV) per calibration level never exceeded the validation-criterion of 
< 15% CV (at LLOQ < 20%) and at 1.6% maximum. 
Sotalol - Serum d,l-sotalol concentrations were analysed using 96-well solid 
phase extraction/liquid chromatography-tandem mass spectrometry with a 
quantifiable range of 1.0 to 750 ng/mL with % CV ranging from 5.86 – 13.29 
and % accuracy ranging from 93.95 – 109.9 %.   
Moxifloxacin - Moxifloxacin was extracted from human plasma by solid-
phase extraction using Oasis HLB cartridges with moxifloxacin-d4 as an 
internal standard. Extracts are analysed by HPLC-MS/MS using a 
TurboIonspray interface and multiple reaction monitoring. This method has 
a lower limit of quantification (LLQ) of 25.0 ng/mL using a 50 μL aliquot of 
human plasma.  The analytical range was 25.0 – 5000 ng/mL.  A calibration 
standard was omitted if the back-calculated concentration deviates from 
actual by more than 20%.  Within and between-run precision, and accuracy 
of quantification during the validation was better than 9.62% across the 
concentration range.  
4.2.3.  ECG MONITORING AND SAMPLING 
Preclinical experiments 
The ECG waveforms were captured with DSI implants, with EMKA IOX 
(EMKA technologies, France). The data were recorded throughout the 
experiments. An EMKA ECG Auto analysis software (IOX EMKA technologies, 
France) was used for the analysis of cisapride, while the Notocord 
(Notocord-hem, KRN42a, Notocord, France) was used for d,l-sotalol and the 
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PONEMAH (Cardiovascular Toxicology Laboratory, Covance Laboratories, 
Greenfield, USA) was used for moxifloxacin. ECG scans were averaged every 
30 sec (cisapride), 1min (moxifloxacin), or 5 min (d,l-sotalol) and 
individually corrected for RR. The QT-intervals were capped if there was 
more than 10% difference between consecutive QT measurements. This was 
done to prevent telemetry equipment noise affecting the assessment of drug-
induced effects on QT-interval.  Capping of the data occurred mainly during 
feeding time (6h after dosing). 
Given the limited number of sampling points required for modeling 
purposes, somewhat sparse sampling times were subsequently extracted 
from the original recordings. Sampling windows were selected according the 
pharmacokinetic properties of each compound, in such a way that data were 
collected more frequently during the absorption phase and during peak 
concentrations. Each data point used in the pharmacokinetic-
pharmacodynamic analysis reflected the average of QT and RR observed 
during the corresponding sampling interval. In brief, the following sampling 
intervals were used:  
Cisapride - 0-2 h after dose: 2 min averaged intervals, 2-10 h after dose: 5 
min averaged intervals, 10-24 h after dose: 15 min averaged intervals.  
Sotalol - 0-10 h after dose: every 5 min averaged, and 10-24 h after dose:  
every 15 min averaged 
Moxifloxacin - 0-2 h after dose: 2 min averaged intervals, 2-10 h after dose: 5 
min average samples, 10- 47 h after dose: 15 min averaged intervals.  
Clinical protocols 
ECG monitoring was performed with 12-lead electrocardiogram, using 
Marquette ECG machines measuring QT, QTc[Bazett], QTc[Fridericia], RR, 
and HR for three compounds.  The time used to reference the ECG 
measurements were actual clock-time as recorded in the data collection 
forms, rather than the planned sampling time indicated in the study protocol.  
For each study, subjects were kept in a supine position while ECG recordings 
were made.   
In general, subjects in all three studies were restricted to the type and 
amount of beverages allowed during the study period.  Food in predefined 
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amount was served at strict times of the day.  Subjects were also asked to 
refrain from strenuous exercises.   
4.2.4.  PHARMACOKINETIC (PK) MODELLING 
Time matched concentration and QT-interval values were required for the 
assessment of the pharmacokinetic-pharmacodynamic relationships. 
Therefore, pharmacokinetic modelling and deconvolution techniques were 
used to generate the corresponding concentration values for each ECG 
sampling time. Pharmacokinetic modelling was performed using non-linear 
mixed effects techniques in NONMEM VI (ICON, Maryland, USA) for the 
clinical data and the d,l-sotalol preclinical data. For the preclinical 
pharmacokinetic modelling of moxifloxacin, NONMEM 7.1.2 (ICON, Maryland, 
USA) was used. Deconvolution was the method of choice  for the description 
of the cisapride data in dogs and was performed using deconvolution and 
noncompartmental analysis methods in WINNONLIN v4.1. (Pharsight, USA).  
Models used and parameters estimated are shown in Tables 2a and b for the 
three different compounds for dogs and human respectively. 
 Cisapride d, l-Sotalol Moxifloxacin 
Graphical 
representation 




estimated AUC**, T1/2** F*, Ka, V1, Vss, Cl, Q Ka, V1, V2, Q, Cl, F* 
BSV NA V1, Vss, Cl, Q Ka, V1, V2, Q, Cl 
Covariates NA NA NA 
Derived PK 
timepoints 
1-2hr: every    
2 mins, 




1-10hr: every 5 mins, 
10-24hr: every 15 mins 
1-2hr: every 2 mins, 
2-10hr: every 5 mins 
10- 47hr: every       
15 mins 
*F estimated separately per dose level **Derived using non-compartmental analysis 
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 Cisapride* d, l-Sotalol Moxifloxacin 
Graphical 
representation 





CL, Vc, Vp, Q, 
Ka, D0, ALAG, 
F 




CL, Vc, Vp, Q, 
Ka, D0, ALAG, 
F 
Ka, ALAG, CL, V, Q D1, Ka, CL, V2, V3, Q 
Covariates N/A Body weight, creatinine clearances N/A 
*Denotes parameters as reported in final clinical study report. 
Table 2b.  PK models used and parameters estimated for clinical protocols. 
4.2.5.  PHARMACOKINETIC-PHARMACODYNAMIC (PKPD) MODELLING 
Model building was performed in WinBUGS version 1.4.2 [16-19].  While the 
same model describing QTc-interval was created for all three compounds for 
both species, each analysis was conducted independently.   A Bayesian 
adaptation of a model comprising of three components: an individual 
correction factor for RR-interval (heart rate), an oscillatory component 
describing the circadian variation and a truncated Emax model to capture 
drug effects [13, 20], was used as presented in Equation1: 
 
        Equation 1 
where, QT0 [msec] is the intercept of the QT-RR relationship (sex was 
included as a covariate for this parameter), RR [sec] is the interval between 
successive R waves, α is the individual heart rate correction factor, A [msec] 
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[msec/concentration] is the linear pharmacodynamic relationship, and C is 
the predicted concentration of drug at the time of QT measurements. 
Priors 
The kth observed QT measurement for the jth occasion for the ith (QTijk) 
individual was assumed to be normally distributed around the individual 
predicted Qt measurement fijk with an unknown precision τ: 
 
 
Non-informative priors were specified as: 
 
 
where θ is a vector of population mean parameter estimates,  is the prior 
of the population means, Σ-1 is the precision of the prior for the population 
mean parameter values and I is the identity matrix.  The inverse of the 
between subject variance, Ω-1, arises from a Wishart distribution: Ω-1 ~W(ρΩ, 
ρ), with ρ=5 degrees of freedom, where Ω represents our prior guess at the 
order of magnitude of the covariance matrix.  Finally, non-informative 
Gamma (0.0001, 0.0001) priors were assumed for measurement precision 
and inter-occasion variability of QT0. 
Goodness -of-fit and modelling diagnostics 
Two MCMC chains were run for 25 000 samples and pooled to provide 
parameter estimates. The posterior distributions provided by WinBUGS 
allowed the model-predicted outcomes to be compared with the observed 
µ
2
1   ),,(~
σ
ττ =ijkijk fNQT
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values. Appropriateness of parametric distributions as well as the drug 
model was assessed using the deviance information criterion (DIC) as a 
measure of the goodness-of-fit [21, 22].  The number of iterations was 
deliberately chosen to exclude any residual correlation.  Further details of 
the model have been described elsewhere [15]. 
The R package R2WinBUGS was used to execute WinBUGS while running a 
session in R (The R project - http://www.r-project.org/). Convergence was 
assessed visually by monitoring the dynamic traces of Gibbs iterations and 
by computing the Gelman–Rubin test statistic [22-25]. 
4.2.6.  PROBABILITY OF QTC-INTERVAL PROLONGATION 
The analysis was performed with a step function in WinBUGS 1.4.3 using the 
slope and an inter-individual correction factor for gender differences (see 
Equation 2) at the following concentrations: 50, 200, 400, 600, 800, 1000, 
1200, 1400, 1600, 1800, 2500, 3000, 3500, 4000, 6000, 9000, 10000, 15000, 
30000nM.  Data was expressed in nano-molar (nM) to allow direct 
comparison of the different compounds. And the concentration steps were 
chosen to cover the sigmoid curve in an appropriate fashion,  
)  
C
10Slope01step(0.000  C)(at on prolongati  msec 10  ofy Probabilit F(Gender) ⋅⋅=≥
 
Equation 2 
where, C is the drug concentration, and slope is the QT increase per unit drug 
concentration.  
Values were plotted for all three compounds to compare the clinical and 
preclinical probabilities of drug induced QTc prolongation. By using the 
nano-molar unit, the potency of increasing QTc between compounds can be 
compared and used to create an interspecies correlation.   
To compare if there was statistically significant differences between the QTc 
prolongation per concentration unit in the different compounds and species, 
we performed Z-score tests, where the the means and standard deviations of 
the parameter estimates of the apriory distributions were used for the 
calculations.  
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4.3 RESULTS 
Pharmacokinetic (PK) models  
Given that most PK observations were at different time points compared to 
the ECG measurements or in a disproportionate fashion with the abundance 
of ECG recordings in dogs, it was necessary to perform PK modeling and 
simulation to obtain a balanced dataset for the subsequent PKPD analysis 
using the Bayesian approach. Each compound was modelled separately for 
each species, with exception of cisapride for which modelling attempts 
yielded unsatisfactory results in dogs, while time-matched pairs of 
concentration and ECG measurements were available in humans. Given the 
variability in the cisapride data and the scope of our analysis,  a 
deconvolution method was applied in dog data instead.  A summary for the 
parameter estiamtes are shown in Tables 3a and b for dog and humans 
respectively. Model performance is depicted in Figures 1b and 1c for d,l-
sotalol and moxifloxacin. Only the observed data and population averages 
are shown for cisapride in Figure 1a.  Details of the pharmacokinetic models 
are found in Tables 2a and b for dogs and humans respectively. 
Compound Cisapride   d, l-Sotalol Moxifloxacin 
Parameter estimates Median Min, Max Mean IIV% Mean IIV% 
             0.6 mg/kg 
 AUC   2.0 mg/kg 







- - - - 
T1/2 4.82 3.57, 7.57 - - - - 
Ka [/h] - - 1.41 - 1.78 - 
CL [L/h] - - 2.79 18.3 3.39 21 
Vss [L] - - - - 43.23 - 
V2 [L] - - 3.15 100 - - 
V3 [L] - - 21.8 15.8 - - 
ALAG [h] - - 1.41 - - - 
Q [/h] - - 16.5 35.4 - - 




-  - 
*F estimated separately per dose level 
Table 3a.  Summary of pharmacokinetic parameter estimates for cisapride,  d,l-sotalol, and moxifloxacin 
using preclinical protocols. 
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Compound Cisapride* d, l-Sotalol Moxifloxacin 
Parameter estimates Median min, max Mean IIV% Mean IIV% 
Ka [/h] - - 1.27 57.36 2.21 88.65 
D0 [/h] - - - - 0.629 85.14 
CL [L/h] 18 7.7, 33.1 9.39 17.15 13.4 12.69 
Vss [L] - - 147 12.73 - - 
V2 [L] 173.5 17.8, 255.1 - - 122 28.77 
V3 [L] 265.8 12.42, 1384 - - 55.4 44.27 
ALAG [h] - - 0.45 38.47 - - 
Q [/h] 34.1 10.1, 395.1 5.58 0 78.4 - 
F 0.75 0.47, 1 - - - - 
*Values for 20 mg dose. 
Table 3b.  Summary of pharmacokinetic parameter estimates for cisapride, d,l-sotalol, and moxifloxacin 
using clinical protocols.  
 
Figure 1a. Observed cisapride concentrations vs. time of a typical subject (upper panel) and observed 
population median concentrations vs. time (lower panel) for dogs (left) and humans (right).  
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 Figure 1b. Individual predicted d,l-sotalol concentration vs. time (top panels), population predicted d,l-
sotalol concentration vs. time (middle panels) and individual predicted d,l-sotalol concentrations vs. 
observed d,l-sotalol concentrations (lower panels) for dogs (left) and humans (right). 
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Figure 1c. Individual predicted moxifloxacin concentration vs. time (top panels), population predicted 
moxifloxacin concentration vs. time (middle panels) and individual predicted moxifloxacin 
concentrations vs. observed moxifloxacin concentrations (lower panels) for dogs (left) and humans 
(right). 
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Pharmacokinetic-pharmacodynamic (PD) modelling 
PKPD modelling was preformed using  the recorded ECG measurements and 
drug concentrations at the corresponding sampling time. If not available at 
the exact  sampling times, concentrations were imputed based on 
simulations and deconvolution techniques, as indicated above. Given the 
overwhelming amount of ECG recordings in dogs, data filtering was applied 
to ensure data sets of comparable  sizes were used in the joint analysis with 
clinical data. Data filtering was performed taking the absorption and 
disposition profiles into account, so that peak and elimination phase were 
accurately represented. The filtering scheme has been summarised in Table 
1a.  
System-specific parameters,  i.e. baseline QT (QT0), the QT-RR correction 
factor (α), the amplitude (A) and phase (Ф), all showed values within the 
same range within each species. The main difference was in the drug-specific 
parameter (slope) between compounds and also between dogs and humans.  
A summary of the analysis for each compound is presented in Tables 3a-c. In 
addition to the typical Bayesian criteria for parameter convergence and 
model acceptance  statistical criteria , graphical summaries using goodness-
of-fit plots (i.e., observed vs. predicted QT values) per compound and species 
are shown in Figures 2a-c. 
Parameters Dogs Total Drug (n = 7) 
Human 
(n = 24) 
QT0 [msec] 238 (237 - 240) 386 (382 - 390) 
α 0.26 (0.20 - 0.33) 0.18 (0.14 - 0.23) 
A [msec] 5.6 (3.9 - 8.1) 3.3 (1.1 - 5.95) 
φ [h] 19.9 (15.8 - 25.8) 4.3 (2.4 - 8.68) 
Slope [msec/conc] 0.0045 (0.00096 - 0.0098) 0.09 (0.087 - 0.12) 
BSV (QT0) % 6.49 (6.46 - 6.48) 2.23 (1.75 - 3.01) 
BSV (α) % 89 (47-190) 17.31 (11.48 - 26.95) 
BSV (A) % 7.14 (5.32 - 10.93) 6.52 (3.73 - 14.57) 
BSV (φ) % 7.08 (4.40 - 13.13) 19.04 (11.79 - 35.3) 
BSV (Slope) % 105 (66 - 180) 48.2 (21.94 - 93.5) 
Residual Error [msec] 5.8 (5.7 - 5.9) 11.66 (11.13 - 13.04) 
Prob Effect > 10 msec 
at Cmax 0.75 1.0 
Cmax [nM] 2808 936 
Table 4a.  Mean parameter estimates of the Bayesian pharmacokinetic-pharmacodynamic model for 
cisapride for dogs and human with 95% confidence intervals. 
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Parameters Dogs Total Drug (n = 5) 
Human 
(n = 30) 
QT0 [msec] 255 (253 - 257) 387 (383 - 392) 
α 0.18 (0.11 - 0.3) 0.27 (0.24 - 0.3) 
A [msec] 6.58 (2.09 - 19.78) 3.3 (2.4 - 4.29) 
φ [h] 12.15 (6.51 - 35.77) 6.22 (5.05 - 7.58) 
Slope [msec/conc] 0.002                               (0.0006 - 0.008) 
0.021                          
(0.017 - 0.026) 
BSV (QT0) % 6.25 (6.23 - 6.28) 5.08 (5.05 - 5.11) 
BSV (α) % 137 (55-410) 80 (54 -123) 
BSV (A) % 11.02 (8.9 - 17.3) 6.38 (4.08 - 10.15) 
BSV (φ) % 11.11 (4.73 - 30.70) 8.44 (13.98 - 24.24) 
BSV (Slope) % 36.8 (22.6 - 71.1) 108 (49.7 - 18.2) 
Residual Error [msec] 9.0 (8.8 - 9.3) 5.9 (5.68 - 6.14) 
Prob Effect > 10 msec at 
Cmax 0.9 1.0 
Cmax [nM] 22310 5605 
Table 4b.  Mean parameter estimates of the Bayesian pharmacokinetic-pharmacodynamic model for d,l-
sotalol for dogs and human with 95% confidence intervals. 
Parameters Dogs Total Drug (n = 8) 
Human 
(n = 137) 
QT0 [msec] 240 (238 - 242) 399 (394 - 403) 
α 0.28 (0.22 - 0.35) 0.40 (0.38 - 0.42) 
A [msec] 4.6 (3.1 - 7.0) 2.4 (1.7 - 2.9) 
φ [h] 23.1 (15.1 - 34.6) 10.0 (7.3 - 12.9) 
Slope [msec/conc] 0.00056                (0.00002 - 0.0014) 
0.0039                        
(0.0033 - 0.0044) 
BSV (QT0) % 6.46 (6.43 - 6.48) 5.01 (4.98 - 5.04) 
BSV (α) % 86 (48 - 177) 41 (33 - 52) 
BSV (A) % 9.8 (7.4 - 14.8) 5.3 (3.6 - 8.0) 
BSV (φ) % 13 (8 - 23) 18 (10 - 31) 
BSV (Slope) % 25 (17 - 39) 41 (29 - 53) 
Residual Error [msec] 9.4 (9.3 - 9.5) 5.3 (5.2 - 5.4) 
Prob Effect > 10 msec at 
Cmax 1.0 1.0 
Cmax [nM] 112930 10300 
Table 4c.  Mean parameter estimates of the Bayesian pharmacokinetic-pharmacodynamic model for 
moxifloxacin for dogs and human with 95% confidence intervals. 
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Figure 2a. Pharmacokinetic-pharmacodynamic relationship between QTc-interval and plasma 
concentrations of cisapride in dogs (left panel) and human (right panels).  The solid line represents the 
regression for the population predicted slope and intercept. Dots show the observed QTc-interval and 
the corresponding (predicted) individual concentration data. 
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Figure 2b. Pharmacokinetic-pharmacodynamic relationship between QTc-interval and plasma 
concentrations of d,l- sotalol in dogs (left panel) and human (right panels).  The solid line represents the 
regression for the population predicted slope and intercept. Dots show the observed QTc-interval and 
the corresponding (predicted) individual concentration data. 
124        Translational pharmacology of QTc-interval prolongation 
 
Figure 2c. Pharmacokinetic-pharmacodynamic relationship between QTc-interval and plasma 
concentrations of moxifloxacin in dogs (left panel) and human (right panels).  The solid line represents 
the regression for the population predicted slope and intercept. Dots show the observed QTc-interval 
and the corresponding (predicted) individual concentration data. 
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Translational pharmacology 
One of the main aspects our modelling exercise was to explore the predictive 
value of establishing PKPD relationships in dogs as basis for translating drug-
induced QTc-interval prolongation from animals to humans. As shown in 
Figure 3, the use of a common model parameterisation allowed direct 
comparison of drug-induced effects across species. As depicted by the 
goodness-of-fit plots showing individual observed vs. predicted QTc-
intervals, PKPD modelling showed similar performance in dogs and humans.  
Using Bayesian inference, it was possible to estimate the cumulative 
distribution of posterior samples for the differences between QTc baseline 
and QT after drug administration. The probability of QTc prolongation 
greater or equal to 10 msec was then calculated for each compound. 
Interestingly, the probability curve in humans clearly show a steeper 
increase across the therapeutic concentration range of each compound, 
indicating the risk of  greater or equal to 10 msec QTc prolongation at such 
exposure levels.  On the other hand, the probability of greater of equal to 10 
msec QTc prolongation reaches maximum value consistently at higher 
exposure in dogs than in humans, suggesting potential differences in the 
sensitivity to the QT-prolonging effects across species. 
 
Figure 3. Top panels - Individual observed versus predicted QTc-intervals for cisapride (left), d,l-sotalol 
(middle) and moxifloxacin (right) for dogs  and humans.  Bottom panels - Corresponding probability 
curves for QTc-interval prolongation > 10 msec versus predicted plasma concentrations for cisapride 
(left), d,l-sotalol (middle) and moxifloxacin (right).  Black dots and dotted lines represent values for dogs 
while grey dots and solid lines are  for human.   
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Significant differences were found in the slope parameters between the 
preclinical studies and clinical trials for all 3 compounds. The Z-scores were 
3.06, 4.47 and 8.26 for cisapride, d,l-sotalol and moxifloxacin respectively. 
4.4 DISCUSSION 
PKPD modelling 
In this study we have shown how a Bayesian hierarchical model can be used 
to describe the relationship between drug concentration and QTc-interval 
prolongation for cisapride, d,l-sotalol and moxifloxacin in conscious dogs, 
establishing their correlation with the pharmacological effects in humans at 
comparable exposure ranges. Thanks to the explicit distinction between 
drug-specific and system-specific parameters, our findings suggest that a 
model-based analysis of pharmacokinetic and QT-interval data in dogs 
allows inferences to be made about the probability of drug-induced QTc 
prolongation in humans.  
Although a direct comparison with published data is not possible, it seems 
that dogs are slightly less sensitive to the QT-prolonging effects, as indicated 
by the somewhat less steep slope of the concentration-effect curves and 
lower probability values observed at concentration levels relevant to human 
therapeutic use. It was also evident from the analysis, that accurate 
interpretation of the preclinical findings require some knowledge about the 
expected therapeutic range, which was known and well established for the 
three reference compounds. This is reflected by the estimates of the drug-
specific parameter in this model (slope), which does not independently 
indicate whether there is a risk associated with the use of the compounds, 
nor whether their development should be stopped. Rather, it provides an 
unambiguous description of the relationship between concentration and QT-
prolonging effects taking into account various sources of variability. 
From a drug development perspective our approach appears to overcome 
one of the main limitations of earlier PKPD modeling efforts in preclinical 
research, i.e., it offers the opportunity to distinguish drug-induced effects in a 
generic manner, enabling the use of the model for prospective evaluation of 
novel compounds.  Previous modelling attempts have focused on parameter 
estimation and goodness-of-fit to describe the observed data , rather than on 
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the use of models as a tool for predictive purposes [26, 27].  Some recent 
examples of model-based analysis of  QTc prolongation often do not correlate 
findings to preclinical effects in a direct and quantitative manner [26, 27].  As 
illustrated by Ollerstam et al., different PKPD models were required to 
describe preclinical and clinical data. In other cases, additional in vitro data 
was required to correlate findings across species [26].  Furthermore, the 
choice of parameterisation in these analysis does not allow for reuse of the 
model for a different compound or compound class [26, 27], defeating the 
main purpose of such models, i.e., their use as a screening tool in early drug 
development.   
Based on the evidence obtained so far, it appears that one of the most 
important factor for accurate translation of preclinical findings is the ability 
to evaluate drug effects across a clinically relevant exposure range.  
Inferences from extremely high dose levels, often used in toxicology 
experiments may lead to biased conclusions about the magnitude of the 
effect on QTc-interval and its clinical implication.  In addition, our 
investigation showed some critical shortcomings in current experimental 
protocols which prevent effective use of model-based approaches in early 
drug development.  Further consideration about these aspects are discussed 
in the subsequent paragraphs. 
Experimental design requirements 
The comparative analysis of preclinical and clinical data has provided the 
basis for further evaluation of the experimental requirements for the 
assessment of drug-induced QTc-interval prolongation using a model-based 
approach.  Clearly, the main shortcoming lies in the way preclinical safety 
experiments are designed, both in terms of dose range and sampling 
schemes.  Furthermore, the sample size should be considered more carefully 
when extrapolating estimates from preclinical safety experiments.  A 
traditional cardiovascular safety study in conscious dogs has a Latin square, 
four-way crossover design, using four animals only.  In this study we used a 
larger number of animals to ensure accurate parameter estimation, including 
estimates of between-subject variability. Yet, variability in dogs was found to 
be much larger than what is commonly observed in clinical trials.  Various 
procedural differences may explain such differences, including the fact that 
dogs are freely moving when performing the ECG scan, while subjects are 
resting in supine or semi-supine position in clinical studies [2].  
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With regard to the use of empirical sampling schemes, it should be noted that 
the choice for limited or sparse sampling (usually 3-8 samples) without clear 
understanding of the pharmacokinetic properties in the species of interest 
renders the assessment of PKPD relationships rather difficult and imprecise. 
Optimal design concepts could be used to prevent or overcome these issues 
[28, 29].  In conjunction with nonlinear mixed effects modeling techniques, 
optimal sampling can be implemented to eliminate some of the technical 
challenges due to serial or frequent sampling (e.g. interference with PD 
measurements, total volume of blood per animal). Sampling matrices can 
also be considered in which some blood samples are collected during ECG 
monitoring and additional samples are taken at a separate occasion after or 
before the actual safety experiment. Other important confounding factors for 
the analysis of PKPD relationships in dogs are variation in age, body 
temperature and body weight of the animals, which are not collected with 
the same accuracy as comparable covariates in humans.  Younger dogs have 
higher heart rates, thereby increasing overall noise:signal ratio and less 
precise baseline (intercept) QTc estimates  [30]. 
Translational modelling of QTc-interval prolongation. 
In drug development, the ideal situation of the prediction of drug-induced 
QTc prolongation would be if in vitro experiments would have a strong 
predictive value of the clinical outcome, both in qualitative (QTc prolongator 
or not) and quantitative (the amount of prolongation per concentration unit) 
terms.  The value of a qualitative correlation (trying to avoid false positive 
and false negative predictions of QTc prolonging compounds) has been 
demonstrated by De Ponti et al. and Redfern et al., [31, 32]. One of the main 
issues with such qualitative approaches is that the potential small QTc 
prolonging compounds are hard to place. Furthermore, the QTc prolongation 
per concentration unit reached in humans cannot be predicted, making it 
impossible to establish recommendations for dosing regimen that yield a 
‘safe’ QTc prolongation of less then 10 msec.  
Although our work has focused on the translation of in vivo data, the 
availability of predictive measures which take in vitro properties into 
account remain highly desirable. The possibility to make inferences from in 
vitro measures would imply the generation of less complex experimental 
data and decision making at an earlier stage of development. Consequently, 
 
    Chapter 4      129 
this could represent an opportunity for less attrition post candidate 
selection. 
We anticipate the possibility of further expanding the concept of a general 
model framework in which in vitro-in vivo correlations are assessed for 
different classses of compounds in terms of their ion-channel binding 
properties and used as ‘scaling factors or covariates on drug-specific 
parameters (i.e. the slope). In fact, we have undertaken an initial evaluation 
of such correlations by analysing hERG assay data for the same compounds 
(data not shown). However, hERG assay was found to yield extremely 
variable results, making the use of in vitro data unreliable without a 
standardised protocol.  As shown by Milnes et al., differences in experimental 
protocols have led to  IC50 estimates for cisapride between 7mM and 72nM 
[33].  Additional complexities can also be anticipated for drugs showing 
multiple ion channel blocking properties, such as cisapride [31, 34].  Another 
issue is that the in vitro experiments using hERG essays only, would not 
detect the effects of  Ca2+ channel blocking compounds.  Martin et al. showed 
the masking effect of the Ca2+ channel inhibition on the APD while there was 
a large hERG inhibition measured, giving a QTc shortening at higher 
concentrations after the QT prolongation at lower concentrations [35]. 
An important aspect of our analysis was the possibility to better understand 
the mismatch often observed between preclinical and clinical findings, which 
is referred to a false-positive or false-negative results. Our findings suggest 
that the assessment of QTc-interval prolongation using different 
experimental protocols in preclinical species appear to be meaningless 
without clear understanding of the underlying exposure and the 
corresponding therapeutic range. On the other hand, thanks to the use of 
PKPD relationships as a common denominator across species, it is possible to 
explain in a more systematic manner whether intrinsic differences exist 
between dogs and humans and how such differences may be related to 
known physiological factors. For instance, it is conceivable that the 
differences in Ikr channel distribution in the left ventricular wall of the canine 
heart [36] may lead to differences in repolarisation of the heart cells and 
consequently to a different degree of QT prolongation [37]. The other factor 
is the difference in basal heart rate, which is considerably higher in dogs.  To 
detect small differences in QT-interval, heart rate correction based on 
population-based correction factors, such as Bazett and Fridericia, may not 
be equally applicable to dogs [38, 39]. 
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Limitations of the approach 
Despite the clear correlation between dogs and humans as well as the 
goodness-of- fit, a potential limitation of our approach  is the fact that it relies 
on a linear regression for the assessment of drug induced QTc prolongation. 
The estimation of a slope contrasts with the more commonly used sigmoidal 
concentration-effect relationship. In clinical trials the Emax (the maximum 
QTc prolongation) will rarely be observed as arrhythmias because the 
subjects are already pulled from the trials due to ECG stopping criteria being 
reached (e.g. QTc > 500 msec). When the Emax cannot be estimated in a 
proper fashion, a small misspecification of this value will have a huge effect 
on the EC50.  As the difference of only 10 msec on a 400 msec average QT-
interval is needed to increase the risk on TdP, the error on the estimation of 
EC50 could imply false positive or false negative results. The use of this 
linear concentration-effect relationship will thereby be more accurate in the 
lower effect range.  
As highlighted previously, another limitation to this method is the 
requirement for higher quality data. When low quality data is used or 
sampling schemes are applied in an empirical manner, without taking into 
account drug absorption, distribution and elimination processes, the PK 
model misspecification can lead to to imprecision and consequently resulting 
in very wide confidence intervals for the slope parameter as derived in  
Equation 1.  
In summary, the possibility of extrapolating data on QTc-interval 
prolongation across species and using the concentration-effect relationships 
in terms of the risk of QTc-interval prolongation > 10 msec can greatly 
enhance the decision-making process for both the regulators and drug 
developers. In addition, our findings also show that accurate evaluation of 
the proarrhythmic potential of a novel chemical or biological entity cannot be 
performed without distinguishing drug-specific parameters from system-
specific parameters. In this sense, we envisage the use of this Bayesian 
approach as the basis for translational pharmacology research, particularly 
at the interface between drug discovery and early drug development, making 
it possible to assess the clinical relevance of drug-induced effects in 
preclinical species.  
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ABSTRACT 
Given the assumed risk of proarrhythmias, assessment of QTc-interval 
prolongation has become a mandatory step in drug development. 
Currently, however, experimental data are generated from randomised 
trials in healthy volunteers. The present study was performed to 
explore discrepancies between drug-induced QTc prolongation in 
clinical trials and real life conditions.  d,l-Sotalol was selected as a 
paradigm compound to illustrate the potential clinical implications of 
such differences. The Rotterdam Study cohort was used as the real life 
reference population. Using clinical trial simulation principles and 
nonlinear mixed effects modelling, we show that significant differences 
exist between the drug-induced increase in QTc-interval and observed 
QTc values. Furthermore, our analysis reveals that the increased 
prevalence of high QTc values in a real-life population is also due to co-
morbidities and concomitant medications, rather than treatment drug 
alone. These findings substantiate the need to account for these factors 
when evaluating cardiovascular risk of novel medicinal products.  
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5.1 INTRODUCTION 
In the last two decades, there have been increased concerns around the 
rising number of proarrhythmia cases due to non-antiarrhythmic drug-
induced QTc prolongation to the extent that it has been referred to as a 
modern “epidemic” [1].  Physiologically, the duration of the QT-interval of 
the surface electrocardiogram (ECG) represents the ventricular action 
potential duration.  As such, prolonged heart-rate corrected QT- (QTc-) 
interval may result in early after-depolarisations (EAD), which may induce 
re-entry, provoke torsade de pointes (TdP) and potentially lead to sudden 
cardiac death (SCD) [2, 3].  
Even though epidemiological evidence regarding the correlation between 
drug-induced  QTc-interval prolongation, risk of fatal arrhythmias and SCD 
remains under scrutiny [4, 5],  QTc prolongation has become the second 
most common cause for post-market drug withdrawal [6].  In other cases, 
severe prescribing restrictions have been imposed by regulatory agencies, 
which impacted on the indication of the drug, its posology, contraindications, 
special warnings and precautions for use, such as baseline and periodic on-
treatment ECGs monitoring. The requirements for information on drug-
disease and drug-drug interactions, full description of cardiotoxic adverse 
effects and their management as well as risk of overdose have also been 
affected [7].  Not only have the regulatory bodies started to closely monitor 
the liability for QTc-interval prolongation in the submissions of new chemical 
entities (NCE), guidelines have also emerged outlining the pre-requisites for 
the evaluation of drug-induced effects on heart conductivity and QTc-interval 
during drug development.  
The first regulatory guidelines regarding clinical evaluation of the QT/QTc-
interval prolongation in the context of new drug development were issued in 
1997 by the Committee for Proprietary Medicinal Products (CPMP) of the 
European Union [8, 9].  More recently, the International Conference on 
Harmonisation (ICH) Topic E14 guideline was published on the clinical 
evaluation of QT/QTc-interval prolongation and proarrhythmic potential for 
non-antiarrhythmic drugs [10].  The ICH guideline introduced the use of the 
“double-delta” method in a thorough-QT study (TQT) as the state-of-the-art 
approach for the assessment of QTc-interval prolongation. Furthermore, it 
recommends a TQT to be completed early in the drug development process 
to guide further studies and decision making. 
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From a methodological perspective, the TQT protocol design relies on the use 
of a positive control as well as supra-therapeutic doses of the investigational 
drug. The outcome of the analysis is based on the upper bound of the 95% 
one-sided confidence interval for the largest time-matched mean effect of the 
drug on the QTc-interval, which may not exceed 10 msec for the study to be 
deemed negative.  Whilst the validity as well as the sensitivity of the 
proposed methodology has been the subject of debate in numerous 
publications, less attention has been paid to other aspects of the preferred 
protocol design and interpretation of the findings, which overlook the 
underlying concentration-QTc effect relationship and consequently 
supporting evidence of causality [11, 12].  
Taking into account concentration-effect relationships, we explore the 
implications of the preferred protocol design for the assessment of 
cardiovascular risk under real life conditions. Although it may be 
understandable and desirable to characterise a drug safety profile in healthy 
subjects, we show how population selection and inclusion/exclusion criteria 
lead to a somewhat biased view of drug-induced effects in the target patient 
population which will receive the treatment after approval. The selected trial 
population, strict inclusion/exclusion criteria and experimental conditions 
may make the extrapolation of the findings to a real life population rather 
cumbersome. In particular, the exclusion of severely ill subgroups, i.e., those 
who are most susceptible to the potential undesired proarrhythmic effect, is 
usually not factored in a quantitative manner when evaluating TQT results. 
In addition, little attention is paid to the role of other factors contributing to 
QTc-interval prolongation in the target population, as compared to the 
observed drug effect in a randomised clinical trial involving healthy subjects.  
The current approach to clinical trials is also too focused on designs aimed at 
demonstrating efficacy. The number of subjects exposed to the NCE is 
powered to show benefit rather than to pick up signals from rare but 
potentially fatal adverse events and no formal procedures exist to mitigate 
the impact of such differences or support the management of cardiovascular 
risk in the target population.  Finally, many patient subgroups with higher 
risk factors for TdP are often excluded from the trials. These subgroups 
include females, elderly subjects, those with predisposed cardiac or non-
cardiac diseases associated with diminished repolarisation reserve (and 
therefore greater susceptibility to QT-interval prolongation), those with 
pharmacogenetic defects of drug metabolising enzymes or pharmacological 
targets such as the potassium channels, those susceptible to bradycardia or 
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electrolyte imbalance, or those receiving drugs with a potential for 
pharmacokinetic or pharmacodynamic interactions [13, 14].   
From a regulatory perspective, questions have also arisen about the 
efficiency and reliability of pre-approval clinical trials in identifying the 
clinical risk of torsade de pointes [12, 15].  Given the patient population 
enrolled, the background noise (arising from spontaneous intra-individual 
variability in QTc-interval) and the relatively low frequency of clinically 
significant drug–induced effects, clinical trials may or may not accurately 
detect the frequency and intensity of QTc-interval prolongation. In fact, it is 
known that the pro-arrhythmic threshold can vary across compounds with 
frequency of such events ranging from approximately 1 in 100 (for 
halofantrine) to 1 in 50000 (for terfenadine) [1].   
The evolving concepts in risk management will inevitably lead sponsors, 
regulatory agencies and other stakeholders to consider how to best evaluate 
causality and identify the contribution of other factors determining increases 
in QTc-interval and consequently in cardiovascular risk in the target 
population. In this investigation we characterise QTc-interval changes 
following administration of d,l-sotalol (paradigm compound) to healthy 
subjects in clinical trials and to patients in real life. Our investigation resorts 
to model-based drug development (MBDD) principles, as the development 
and application of pharmaco-statistical models of drug efficacy and safety 
from preclinical and clinical data, to improve drug development knowledge 
management and decision making [16, 17].  In contrast to typical clinical trial 
simulations [18-20], we make use of simulations to characterise the role of 
design factors which have been omitted or excluded from a randomised trial, 
among which those listed under the exclusion criteria or diverging from the 
clinical conditions relevant for the target population.  Thus, we anticipate 
that our approach will represent a natural extension of ongoing efforts 
within pharmaceutical industry to improve safety signal detection [21-25].   
5.2 METHODS 
Real life study population 
The real life population setting was derived from the Rotterdam Study. It is a 
prospective population-based cohort study, which started with a baseline 
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visit between 1990 and 1993.  All inhabitants of a suburb in Rotterdam, 
Ommoord, aged 55 years and over were invited to participate.  Of the 10 275 
subjects invited, 7983 (78%) gave their written informed consent and took 
part in the baseline examination. The study was approved by the Medical 
Ethics Committee of the Erasmus Medical Center, Rotterdam, The 
Netherlands.  Objectives and methods of investigation have been described in 
detail in other publications [35].  All participants were visited at home for a 
standardised questionnaire and 7151 were subsequently examined at the 
research center.  A second, third and fourth follow up visit took place, 
respectively, between 1993 - 1995, 1997 - 1999 and 2002 - 2004.  In addition 
to follow-up examinations, the cohort is continuously monitored for major 
morbidity and mortality through linkage with general practitioner and 
municipality records. Drug prescriptions dispensed to participants by 
automated pharmacies have been routinely stored in the database since 1 
January, 1991.  For the present study, we included all participants in the 
Rotterdam Study with at least two consecutive ECG assessments. 
All subjects who started treatment with d,l-sotalol during follow-up were 
included in the this study, with the exception of prevalent users and subjects 
with left ventricular hypertrophy (LVH), right bundle-branch block (RBBB) 
and left bundle-branch block (LBBB), who were excluded. The reason for the 
exclusion of these patients is that LVH, RBBB and LBBB can cause secondary 
repolarisation changes and atrial fibrillation can cause difficulties in 
measuring QT-intervals. From the remaining population, “new” d,l-sotalol 
users were identified as those receiving their first prescription after 
enrolment into the study.  Our analysis included all QTc measurements after 
the start of d,l-sotalol for all new users.     
During the research center visit, non-fasting blood samples were obtained 
[36].  Body mass index (BMI) was computed as weight divided by height 
squared. Comorbidities were screened and identified according to standard 
clinical criteria.  Hypertension was defined as systolic blood pressure > 160 
mm Hg or diastolic blood pressure > 100 mm Hg and/or use of 
antihypertensive medications, encompassing grade 2 and grade 3 
hypertension compounds according to the World Health Organisation (WHO) 
criteria [37].  Diabetes mellitus was defined as the use of blood glucose-
lowering medication and / or a non-fasting or post-load serum glucose level 
of 11.1 nmol/L or higher according to the WHO [38].  A history of myocardial 
infarction was assessed by self-report checked with records from the general 
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practitioner or cardiologist and/or electrocardiographic evidence.  All 
reported myocardial infarctions were verified against medical records as 
described in detail previously [39]. Assessment of heart failure at baseline 
and during follow-up was assessed by reviewing all medical records for the 
occurrence of at least two signs and symptoms suggestive of heart failure or 
the use of medication for the indication heart failure and hospital discharge 
letters. Cases of incident heart failure were obtained by continuously 
monitoring the participants [40, 41]. The ankle arm index (AAI) was used as 
potential predictor of cardiovascular diseases and mortality [42].  
Healthy volunteer study population 
A healthy volunteer clinical trial for d,l-sotalol was selected from 
GlaxoSmithKline’s clinical data repository (study number EXP20001).  The 
primary objective of this study was to assess the role of intrinsic and 
extrinsic factors on the variability of QTc-interval and was powered to detect 
a 10 msec increase in QTc according to the ICH E14 double-delta method. 
The study had a placebo-controlled, three-way crossover design with two 
placebo periods and one active treatment period.  Blood concentrations were 
taken at -30, 5, 15, 30 and 45 minutes relative to dosing time as well as 1, 2, 
4, 8, 10, 18 and 24 hours after dose.  The study population comprised of 30 
subjects (12 females, 18 males), between the ages of 19 and 47.   
Relevant eligibility criteria for inclusion into (items 1-3) / exclusion from 
(items 4-8) the study for the purposes of our investigation included: 
1. Age between 18-55 years, inclusive 
2. Non-smoker (subject must have been a non-smoker for at least 3 
months prior to screening) 
3. Body mass index between 19-30 kg/m2, with a weight of 50 – 95 kg, 
inclusive 
4. At screening ECG recording showed abnormal QRST complex 
morphology, sinus bradycardia (HR<45 bmp, PR > 210 msec) or QTc-
interval values above 420 or 440 msec for male and female, 
respectively. 
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5. Any medical history which was contra-indicated in the SOTACORTM 
product label 
6. History of hypertension, asthma, bronchial hyperactivity or 
peripheral vascular disease, including diabetes. 
7. The subject had a history of alcohol or drug abuse  
8. The subject was positive for HIV, hepatitis C or hepatitis B surface 
antigen 
Drug-induced QTc-interval prolongation  
The primary objective of this study was to identify differences in the baseline 
QTc-interval (i.e. before d,l-sotalol use) between target patient population 
and healthy volunteers. The simulation of QTc-intervals was performed in a 
two-step approach. First, drug concentrations in the target population (i.e., 
d,l-sotalol users) were derived using a pharmacokinetic model. QTc-intervals 
were subsequently obtained using final population pharmacokinetic-
pharmacodynamic (PKPD) parameter estimates. 
The pharmacokinetics of d,l-sotalol was described by a two compartment, 
first-order absorption model with weight as a covariate on clearance using 
nonlinear mixed effects modelling, as implemented in NONMEM (v5.1, ICON 
Development Solutions, Ellicott City, MD, USA) [43].  Heart-rate corrected 
QT-intervals were described by a PKPD model using a Bayesian approach in 
which physiological (QT and RR) and drug specific (concentration) 
parameters are parameterised in an independent manner (Equation 1)  [44].  






         
    Equation 1 
where, QT0 [msec] is the intercept of the QT-RR relationship. Sex was 
included as a covariate for this parameter whenever applicable. RR [sec] is 










    Chapter 5      147 
correction factor, A [msec] is the amplitude of circadian rhythm, t is the clock 
time, φ is the phase, slope [msec/concentration] is the linear 
pharmacodynamic relationship, and C is the predicted concentration of drug 
at the time of QT-interval measurements.  
Drug-induced QTc-intervals in the Rotterdam Study population were then 
simulated using the PKPD model, taking into account patient characteristics 
in the real life population. The QTc-interval distribution associated with d,l-
sotalol exposure in the reference population was simulated assuming full 
compliance to treatment. Population parameter estimates were used for the 
simulations (slope = 0.02 msec/ng/ml, intercept (QT0) = 380 msec).  Finally, 
QTc values in the Rotterdam Study population were compared non-
parametrically with the observed data. 
ECG measurements 
For the Rotterdam Study cohort, a 10 sec 12-lead ECG, resulting on average 
of 8-10 heart beats, was recorded with an ACTA electrocardiograph 
(ESAOTE, Florence, Italy) at a sampling frequency of 500 Hz and stored 
digitally.  All ECGs were processed by the Modular ECG Analysis System 
(MEANS) to obtain the ECG parameters of interest.  The MEANS program has 
been evaluated extensively and described elsewhere [45, 46].  MEANS 
determines common onset and offset for all 12 leads together for one 
representative averaged beat, with the use of template matching techniques, 
until the end of the T wave.  To adjust for heart rate, Bazett’s formula (QTc = 
QT / RR ^ ½) was used [47].  A total of 1387 digitally stored ECG records 
were used for this study. On the other hand, ECG measurements in healthy 
volunteers were recorded in triplicate and read manually from lead II by a 
blinded cardiographist. The average value from the triplicates was used for 
data analysis and development of the PKPD model.   
Statistical analysis 
Differences between clinical trials and real-life population: 
Observed and expected QTc-intervals were non-parametrically compared 
visually and statistically, by determining the significance of the differences 
between the two distributions.  Specifically, the Wilcoxon signed-rank test 
was used to evaluate if the distributions significantly differ from each other 
with p-value < 0.05.  
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Covariate effects:   
The relative risk (RR) and 95% confidence interval (CI) of the association 
between “prolonged” QTc, as defined as > 450 ms for males and > 470 msec 
for females, and  concomitant use of medications and presence of 
comorbidities while on d,l-sotalol prescription were estimated using Cox’s 
proportional hazards analysis [48].  At each ECG measurement, all 
information concerning medications and comorbidities was updated.  For the 
purpose of this analysis, each measurement from the same subject was 
treated independently since within-subject variability could not be 
considered in this analysis.  
5.3 RESULTS 
After applying the target population selection criteria to the Rotterdam 
cohort as described in the methods section, 608 subjects were classified as 
“new” d,l-sotalol users without left ventricular hypertrophy (LVH), right 
bundle-branch block (RBBB) or left-bundle-branch block (LBBB). The total 
accumulated follow-up was 4864 years (i.e., an average and standard 
deviation of 8 + 1.5 years/subject), during which they all had at least one ECG 
measurement. At the end, there were a total of 1375 available ECGs, with an 
average of two per person. Inclusion and exclusion criteria from the phase I 
d,l-sotalol trials were then applied to this subset to allow further 
characterisation of the differences between the real life conditions and the 
clinical trial protocols. Figure 1 reveals that 10.8% of the male population 
and 3.4% of the female population from the Rotterdam cohort, would have 
been excluded based on their weight values, which is a covariate used in the 
clinical pharmacokinetic-pharmacodynamic (PK/PD) model.  Similarly, 
21.9% male and 14.9% female would not be included due to their baseline 
QT-interval measurements (Figure 2). 
Pharmacokinetic and PKPD model parameters were used to simulate d,l-
sotalol concentrations and corresponding QT-intervals and to test if drug 
effects alone can explain the observed QTc values in observational real life 
cohort. Drug concentrations were simulated taking into account the 
individual weights of the elderly population. The simulated QTc-intervals (i.e. 
the expected QTc) were found to be at variance with the observed values 
(Figure 3), especially in the male population.  Using Wilcoxon T-test, the 
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results showed that the two distributions significantly differed from each 
other for both genders with p-values < 0.05.  The distribution of QTc values 
of the d,l-sotalol users in the real life elderly population revealed some 
dangerously high observed measurements.  The model-based predictions for 
a real life population demonstrated that drug-induced effects alone cannot 




Figure  1.  Weight distribution of males and females in the Rotterdam Study cohortt. 
 
 
Figure 2.  Baseline distribution of males and females in the Rotterdam Study cohort. 
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Figure 3. (a) Overlapping distributions showing the discrepancies between observed and simulated 
results in the male population (left panel) and female population (right panel).  The darker colour 
represents the simulated QTc values and the light colour represents the observed QTc-intervals. The 
medium shades denote the overlapping areas.  (b) QQ-plots comparing the distributions of the QTc-
values for male population (left) and female population (right). The deviation from the identity line 
reflects the residual difference between the observed QTc-intervals and model-predicted d,l-sotalol 
effects under the assumption of comparable pharmacokinetic-pharmacodynamic relationship, as 
determined in Phase I clinical trials. 
The differences between the two populations were evaluated by binary 
logistic regression, which revealed the contribution of concomitant 
medications and comorbidities as QTc-prolonging factors. It was found that 
heart failure, diabetes mellitus, myocardial infarction and hypertension 
increase the risks of a male having QTc >450 msec and female with QTc >470 
msec by 0.4-11.5 fold (Table 1). 












alone - < 0.01 4.0 (2.7 - 5.8) < 0.01 
Diabetes 4.0 (2.7 - 5.8) < 0.01 6.5 (1.6 - 27.1) < 0.01 
Heart Failure 4.4 (3.0 - 6.6) < 0.01 0.8 (0.2 - 3.4) > 0.01 
Hypertension 7.4 (4.3 - 12.7) < 0.01 2.4 (1.3 - 4.2) < 0.01 
Myocardial 
Infarction 3.4 (2.3 - 5.127) < 0.01 15.5 (4.9 - 49.3) < 0.01 
Table 1.  Results of relative risk calculations of the association between “prolonged” QTc and 
concomitant use of medications and presence of comorbidities while under d,l-sotalol prescription.  
Significance level was set at p < 0.05. 
5.4  DISCUSSION 
In the current investigation we have shown that population selection and 
inclusion/exclusion criteria applied to clinical protocols in early drug 
development may lead to significant differences between drug-induced and 
overall treatment effect size in the target population. Thus far, the evidence 
of pro-arrhythmia associated with QTc prolongation in real life patients has 
been primarily linked to drug-induced effects. On the other hand, the signal 
detected during a TQT study has been deemed sensitive enough to reflect the 
increase in cardiovascular risk associated with torsadogenic or 
arrythmogenic effects of a drug in the target patient population.  
Thanks to the use of a model-based approach it was possible to make 
inferences about drug exposure in patients and evaluate in an integrated 
manner, how different covariates and sources of variability affect the 
observed QTc values in real life patients. Our findings suggest that the 
distribution of observed QTc values in the real life cohort cannot be 
explained by the effects of d,l-sotalol alone. Other causal factors are present, 
which significantly affect the observed QTc values. In fact, previous 
publications showed that heart failure, hypertension, diabetes and 
myocardial infarction increase the risk of QTc prolongation [26-29]. The 
binary logistic regressions performed on our data revealed that diabetes, 
heart failure, hypertension and myocardial infarction are indeed risk factors 
for QTc prolongation in this population. In addition to comorbidities, we 
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have also identified statistically significant effects of co-medication, both of 
which contribute to upper tail of the distribution of observed QTc values.  
The concepts outlined in the current investigation also show how both 
clinical trial and epidemiological data can be used in an integrated manner 
for the purpose of signal detection and improved risk management. Our 
findings appear to confirm the points highlighted by Black on  “the false 
conflict between those who advocate randomised trials in all situations and 
those who believe observational data provide sufficient evidence needs to be 
replaced with mutual recognition of the complementary roles of the two 
approaches.” [30]  Others have also advocated the synergistic potential for 
using both kinds of data to aid decision making [31-34].  In the design of this 
study, we apply a parametric approach in which simulations play a central 
role. As a matter of fact, this is the first time that simulations based on 
nonlinear hierarchical models are used to characterise the implications of 
exclusion criteria on overall treatment safety profile. 
By applying PKPD modelling concepts to epidemiological data, we have also 
shown that the concentration-effect relationship achieved from a healthy 
volunteer trial cannot adequately describe nor predict what is actually 
happening in real life. The results from the present study suggest that new 
methodology is required to assess the impact of QTc prolongation in real life 
population for future compounds.  By extension, the relevance of a TQT 
study, as mandated in the ICH E14 guideline, becomes questionable. Our 
findings clearly challenge the validity of TQT trials as the state-of-the-art 
approach for determining the risk of pro-arrhythmia or TdP.  Indirectly, our 
analysis also reveals the shortcomings of the double-delta method currently 
suggested for the TQT studies. The use of time-matched differences between 
active and placebo arms does not allow the assessment of potential QTc 
prolongation in real life situations; as such calculations have no predictive 
value, nor can be parameterised for the purposes of non-random effects in 
clinical trial simulations. Another advantage associated with the use of a 
PKPD model is that even if the pharmacokinetics has been evaluated at 
supra-therapeutic levels, drug exposure can be extrapolated to reflect drug 
concentrations observed after therapeutic doses, so that accurate inferences 
can be made of the corresponding effect on QT-interval.  We also anticipate 
the importance of our approach to assess the characteristics of high-risk 
population subgroups by introducing such patients into simulation scenarios.    
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Despite the potential impact of a tool for "not-in-trial" simulations, the 
proposed approach in this investigation has some limitations. First, it should 
be noted that the population estimated parameters rather than the individual 
estimated parameters were used in the PKPD simulations.  This reduces the 
overall inter-individual variability that exists within a population.  In 
addition, an assumption was made that all the subjects in the Rotterdam 
cohort were fully compliant with medication consumption so that the same 
plasma concentration range is reached as those in the clinical trial. QT 
measurements in the Rotterdam Study cohort were taken during the d,l-
sotalol prescription. It was therefore assumed that the timing of the QT 
measurement as well as the differences in measurement equipment 
contribute to increased random variation without introducing significant 
bias. Fully automated machine read measurements were used in the 
Rotterdam cohort, whilst QT-intervals were manually measured by a 
cardiographist in the clinical trial.  
In summary, integration of clinical trial and epidemiological data reveals a 
flaw in the assumption that findings about drug effects in a clinical trial may 
be generalisable to the real life population. The assessment of concentration-
effect relationships was pivotal for estimating the contribution of drug-
induced increase in QTc-intervals.  Furthermore, the use of a hierarchical 
nonlinear mixed effects modelling enabled other causal factors to be 
incorporated into the evaluation of the overall treatment effect. Our findings 
show that accurate evaluation of safety requires understanding of treatment 
response of subjects who are "not-in-trial".  
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ABSTRACT 
Model-based techniques have become an established approach in drug 
development. Less attention however has been paid to the role of 
simulations for the evaluation of safety data, which is fraught with 
ethical and clinical hurdles. Here we materialise the implementation of 
Not-In-Trial Simulations as an inferential tool for predicting and 
translating drug-induced effects from clinical settings to real life 
situations.  We illustrate the concept using QTc-interval prolongation 
as example of safety concern for both industry and regulatory agencies. 
In a previous work, we have demonstrated that observed QTc 
prolongation in a patient population can be only partially explained by 
the underlying treatment effects.  Using a series of simulations, the 
current investigation shows how QTc-intervals can be modelled as a 
function of baseline QT-interval, drug exposure, concomitant 
medications and comorbidity conditions. Our method offers the basis 
for improved risk management, dissecting drug-specific contribution to 
pre- or post-approval safety findings.  
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6.1 INTRODUCTION 
Generating safety data that reflects the actual risk (and consequently 
risk:benefit ratio) for the target population during the course of drug 
development is fraught with practical and ethical hurdles, particularly if 
safety concerns regard low frequency or rare events. Such information can 
only be derived from epidemiological or pharmacoepidemiological studies, 
which are planned and performed after drug approval. Furthermore, 
inclusion and exclusion criteria are imposed on clinical trial protocols to 
mitigate risk and prevent the most vulnerable patients from exposure to an 
experimental agent for which the risk:benefit ratio is unknown at the time of 
the investigation. Subsequently, however, drug prescription is not restricted 
or contra-indicated for those patients who were excluded during the clinical 
development phase. Implicitly, such practice imposes the assumption that 
such inclusion/exclusion criteria do not alter treatment outcome. Inferential 
methods offer an opportunity to address this issue in a more quantitative 
and systematic manner. 
With the exception of signal detection methodologies used for 
pharmacovigilance purposes [1, 2], the integrated use of clinical trial and 
epidemiological data for the prediction and interpretation of safety findings 
in clinical drug development remains very limited [3, 4]. Simulation 
techniques can play an important role in the implementation of such 
methods. Unfortunately, the use of simulations has been rather limited in the 
evaluation of the safety profile whether in epidemiological cohorts or in 
randomised clinical trials [5]. 
Using a model-based approach that allows the integration of 
pharmacokinetic-pharmacodynamic relationships for the evaluation of drug-
induced QTc-interval prolongation, we illustrate the concept of Not-In-Trial 
Simulation (NITS) as an inferential tool for the quantification of the 
contribution of intrinsic and extrinsic factors on the risk of pro-arrhythmic 
events, i.e. QTc-interval prolongation.  In contrast to typical clinical trial 
simulations [6-8], we make use of simulations to characterise the role of 
design factors which have been omitted or excluded from a randomised trial, 
among which those listed under the exclusion criteria or diverging from the 
clinical conditions relevant for the target population.  Thus, our approach 
will represent a natural extension of ongoing efforts within the 
pharmaceutical industry to improve safety signal detection [9-15]. This 
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approach provides the pharmacological basis for the assessment of causality, 
discriminating drug-induced from other (drug-unrelated) effects.  
The objective of this study was therefore to show how clinical findings 
translate into real life observations and resolve some of the discrepancies 
commonly observed between pre- vs. post-market estimates of the pro-
arrhythmic effects associated with a new therapeutic agent. Drug-induced 
QTc-interval prolongation has become one of the most widely debated topics 
in the past decade [16-19], given its presumed association with increased 
risk for ventricular arrhythmias, which can potentially lead to sudden cardiac 
death [20, 21].  d,l-Sotalol was selected as a paradigm compound for the 
purposes of our investigation. Based on simulation scenarios we explain the 
impact and clinical implications of additional factors on QTc-interval 
prolongation for the real life population.   
Despite numerous efforts aimed at improving signal detection of 
cardiovascular events for new medicines [22-24], none of them has focused 
on what actually happens after the drug has been approved and released into 
the general population.  Although many post-marketing surveillance trials 
and spontaneous adverse events reporting have been used to monitor the 
incidence of (supra)ventricular arrhythmias, torsade de pointes and other 
safety events [25-27], there is still an important advantage to knowing what 
can be expected so that mitigation plans can be made in advance. Thus, we 
anticipate that our approach will widen the views on risk management 
beyond the evolving perspective from clinical pharmacology experts and 
regulators, i.e., that the liability for QTc-interval prolongation cannot be 
assessed accurately without an assessment of the concentration-effect 
relationships [28].  Not-In-Trial Simulations will enable quantitative 
evaluation of the implication of other factors contributing to QTc-interval 
prolongation in real life population, as compared to the observed drug effects 
in clinical trials.  Among various factors [15], our example reveals how 
gender [29], congestive heart failure [30] and baseline QT-intervals [31] can 
have equally important impact on treatment outcome. 
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6.2 METHODS  
Evaluation of the effect of age on QTc-interval 
Baseline information from seven healthy volunteer studies was used for the 
development of the relationship between baseline QTc-intervals and age.  
These data were combined with elderly patient data that were classified as 
healthy in the Rotterdam Study cohort described below.  The healthy elderly 
subjects were defined as those who were not on any medications and not 
have any comorbidity conditions recorded at the time of the ECG 
measurement.  Only the Bazett correction factor was used for the assessment 
of the effect of age on QT-interval due to the consistency availability of data 
across all datasets.  Other correction factors were not explored nor did we 
explore the effect of age on RR-intervals.  Finally, a quadratic regression was 
used to describe the age-dependent QTc data.  Based on the resulting 
parameter estimates, the regression was reduced to a linear relationship in 
R2.8 (The R project - http://www.r-project.org/). 
Evaluation of drug-induced effects in healthy volunteers 
Data from a Phase I healthy volunteer study with d,l-sotalol was selected 
from GlaxoSmithKline’s clinical data repository (study number EXP20001).  
The study was performed according to a placebo-controlled, three-way 
crossover design with two placebo periods. The study population comprised 
of 30 subjects (12 females, 18 males), between the ages of 19 and 47.  Other 
relevant eligibility criteria for inclusion into the study for the purposes of our 
investigation were non-smoking status, body mass index between 19-30 
kg/m2, with a weight of 50 – 95 kg, inclusive. Subjects with a history of 
hypertension, asthma, bronchial hyperactivity or peripheral vascular disease, 
including diabetes or previous alcohol or drug abuse were excluded at 
screening. In addition, subjects showing abnormal QRST complex 
morphology, sinus bradycardia (HR<45 bmp, PR > 210 msec) or QTc-interval 
values above 420 or 440 msec (for male and female, respectively) were also 
excluded. 
Modelling of  QTc-interval prolongation: 
The primary outcome of this study was to demonstrate the use of the Not-In-
Trial Simulation concept as a tool to quantify the contribution of additional 
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factors to QTc-interval prolongation.  The simulation of QTc-intervals was 
performed in a two-step approach. First, drug exposure in the target 
population (i.e., d,l-sotalol users) were derived using a pharmacokinetic 
model previously published [37]. Briefly, the pharmacokinetics of d, l-sotalol 
was described by a two compartment, first-order absorption model with 
weight as a covariate on clearance using nonlinear mixed effects modelling, 
as implemented in NONMEM (v5.1, ICON Development Solutions, Ellicott 
City, MD, USA) [38].  
Heart-rate corrected QT-intervals were described by a pharmacokinetic-
pharmacodynamic (PKPD) model using a Bayesian approach in which 
physiological (QT and RR) and drug specific (concentration) parameters are 
parameterised in an independent manner (Equation 1) [39].  A detailed 








where, QT0 [msec] is the intercept of the QT-RR relationship. Sex was 
included as a covariate for this parameter whenever applicable. RR [sec] is 
the interval between successive R waves, α is the individual heart rate 
correction factor, A [msec] is the amplitude of circadian rhythm, t is the clock 
time, φ is the phase, slope [msec/concentration] is the linear 
pharmacodynamic relationship, and C is the predicted concentration of drug 
at the time of QT-interval measurements.  
Drug-induced QTc-intervals in patients was simulated assuming full 
compliance to treatment. Population parameter estimates were used for the 
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Evaluation of effect of intrinsic and extrinsic factors on QTc-interval in real 
life patients 
Data from a real life population setting was obtained from the Rotterdam 
Study. The study is a prospective population-based cohort study, which 
started with a baseline visit between 1990 and 1993.  All inhabitants of a 
suburb in Rotterdam, Ommoord, aged 55 years and over were invited to 
participate.  Of the 10 275 subjects invited, 7983 (78%) gave their written 
informed consent and took part in the baseline examination. The study was 
approved by the Medical Ethics Committee of the Erasmus Medical Center, 
Rotterdam, The Netherlands.  Objectives and methods of investigation have 
been described in detail in other publications [40].  All participants were 
visited at home for a standardised questionnaire and 7151 were 
subsequently examined at the research center. A second, third and fourth 
follow up visit took place, respectively, between 1993 - 1995, 1997 - 1999 
and 2002 - 2004.  In addition to follow-up examinations, the cohort is 
continuously monitored for major morbidity and mortality through linkage 
with general practitioner and municipality records.  
All subjects who started treatment with d,l-sotalol during follow-up were 
included in the present study, with the exception of prevalent users and 
subjects with left ventricular hypertrophy (LVH), right bundle-branch block 
(RBBB) and left bundle-branch block (LBBB), who were excluded. The 
reason for the exclusion of these patients is that LVH, RBBB and LBBB can 
cause secondary repolarisation changes and atrial fibrillation can cause 
difficulties in measuring QT-intervals. From the remaining population, “new” 
d,l-sotalol users were identified as those receiving their first prescription 
after enrolment into the study. Our analysis included all QTc measurements 
after the start of d,l-sotalol for all new users.   
Comorbidities were screened and identified according to standard clinical 
criteria.  Hypertension was defined as systolic blood pressure > 160 mm Hg 
or diastolic blood pressure > 100 mm Hg and/or use of antihypertensive 
medications, encompassing grade 2 and grade 3 hypertension compounds 
according to the World Health Organisation (WHO) criteria [41].  Diabetes 
mellitus was defined as the use of blood glucose-lowering medication and / 
or a non-fasting or post-load serum glucose level of 11.1 nmol/L or higher 
according to the WHO [42].  A history of myocardial infarction was assessed 
by self-report, checked with records from the general practitioner or 
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cardiologist and/or electrocardiographic evidence.  All reported myocardial 
infarctions were verified against the medical records as described in detail 
previously [43]. Assessment of heart failure at baseline and during follow-up 
was assessed by reviewing all medical records for the occurrence of at least 
two signs and symptoms suggestive of heart failure or the use of medication 
for the indication heart failure and hospital discharge letters. Cases of 
incident heart failure were obtained by continuously monitoring the 
participants [44, 45]. The ankle arm index (AAI) was used as potential 
predictor of cardiovascular diseases and mortality  [46].  
The impact of co-medications and comorbidities were evaluated using a 
linear regression in R2.8 where the absolute differences in QTc prolongation 
between taking d,l-sotalol alone and in conjunction with co-medications and 
comorbidities were calculated with standard deviation.  The same evaluation 
was performed for non-users.   
ECG measurement in clinical trials and real life population  
A 10 sec 12-lead ECG, resulting on average 8-10 heart beats, was recorded 
with an ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sampling 
frequency of 500 Hz and stored digitally.  All ECGs were processed by the 
Modular ECG Analysis System (MEANS) to obtain ECG measurements.  The 
MEANS program has been evaluated extensively and reported elsewhere 
[47-49].  MEANS determines common onsets and offsets for all 12 leads 
together for one representative averaged beat, with the use of template 
matching techniques [48], until the end of the T wave.  To adjust for heart 
rate, Bazett’s formula (QTc = QT / RR ^ ½) was used [50].   
Not-In-Trial Simulation 
The final distribution of QTc values associated with all causal factors was 
simulated stepwise in R2.8. Differences between observed and expected QTc-
intervals were compared non-parametrically by visual inspection.    
6.3 RESULTS 
From the Rotterdam Study  cohort, 158 “new” d,l-sotalol users were 
identified which was defined as only those who have started a prescription 
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for the drug after the beginning of the study in 1990.    The final simulated 
QTc-interval (expected) distribution of the real life d,l-sotalol users is 
composed of four parts.  It is a cumulative function of age-dependent 
baseline QTc values, drug effects from d,l-sotalol, contribution from 
concomitant medication and comorbidity conditions as well as a between-
subject variability term.  The Bazett formula has been used throughout this 
study for the heart rate-corrected QT values as this was a consistent output 
between various data used for the investigation.   
Age-dependent baseline QTc values 
Using all the available baseline QTc values for healthy subjects in this study, a 
linear relationship was found to best describe the data.  The results are also 
separated by gender because of the known differences in cardiac outputs 
between men and women [32].  The correlation between age and baseline 
QTc was modelled according to equations: QTc = 0.5096(Age) + 386.52 for 
the male population and QTc = 0.8617(Age) + 371.34 for the female 
population as captured in Figure 1.  
 
Figure 1.   The relationship between age and healthy baseline QTc values, separated by gender. 
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PKPD modelling of QTc-interval prolongation 
Pharmacokinetics (PK) was modelled separately where it was found that a 
two compartment model best described the time course of concentrations in 
plasma. The absorption phase was characterised by a lag time, and 
furthermore, it was found that body weight had a significant effect on the 
volume of distribution.  The PKPD model, shown in Figure 2, allowed the 
system-specific parameters (i.e., those related to the individual correction for 
the QT-RR relationship and circadian rhythm) to be estimated separately 
from the drug-specific parameters (i.e., drug-induced QTc-interval 
prolongation).   
 
Figure 2. Pharmacokinetic-pharmacodynamic relationship of d,l-sotalol in healthy subjects following 
administration of 160 mg. 
Effects of concomitant medications and comorbidity conditions 
Linear regression calculations assessing the impact of various concomitant 
medications and comorbidity conditions revealed different increase of QTc 
values in milliseconds.  There was also no interactions found between d,l-
sotalol and any of the conditions, thus the results found with the users and 
non-users were not statistically different.  Since the power for the non-user 
group was greater, the results were used in the simulation and the increase 
in QTc values are summarised in Table 1. 
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 Increase in QTc [msec] 
 Male, (CI) Female, (CI) 
Heart Failure 7.7 (+/- 4.02) 5.8 (+/- 3.49) 
Myocardial Infarction 3 (+/- 2.11) 3.2 (+/- 2.31) 
Arrhythmia 18.5 (+/- 9.24) 20.4 (+/- 9.51) 
Diabetes 3.0 (+/- 2.28) 5.4 (+/- 2.0) 
 
Table 1.   Increase in QTc [msec] due to various concomitant medications and comorbidity conditions 
Not-In-Trial Simulation 
The newly proposed Not-In-Trial Simulation model yielded the results 
shown in Figures 3a-f.  First using the ages of the 158 real life d,l-sotalol 
users in the Rotterdam Study, the baseline QTc values were simulated 
(Figure 3a) using age-dependent relationships shown above.  In Figure 3b, 
the baseline QTc distributions of the real life population is compared with 
the baseline distributions from the Phase I clinical trial of healthy volunteers.  
From the comparison, it was found that there were discrepancies of 33 msec 
and 29 msec in male and female respectively.  Then the effect of d,l-sotalol 
was added to the baseline distributions of the real life population.  The QTc 
values were shifted by 22 msec in both genders in Figure 3c.  Afterwards, 
taking the comorbidity and concomitant medications of the real life d,l-
sotalol users were taken into consideration, the mean QTc values were 
increased by 3 msec in the male population and 1 msec in the female 
population (Figure 3d).    In Figure 3e, the between-subject variability 
boundaries around the QTc distributions were added, which has until now 
been constructed using only the mean values from each step.  Finally in 
Figure 3f, the observed QTc values from the 158 d,l-sotalol users were 
superimposed onto the simulated distributions.  It can be visually confirmed 
that real life observed QTc measurements fell within the boundaries of the 
final simulated QTc distributions along with the between-subject variability 
found in the age-dependent baseline values.   
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Figure 3.   Overall simulation model results (a-f).  The left panel depicts results for the male population 
and female outcome is shown on the right.  The lighter colours represent the actual observed QTc values 
as recorded in the Rotterdam Study while the simulated results are superimposed in a darker colour.  
The Gaussian distribution curve represents the lower and upper bound of the between-subject 
variability in baseline values. 
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6.4 DISCUSSIONS 
In contrast to current practice which relies on the evidence from a thorough 
QTc study for the assessment of the risk of pro-arrhythmic events, we 
present a model-based approach for the characterisation of drug-induced 
effects which enables explicit assessment of causality, distinguishing drug-
related effects from other factors contributing to the QTc-interval 
prolongation, namely that, QTc (real life population) = age-dependent 
baseline QTc values + fluctuation in QTc due to drug effects + effects on QTc 
due to concomitant medications and comorbidity conditions.   
Although QT-interval prolongation is not necessarily harmful, it is at present 
perhaps the best and only surrogate marker for torsade de pointes, 
especially so because the definition of this arrhythmia requires prolongation 
of QT-interval as a preceding event.  The crucial question from regulatory 
perspective is “How efficient and reliable are the pre-approval clinical trials 
in identifying the clinical risk of torsade de pointes, given the patient 
population enrolled, background noise arising from spontaneous intra-
individual variability in QTc-interval and the relatively low frequency of the 
clinically significant drug-induced effect” [33].  For a variety of reasons, 
clinical trials may or may not detect the frequency and intensity of QT- 
interval prolongation but they are most unlikely to detect the risk of torsade 
de pointes.  Firstly, safety trial designs are highly efficacy-oriented.  Secondly, 
the number of patients exposed to the drug in the pre-approval phase is not 
large enough to detect a relatively rare but potentially fatal risk.  Thirdly, 
many subgroups of patients most at risk of torsade de pointes during the 
uncontrolled clinical use to the drug in question are usually excluded from 
these trials.  These subgroups include: females; the elderly, those with 
predisposing cardiac or noncardiac diseases associated with diminished 
repolarisation reserve (and therefore greater susceptibility to prolongation 
of the QT-interval); those with pharmacogenetic defects of drug metabolising 
enzymes or pharmacological targets such as the potassium channels; those 
susceptible to bradycardia or electrolyte imbalance; or those receiving drugs 
with a potential for pharmacokinetic or pharmacodynamic interactions.  
Therefore the scope for detecting drug-drug or drug-disease interactions in 
clinical trials is also very limited.  And yet, experience has shown that these 
are among the most important risk factors. 
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Based on the aforementioned, one may question whether conducting the 
thorough-QT (TQT) studies yield the best indicator of risk for new 
therapeutic agents.  This regulatory practice is further challenged by 
increasing clinical evidence that there is no fixed relationship between the 
extent of QT-interval prolongation and the risk of a patient developing 
torsade de pointes [34].  
Our findings show that baseline QTc values are age and gender dependent. 
This correlation plays an important role in that observed QTc values will 
increase over time irrespective of drug treatment. Drug effect and 
comorbidity conditions also contribute to further increase in QTc values.  In 
this study, simulation scenarios were implemented in such a way that all 
relevant causal factors affecting QTc prolongation are combined in an 
integrated manner. It is envisioned that this approach may provide more 
accurate estimates of cardiovascular risks and enable mitigation of these 
risks in the target population, preventing future drug-withdrawal due to 
cardiovascular safety. 
Limitations 
In this study we have successfully demonstrated the concept of Not-In-Trial 
Simulation.  However, there are limitations in this present study that should 
be mentioned as this is the first attempt at realising the idea of using 
simulation as a technique to translate real life observations using clinical 
trial findings.  First and foremost is the lack of hierarchical modeling 
techniques used in estimating the relationship between age and QTc values 
as well as the increase due to comorbidity conditions and concomitant drugs 
which can affect the accuracy or precision of effect sizes and the parameter 
estimations.  Currently, we can verify that our simulation encompasses the 
range of values in real life situations, but to be able to improve the precision 
of the parameter estimations would lead to more confidence when 
performing the simulations for future compounds prospectively.   
Another limitation to this study is that the age-QTc relationships in healthy 
subjects as well as the contributions from comorbidities and co-medications 
are limited to only the datasets used presently.  This approach would no 
doubt benefit from a larger database to improve all the parameter estimates. 
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Model-based risk management  
Currently, both the US and Europe regulatory agencies have produced 
guidelines that outline efforts in managing the safety and risk of pre- and 
post-market  medical products [35, 36].  Enhancing internal and external 
epidemiologic and informatics capabilities, strengthening methods and tools 
of safety surveillance, developing and incorporating new quantitative tools in 
the assessment of benefit and risk are examples of ongoing activities.   
To date, recommendations on how best to detect safety signals such as the 
introduction of the thorough-QT studies are being published.  However, 
utilising modeling and simulation techniques as a quantitative tool to assess 
clinical relevance prior to implementation of mitigation measures or 
eventually as basis for appropriate recommendations is still not adequately 
advocated.   
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ABSTRACT 
Previously, a tool was developed to translate clinical trial findings to 
real life settings by resolving the discrepancies between pre- vs. post-
market estimates of QTc-interval prolongation using d,l-sotalol as the 
paradigm compound.  The tool consisted of a prediction model for QTc 
measurements based on baseline values, QTc model for drug effect from 
clinical population and effects of concomitant drugs and comorbidities.  
The objective of this study was to apply the same model to cisapride, as 
a form of external model validation.  There were 87 new cisapride 
users in the Rotterdam Study cohort (60 female and 27 male) with the 
average observed QTc of 432.4 msec and 423.5 msec for women and 
men respectively.  The average simulated QTc for female was 435.8 (sd. 
15.83) and 424.1 (sd. 19.5) for male.  It was verified that same tool can 
be used to predict real life QTc values for cisapride users gaining 








    Chapter 7      183 
7.1  INTRODUCTION 
One of the main objectives of clinical trials is to test whether a new chemical 
entity (NCE) is efficacious towards the condition it is targeted to treat and 
whether it is safe for human usage.  Together, evidence on efficacy and safety 
allow for the assessment of the expected risk-benefit ratio [1].  However, 
such estimates are only readily available for events which occur frequently 
enough, i.e. those with high incidence.  Less frequent or rare events require 
larger populations or longer trials and are usually evaluated during the post-
approval phase [2].  On the other hand, there are cases in which it is not the 
frequency of an adverse event, but its magnitude that cannot be accurately 
determined during the clinical development phase.  In these circumstances 
the observed risk-benefit ratio may not reflect the actual implications of the 
therapeutic intervention in the target population; QTc-interval prolongation 
is an example of such a case.  
QTc-interval has been considered a risk factor for torsade de pointes (TdP), 
and has become a major cause for drug withdrawal [3].  Mitigation measures 
have been implemented by the International Conference on Harmonisation 
(ICH) [4], which  proposes the use of thorough-QT (TQT) studies to detect 
QTc-interval prolongation as part of the clinical evaluation package for 
regulatory submissions.  Despite these efforts, important limitations are 
being overlooked because of the mandatory status these studies have.  In 
addition to the lack of quantitative evidence, i.e., the absence of explicit 
details on the underlying concentration-QTc effect relationship, the current 
approach often relies on data from healthy subjects who are enrolled 
according to strict inclusion / exclusion criteria, which does not necessarily 
reflect the demographic characteristics in the patient population.  Moreover, 
in a TQT trial, supra-therapeutic levels of the drug are used under the 
assumption that the resulting effects would be representative of the risk in 
patients, who may be more vulnerable or sensitive to the pro-arrhythmic 
effects. 
Nonetheless, mounting evidence suggests that current TQT protocols may 
provide biased estimates of the actual risk of QTc-interval prolongation, with 
high rates of false positive results due to the accepted data analysis method 
[5]. These findings raise important questions both from a drug development 
and from a pharmacovigilance perspective.  It is in everyone’s best interest to 
ensure accurate assessment of the risk-benefit ratio, so that decision making 
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regarding the development, approval or risk management is effective and 
timely. 
Recently, to address this issue we have developed a model-based approach 
that allows better translation of clinical trial findings into real life conditions.  
Thanks to the use of a Bayesian hierarchical model, it is possible to integrate 
pharmacokinetic-pharmacodynamic relationships with disease and other 
patient-specific characteristics, discriminating drug-induced effects under 
controlled and uncontrolled conditions [6].  In fact, we have shown that the 
use of model parameter estimates in conjunction with Not-In-Trial-
Simulations (NITS) provides a framework for evaluating drug vs. disease-
specific properties, which facilitates the assessment of causality.  
Unfortunately, those who defend the status quo, i.e., the requirement for a 
TQT study as the best approach to gather evidence on the propensity for 
QTc-interval prolongation, continue to use patient safety as a cogent 
argument for adhering to current practices.  There is an urgent need to 
consider alternative methods which do not only ensure lower false positive 
rates, but also provide accurate estimation of the pro-arrhythmic risk taking 
into account other factors relevant to the target population in clinical 
practice.  Essentially, there needs to be an increase in operational 
effectiveness in drug development. We envisage therefore the use of a Not-
In-Trial Simulation as a risk management tool for the evaluation of causality 
and assessment of the impact of mitigation measures as shown in Figure 1.  
 
Figure 1.  Not-In-Trial Simulation can be used as a framework for risk management and assessment of 
the impact of mitigation measures. Most importantly, it provides quantitative estimates of the 
contribution of drug-related vs. drug-unrelated factors. 
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In a previous publication we have shown that the method resolves the 
discrepancies in pre- vs. post-market estimates of QTc-interval prolongation.  
d,l-Sotalol was used as the paradigm compound in which QTc changes are 
described as a function of baseline QTc measurements, drug-induced effects, 
and contributions of concomitant drugs and comorbidities.  Furthermore, the 
model also demonstrated that the relationship between exposure and QTc-
interval is best characterised in terms of drug concentrations rather than the 
traditional concept of defined daily dose (DDD) in epidemiology studies.  The 
objective of the current investigation is therefore to demonstrate the 
generalisability of the approach to other areas of drug development by 
performing an external validation.  External validation is an essential step for 
the use of predictive or prognostic tools in clinical practice [7]. 
Here we apply hierarchical modeling and Not-In-Trial Simulations to 
characterise the impact of pro-arrhythmic effects of cisapride in real life 
conditions.  Cisapride is a gastroprokinetic agent which is used to increase 
motility in the upper gastrointestinal tract.  It was first introduced in 1990 
after showing promising clinical trial results in healing and producing 
symptomatic improvement among patients with esophagitis [8-12] as well as 
improving symptoms among those with symptomatic heartburn [13, 14], 
preventing the provocation of heartburn by a fatty meal in susceptible 
individuals [15] and reducing relapse rates among those with healed 
esophagitis [16].   
From a safety perspective, evidence including post-marketing data from two 
study groups totaling over 23 000 patients suggested that the drug was safe, 
with diarrhea, abdominal pain, nausea or vomiting, headache and 
constipation being the most frequent reported adverse events [17].   
Furthermore, serious cardiac rhythm disorders were not found to be 
associated with cisapride use in a review of almost 37 000 patients who were 
prescribed cisapride in the UK and Canada [18].  However, reports of cardiac 
events began to accumulate, beginning with a report of palpitations [19], 
followed by culmulating instances of unusual tachyarrhythmia, torsades de 
pointes, ventricular fibrillation and sudden death [20].  Eventually, it came to 
be recognised that cisapride use could result in the prolongation of the QT-
interval and, thereby increasing the risk of arrhythmia.  It was later revealed 
that cisapride’s arrhythmogenic potential existed at the cellular and 
molecular level. In in vitro studies, cisapride was found to be a potent and 
dose-dependent blocker of the human ether-a-go-go-related gene (hERG) 
186        Validation of Not-In-Trial Simulation 
channel [21], which is the main channel responsible for the repolarisation 
phase of the cardiac action potential [22].   
In 1995, a black box warning contraindicating the use of cisapride among 
those taking drugs that affected its metabolism was issued by the FDA; at 
that time thirty-four cases of torsades de pointes, twenty-three of prolonged 
QT-interval and four deaths had been reported (103).  A further warning was 
issued in 1996 regarding to its use with medications that also prolonged the 
QT-interval and in patients with conditions that predisposed to cardiac 
arrhythmias.  The black box warning was again expanded in 1998.  However, 
the subsequent realisation that serious adverse cardiac events could occur 
even among low-risk groups, including children, coupled with the 
documentation of continued cisapride use in contraindicated situations 
(112) led to the withdrawal of the drug worldwide in July 2000.  Thus 
cisapride is an example, given its sensational rise and demise, where a tool 
should be in place that can anticipate events, such as QT-interval 
prolongation, in the future for new compounds in clinical development. 
7.2  METHODS  
Evaluation of the effect of age on QTc-interval 
Baseline information from healthy subjects participating in seven Phase I 
studies was used for the development of the relationship between baseline 
QTc-interval and age.  The meta-data consisted of approximately 1000 
subjects.  These data were combined with elderly patient data that were 
classified as healthy in the Rotterdam Study cohort described below.  The 
healthy elderly subjects were defined as those who were not on any 
medications and not have any comorbidity conditions recorded at the time of 
the ECG measurement.  The Bazett formula was used as the RR correction 
factor for QT-intervals as it was a consistent output for all the data used in 
the study.  Only QTc values vs. age relationship was explored for this analysis 
while the effect of age on RR-interval was not explored.   
In the original simulation model, a quadratic regression was used to describe 
the age-dependent QTc data.  Based on the resulting parameter estimates, 
the regression was reduced to a linear relationship in R2.8 (The R project - 
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http://www.r-project.org/), where QTc = 0.5096(Age) + 386.52 for the male 
population and QTc = 0.8617(Age) + 371.34 for the female population. 
ECG measurement in clinical trials and real life population  
A 10 sec 12-lead ECG, resulting on average 8-10 heart beats, was recorded 
with an ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sampling 
frequency of 500 Hz and stored digitally.  All ECGs were processed by the 
Modular ECG Analysis System (MEANS) to obtain ECG measurements.  The 
MEANS program has been evaluated extensively and reported elsewhere 
[28-30].  MEANS determines common onsets and offsets for all 12 leads 
together for one representative averaged beat, with the use of template 
matching techniques [29], until the end of the T wave.  To adjust for heart 
rate, Bazett’s formula (QTc = QT / RR ^ ½) was used [31].   
Evaluation of drug-induced effects in healthy subjects 
Data on the pharmacokinetics and pharmacodynamics of cisapride was 
derived from a randomised, placebo-controlled, dose-escalating Phase-I trial 
with up to 6 sessions. The primary objective was to assess the cardiovascular 
safety of single doses of 10, 20, 40, 80, 130 and 200 mg cisapride.  Secondary 
objectives were to determine the pharmacokinetics of cisapride at these 
single doses, to search for a correlation between pharmacokinetics and 
cardiovascular parameters, and to evaluate an experimental beat-to-beat 
computerised analysis of electrocardiograms (ECGs) recorded by Holter 
monitoring in comparison with the analysis of traditional 12-lead timed ECGs 
taken at pharmacokinetic blood sampling times.  Subjects were randomised 
in 4 blocks to treatments so that for each block and for each dose, 5 subjects 
received cisapride and 1 subject received placebo.  There was a 48-hour 
wash-out interval between consecutive doses. A total of 24 healthy subjects 
participated in the trial.  The dose escalation was stopped after dosing with 
130 mg cisapride (or placebo) on Day 9, because of the investigator’s medical 
judgment of a potential risk if dose escalation would proceed to the highest 
dose level of 200 mg of cisapride.  
Other relevant eligibility criteria for inclusion into the study for the purposes 
of our investigation were non-smoking status and body mass index between 
18-28 kg/m2, inclusive. Subjects with a history of syncope and a family 
history of sudden death or long QT syndrome were excluded at screening. In 
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addition, subjects showing an increase in number of premature ventricular 
beats at a heart rate of >120 bpm, >500 premature ventricular beats per 24 
hours, abnormal STU dynamics, a RR-interval > 3 sec, an average heart rate < 
50 bpm or > 95 bpm, apparent QT prolongation, ventricular tachycardia of 
>3 beats at a rate of 100bpm, QRS-interval > 0.12 sec, apparent ST 
abnormalities, second degree atrioventricular block, supraventricular 
tachycardias with rates > 150 bpm, QTc-intervals above 450 or 430 msec (for 
male and female, respectively) were also excluded. 
Modeling of QTc-interval prolongation 
The pharmacokinetic model (PK) as well as the pharmacokinetic 
pharmacodynamic (PKPD) model of cisapride was taken as reported from 
the analysis report for the study to demonstrate that Not-In-Trial 
Simulations can be applied to the current workflow.  In the report, it was 
indicated that the models were fitted to the data using NONMEM V software 
version 1.1, by applying the first-order conditional estimation (FOCE) 
method. The package was installed on a PC platform using Compaq Visual 
Fortran version 6.6 under Microsoft Windows 2000. 
A two-step sequential approach was adopted, including a pharmacokinetic 
modeling step followed by a pharmacodynamic modeling step.  The 
pharmacokinetic model included a two-compartment disposition and a 
sequential zero- and first-order absorption with a lag time.  The relationship 
between cisapride concentration in plasma and heart rate, RR-interval, 
uncorrected QT-intervals, corrected QT-intervals using the Bazett and 
Fridericia formulas as well as other correction formulas, was explored 
graphically, and by means of linear regression. 
The ECG parameters were fitted linearly on the cisapride concentrations.  
The regressions were based on the ECGs taken immediately before the 
corresponding pharmacokinetic blood sampling.  Plasma concentrations that 
were below the lower limit of quantification (5 ng/mL) were replaced by 
zero.  Since both heart rate and QT-interval tended to increase with higher 
cisapride concentrations, all QT corrections also increased with 
concentration. The tests for the model parameters were always statistically 
significant (p=0.0001), indicating that the relationship between ECG 
parameters and cisapride concentrations was most likely not an observation 
by chance. 
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Drug-induced QTc-intervals in patients was simulated assuming full 
compliance to treatment. Population parameter estimates were used for the 
simulations (slope = 0.179 msec/ng/ml, and intercept (QT0) = 393.5 msec).  
Evaluation of the effect of intrinsic and extrinsic factors on QTc-interval in 
real life patients 
Data from a real life population setting was obtained from the Rotterdam 
Study. The study is a prospective population-based cohort study, which 
started with a baseline visit between 1990 and 1993.  All inhabitants of a 
suburb in Rotterdam, Ommoord, aged 55 years and over were invited to 
participate.  Of the 10 275 subjects invited, 7983 (78%) gave their written 
informed consent and took part in the baseline examination. The study was 
approved by the Medical Ethics Committee of the Erasmus Medical Center, 
Rotterdam, The Netherlands.  Objectives and methods of investigation have 
been described in detail in other publications [32].  All participants were 
visited at home for a standardised questionnaire and 7151 were 
subsequently examined at the research center. A second, third and fourth 
follow up visit took place, respectively, between 1993 - 1995, 1997 - 1999 
and 2002 - 2004.  In addition to follow-up examinations, the cohort is 
continuously monitored for major morbidity and mortality through linkage 
with general practitioner and municipality records.  
All subjects who started treatment with cisapride during follow-up were 
included in the present study, with the exception of prevalent users and 
subjects with left ventricular hypertrophy (LVH), right bundle-branch block 
(RBBB) and left bundle-branch block (LBBB), who were excluded. The 
reason for the exclusion of these patients is that LVH, RBBB and LBBB can 
cause secondary repolarisation changes and atrial fibrillation can cause 
difficulties in measuring QT-intervals. From the remaining population, “new” 
cisapride users were identified as those receiving their first prescription 
after enrolment into the study. Our analysis included all QTc measurements 
after the start of cisapride for all new users.   
Comorbidities were screened and identified according to standard clinical 
criteria.  Hypertension was defined as systolic blood pressure > 160 mm Hg 
or diastolic blood pressure > 100 mm Hg and/or use of antihypertensive 
medications, encompassing grade 2 and grade 3 hypertension compounds 
according to the World Health Organisation (WHO) criteria [33].  Diabetes 
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mellitus was defined as the use of blood glucose-lowering medication and / 
or a non-fasting or post-load serum glucose level of 11.1 nmol/L or higher 
according to the WHO [34].  A history of myocardial infarction was assessed 
by self-report checked with records from the general practitioner or 
cardiologist and/or electrocardiographic evidence.  All reported myocardial 
infarctions were verified against the medical records as described in detail 
previously [35]. Assessment of heart failure at baseline and during follow-up 
was assessed by reviewing all medical records for the occurrence of at least 
two signs and symptoms suggestive of heart failure or the use of medication 
for the indication heart failure and hospital discharge letters. Cases of 
incident heart failure were obtained by continuously monitoring the 
participants [36, 37]. The ankle arm index (AAI) was used as potential 
predictor of cardiovascular diseases and mortality [38].  
The impact of co-medications and comorbidities were evaluated using a 
linear regression where the absolute differences in QTc prolongation 
between taking d,l-sotalol alone and in conjunction with co-medications and 
comorbidities were calculated with standard deviation.  In the original 
model, the increases of QTc-interval values were derived from non-d,l-sotalol 
users.  Therefore, the same values can be applied here for the validation of 
the simulation model using cisapride.  These values are indicated in table 1.   
 Increase in QTc [msec] 
 Male (CI) Female (CI) 
Heart Failure 7.7 (+/- 4.02) 5.8 (+/- 3.49) 
Myocardial Infarction 3 (+/- 2.11) 3.2 (+/- 2.31) 
Arrhythmia 18.5 (+/- 9.24) 20.4 (+/- 9.51) 
Diabetes 3.0 (+/- 2.28) 5.4 (+/- 2.0) 
Hypertension 0.117 (+/- 0.08) -0.142 (+/- 0.05) 
Table 1.  Increase in QTc [msec] due to various concomitant medications and comorbidity conditions 
Not-In-Trial Simulation 
The final distribution of QTc values associated with all causal factors was 
simulated stepwise in R2.8. Differences between observed and expected QTc-
intervals were compared non-parametrically by visual inspection.    
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7.3  RESULTS 
PKPD modeling of QTc-interval prolongation 
Drug effect-concentration relationships are routinely investigated as part of 
the drug development process.  The relationship of cisapride, shown in 
Figure 2, has been directly taken from the original Phase I clinical trial 
report.  This illustrate that Not-In-Trial Simulation can be applied in addition 
to the current workflow, rather than changing the drug development 
paradigm. 
 
Figure 2.  Drug effect – concentration relationship of cispride. 
Not-In-Trial Simulation 
By combining the drug model with the age-dependent baseline relationship, 
along with the added contributions from comorbidities and concomitant 
medications, the progression of QTc-interval prolongation in the real life 
cisapride users is displayed in Figure 3.  The distribution of the observed QTc 
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values (light colours) fell within the simulated distribution (dark colours).  
After applying the model developed using d,l-sotalol, it was verified that 
same tool can be used to predict real life QTc values for cisapride users. 
    Chapter 7      193 
 
Figure 3.  Not-In-Trial Simulation of real life cispride users.  From hypothetical age-dependent baseline 
values, to drug-induced QTc prolongation, to added effects from comorbidity conditions and co-
medication and finally comparing the simulated values to observed measurements with between subject 
variability (BSV) shown. 
7.4  DISCUSSIONS 
Operational effectiveness 
Understanding the actual benefit-risk ratio in the target population has 
become paramount for the development of successful candidate molecules 
and prevention of attrition at the post-approval phase. The assessment of the 
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propensity for QTc-interval prolongation is a very pertinent example of this 
requirement, as these events have become a major cause of drug withdrawal. 
Current regulatory and clinical efforts regarding the effective use of drugs 
rely on the concept of positive benefit-risk ratio and as such depend 
primarily on the availability of oncoming evidence from clinical or 
observational trials [1]. These are often defined by Phase IV long term safety 
trials or more recently by progressive licensing proposal, which ultimately 
imposes the burden on patients and drug developers, with the caveat of the 
having the evidence after the facts [23-25].  Thus far, alternative methods to 
formalise prospective trials have been limited to “retrospective” meta-
analytical approaches on data arising from empirical data, i.e., from clinical 
practice as well as from randomised clinical trials [26, 27].  
In the current investigation we have shown once more that evidence 
synthesis can indeed be performed prospectively by the implementation of 
model-based approaches in which both fixed effects (drug-related as well as 
disease-related factors) as well random effects (including parameter and 
model uncertainty) are integrated.  Our results reveal that Not-In-Trial 
Simulations can be used to predict real life impact of drug intervention on 
actual patients under real life conditions.  QTc measurements in cisapride 
users were accurately described especially the extremely high values.  The 
lower values were not as well described.  One possible explanation that 
cannot be excluded is that those figures reflect measurement errors, despite 
quality control and review of the data entry.  In fact, the readings showed 
values that are considerably low for an elderly population.  Another possible 
explanation is due to the pharmacological effects of cisapride where short 
term usage would induce QTc prolongation; however, longer therapy might 
also cause a shortening phenomenon which cannot be anticipated by the 
model. 
Validation procedures 
Various requirements exist for the assessment of the predictive or prognostic 
value of a model. Predictive value refers to the ability to assess the 
probability of a target outcome while prognostic value defines the factors 
that predict prevalence.  Among other things, internal and external validation 
procedures provide evidence of consistency, accuracy and precision of the 
estimates. 
    Chapter 7      195 
It is also essential to consider specificity and sensitivity of the model in 
discriminating drug-induced effects from other confounding factors, in 
particular when drug-drug interactions or drug-disease interactions may 
occur which are compound-specific and may not have been identified yet, i.e., 
where uncertainty exists about the actual effects. 
The major limitation to our approach at this point of development is the 
exclusion of random effects.  The inclusion of random effects and variabilities 
would further improve the assessment and predictability of the exposure-
effect relationship.  Further work will be required to incorporate various 
sources of variability and uncertainties in the model.  Specifically, 
hierarchical modeling techniques can be applied to the relationship 
describing age and QTc values in healthy subjects.  Alternatively, since age, 
concomitant medications as well as comorbidity conditions can all be 
considered systems-related factors affecting QT/QTc-intervals, a combined 
estimation approach can be taken with uncertainties built in.   
In summary, having been able to successfully predict QTc values in real life 
for two different compounds using an age-dependent baseline QTc 
relationship, in conjunction with the effects from co-medications and 
comorbidities, we have gained confidence that Not-In-Trial Simulation will 
become a framework for signal detection in clinical development.  Although 
our work has been limited to QTc-interval prolongation, we envision the 
application of the concept for any adverse event.  This framework offers 
advantages compared to meta-analysis where the resulting model can only 
describe a large, pooled dataset rather than being predictive. Based on Not-
In-Trial Simulation scenarios, investigators will have the freedom to explore 
hypothetical populations and test different doses which are not confined to 
the observed data.   
196        Validation of Not-In-Trial Simulation 
REFERENCES   
[1] Curtin F, Schulz P. Assessing the benefit: risk ratio of a drug--randomized and 
naturalistic evidence. Dialogues Clin Neurosci 2011;13(2):183-90. 
[2] Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. In: IV 
CWG, editor. Geneva, Switzerland; 2004. 
[3] Shah RR. Drug-induced QT interval prolongation: regulatory perspectives 
and drug development. Ann Med 2004;36 Suppl 1:47-52. 
[4] Guidance for Industry: ICH E14 Clinical Evaluation of QT/QTc Interval 
Prolongation and Proarrythmic Potential for Non-Antiarrythmic Drugs. U.S. Depart of 
Health and Human Services.  Food and Drug Administration. (2005) 
[5] Hutmacher MM, Chapel S, Agin MA, Fleishaker JC, Lalonde RL. Performance 
characteristics for some typical QT study designs under the ICH E-14 guidance. J Clin 
Pharmacol 2008 Feb;48(2):215-24. 
[6] Chain AS, Krudys KM, Danhof M, Della Pasqua O. Assessing the Probability of 
Drug-Induced QTc-Interval Prolongation During Clinical Drug Development. Clin 
Pharmacol Ther 2011 Dec;90(6):867-75. 
[7] Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, 
Grobbee DE, et al. External validation is necessary in prediction research: a clinical 
example. J Clin Epidemiol 2003 Sep;56(9):826-32. 
[8] Arvanitakis C, Nikopoulos A, Theoharidis A, Giannoulis E, Vagios I, 
Anthopoulou H, et al. Cisapride and ranitidine in the treatment of gastro-
oesophageal reflux disease--a comparative randomized double-blind trial. Aliment 
Pharmacol Ther 1993 Dec;7(6):635-41. 
[9] Baldi F, Bianchi Porro G, Dobrilla G, Iascone C, Lobello R, Marzio L, et al. 
Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial. J Clin 
Gastroenterol 1988 Dec;10(6):614-8. 
[10] Galmiche JP, Fraitag B, Filoche B, Evreux M, Vitaux J, Zeitoun P, et al. Double-
blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig 
Dis Sci 1990 May;35(5):649-55. 
[11] Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in 
the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. 
Aliment Pharmacol Ther 1993 Aug;7(4):409-15. 
[12] Schutze K, Bigard MA, Van Waes L, Hinojosa J, Bedogni G, Hentschel E. 
Comparison of two dosing regimens of cisapride in the treatment of reflux 
oesophagitis. Aliment Pharmacol Ther 1997 Jun;11(3):497-503. 
    Chapter 7      197 
[13] Castell DO, Sigmund C, Jr., Patterson D, Lambert R, Hasner D, Clyde C, et al. 
Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related 
symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 
Investigator Group. Am J Gastroenterol 1998 Apr;93(4):547-52. 
[14] Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo-
controlled, double-blind study. Am J Gastroenterol 1995 Mar;90(3):423-30. 
[15] Castell D, Silvers D, Littlejohn T, Orr W, Napolitano J, Oleka N, et al. Cisapride 
20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-
USA-89 Study Group. Aliment Pharmacol Ther 1999 Jun;13(6):787-94. 
[16] Toussaint J, Gossuin A, Deruyttere M, Huble F, Devis G. Healing and 
prevention of relapse of reflux oesophagitis by cisapride. Gut 1991 Nov;32(11):1280-
5. 
[17] Wager E, Tooley PJ, Pearce GL, Wilton LV, Mann RD. A comparison of two 
cohort studies evaluating the safety of cisapride: Prescription-Event Monitoring and a 
large phase IV study. Eur J Clin Pharmacol 1997;52(2):87-94. 
[18] Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, et al. 
The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom 
and Canada. Am J Med 1999 Oct;107(4):356-62. 
[19] Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992 Sep 
26;305(6856):748-9. 
[20] Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et 
al. Contraindicated use of cisapride: impact of food and drug administration 
regulatory action. JAMA 2000 Dec 20;284(23):3036-9. 
[21] Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human 
cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 
1997 Nov;273(5 Pt 2):H2534-8. 
[22] Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid 
component of the delayed rectifier potassium current by the prokinetic agent 
cisapride underlies drug-related lengthening of the QT interval. Circulation 1998 Jan 
20;97(2):204-10. 
[23] Lexchin J. Progressive Licensing of Drugs: Music or Noise? Healthc Policy 
2008 May;3(4):11-20. 
[24] Yeates N, Lee DK, Maher M. Health Canada's Progressive Licensing 
Framework. CMAJ 2007 Jun 19;176(13):1845-7. 
[25] Hebert PC, Stanbrook M, Sibbald B, Flegel K, MacDonald N, Attaran A. 
Progressive licensing needs progressive open debate. CMAJ 2007 Jun 
19;176(13):1801, 3. 
198        Validation of Not-In-Trial Simulation 
[26] McKenna C, Claxton K. Addressing adoption and research design decisions 
simultaneously: the role of value of sample information analysis. Med Decis Making 
2011 Nov-Dec;31(6):853-65. 
[27] Presanis AM, De Angelis D, Goubar A, Gill ON, Ades AE. Bayesian evidence 
synthesis for a transmission dynamic model for HIV among men who have sex with 
men. Biostatistics 2011 Oct;12(4):666-81. 
[28] de Bruyne MC, Kors JA, Hoes AW, Kruijssen DA, Deckers JW, Grosfeld M, et al. 
Diagnostic interpretation of electrocardiograms in population-based research: 
computer program research physicians, or cardiologists? J Clin Epidemiol 1997 
Aug;50(8):947-52. 
[29] van Bemmel JH, Kors JA, van Herpen G. Methodology of the modular ECG 
analysis system MEANS. Methods Inf Med 1990 Sep;29(4):346-53. 
[30] Willems JL, Abreu-Lima C, Arnaud P, van Bemmel JH, Brohet C, Degani R, et 
al. The diagnostic performance of computer programs for the interpretation of 
electrocardiograms. N Engl J Med 1991 Dec 19;325(25):1767-73. 
[31] Bazett HC. The time relations of the blood-pressure changes after excision of 
the adrenal glands, with some observations on blood volume changes. J Physiol 1920 
Feb 20;53(5):320-39. 
[32] Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of 
disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 
1991 Jul;7(4):403-22. 
[33] 1999 World Health Organization-International Society of Hypertension 
Guidelines for the Management of Hypertension. Guidelines Subcommittee. J 
Hypertens 1999 Feb;17(2):151-83. 
[34] Diabetes Mellitus.  Technical Reports series 894. Geneva; 1985. 
[35] Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid 
intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam 
Study. Circulation 1997 Sep 2;96(5):1432-7. 
[36] Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers 
JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime 
risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004 
Sep;25(18):1614-9. 
[37] Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. 
Prevalence of heart failure and left ventricular dysfunction in the general population; 
The Rotterdam Study. Eur Heart J 1999 Mar;20(6):447-55. 





202      Sudden Cardiac Death 
ABSTRACT 
Context:  Currently, specific clinical studies are mandated before drug 
approval to ensure accurate evaluation of the risk of drug-induced 
arrhythmias. The underlying assumption for this requirement is that 
QTc-interval prolongation >10 msec leads to an increase in the risk of 
torsade de pointes (TdP). However, the evidence for such a correlation 
remains debatable.  
Objective:  To challenge the notion of increased TdP risk with QTc-
interval prolongation >10msec and to explore whether sudden cardiac 
death (SCD), a potential surrogate for TdP, is correlated with increases 
from baseline QTc or to high baseline values. 
Design, Setting, and Patients:  The incidence of SCD in the population 
was derived from data in the Rotterdam Study cohort observed 
between 1997 and 2004 (n=282).  
Main Outcome Measures:  Trend-analysis was applied to evaluate SCD 
rates in patients showing increasing, decreasing and no change in QTc-
interval measurements.   A sensitivity analysis was also performed on 
the impact of the time span between death and last ECG measurement.  
Results: Incidence rates of SCD increased significantly with higher 
baseline QTc values. This increase was independent of the time elapsed 
between the last ECG and death. In contrast to current belief, the 
incidence rates in subjects showing QTc prolongation <10 msec and 
>10 msec varied from 4.6 to 4.0 cases per 1000 person years (p<0.261). 
Conclusions: QTc-interval prolongation by >10 msec does not appear to 
affect the incidence rate of SCD. Instead, increased rates were found to 
better correlate with high baseline QTc values. Despite the limited size 
of the cohort, these findings prompt for careful revision of the 
guidelines for evaluating the pro-arrhythmic risk of new medicines.  
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8.1 INTRODUCTION 
Approximately 50% of all cardiac deaths are estimated to be of sudden 
nature.1-3  Sudden cardiac death (SCD) is defined as “natural death due to 
cardiac causes, heralded by abrupt loss of consciousness within one hour 
after the onset of acute symptoms; pre-existing heart disease may have been 
known to be present, but the time and mode of death are unexpected”.4 
Irrespective of other triggering conditions, ventricular arrhythmias 
associated with an acquired long-QT syndrome (LQTS) are considered a risk 
factor for SCD.3 In addition, it is also assumed that QT-interval prolongation 
can provoke torsades de pointes (TdP), which in turn can either resolve 
spontaneously or deteriorate into ventricular fibrillation and potentially into 
SCD.5  
The alleged link between LQTS and SCD has become a real concern for the 
medical community 3 given that a variety of drugs have been recognised to 
possess substantial pro-arrhythmic potential by inducing QTc-interval 
prolongation and consequently increasing the risk of TdP. Whilst the 
mechanism by which prolonged QTc-intervals can degrade into fatal 
arrhythmias is well described in various publications 6,7, there is still an 
ongoing debate in the literature on the clinical significance of its 
prolongation 1. Yet, QTc-interval prolongation has become one of the most 
common causes of post-market withdrawal as well as restriction of use of 
drugs.7 
Several large population-based studies evaluating the association between 
the heart-rate corrected QT-interval and mortality in apparently healthy 
persons did not find a consistent association between the length of the QTc-
interval and total or cardiovascular mortality8-14. Only few of these studies 
specifically explored events such as sudden cardiac death and when they did, 
the number of cases was often too small to detect statistically significant 
differences.9,15,16.  Nevertheless, SCD has been found to be associated with 
high values of QTc-interval in a study conducted by Straus et al..17  In view of 
the potential implications of drug-induced LQTS, the use of QTc-interval 
prolongation has been proposed as a marker of cardiovascular risk for both 
pre- and post-market studies, regardless of the supporting evidence.18  
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To mitigate such risks, the European Agency for Evaluation of Medicinal 
Products (EMA) was the first to issue a “points to consider” document from 
the Committee for Proprietary Medicinal Products (CPMP) in 1997.19 In the 
early 2000s, regulatory scrutiny continued to increase 20, leading to the 
development of the latest guideline from the International Conference on 
Harmonisation (ICH), topic E14, which introduced the requirement for a 
thorough-QT (TQT) study.  A TQT study will only be considered negative for 
a new chemical entity (NCE) if the 95% upper interval of the largest time-
matched QTc measurements after active treatment does not include 10 msec 
after adjusting for baseline and placebo effects.21  Yet, the guideline states 
that it is not clear whether arrhythmia development is more closely related 
to an increase in the absolute QT or QTc.  
Irrespective of the premises adopted by regulatory agencies and recent 
advancements in the detection of QT-interval prolongation, it remains 
unclear whether TdP and SCD are indeed correlated with each other in a 
cause-and-effect manner. As a result, any meaningful attempt to further 
implement QT-interval as a prognostic marker of cardiovascular risk must 
take into consideration the basic operating characteristics of working 
variables, i.e., its sensitivity and specificity to detect the signal of interest. 
Among other things, it is of interest to investigate whether increases in QTc 
values, calculated as changes from baseline measurements or absolute 
measured QTc values, are associated with SCD using traditional 
epidemiological methodologies. The aim of this study was therefore to 
explore whether the incidence rate of SCD is correlated with high baseline 
values or increases from baseline QTc-interval.     
8.2 METHODS  
Protocol design and study population 
This study was conducted using the Rotterdam Study cohort.  All inhabitants 
of a suburb in Rotterdam, Ommoord, aged 55 years and over (n = 10275), 
were invited to participate.  Of these, 7983 (78%) gave their written 
informed consent and took part in the baseline examination.  Objectives and 
methods of the Rotterdam Study have been described in detail elsewhere.22,23  
During baseline assessment, all participants were visited at home for a 
standardised questionnaire and 7151 were subsequently examined at the 
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research centre.  A second, third and fourth follow up visit took place 
between 1993 and 2004.  In addition to follow-up examinations, the cohort 
was continuously monitored for major morbidity and mortality through 
linkage with general practitioner and municipality records. Drug 
prescriptions dispensed to participants have been stored in the database by 
automated pharmacy procedures. All participants in the Rotterdam Study 
with at least two consecutive ECG assessments were included in this analysis. 
Sudden cardiac death assessment 
In case of a fatal event, general practitioners (GP) filled in a questionnaire 
describing the circumstances of the death, including time since the 
occurrence of first symptoms, most likely cause of death according to the 
physician, actual time and place of death.  All questionnaires and a copy of 
the medical records were used to assess if the death could be classified as a 
sudden cardiac death.5  If death was witnessed and occurred within one hour 
after the start of symptoms, we assumed it to be a sudden cardiac death, 
without additional review of the medical records for a medical history of 
cardiovascular disease or the presence of cardiovascular risk factors.  In case 
of an un-witnessed death, evidence of cardiac causes was searched for using 
all available information. Two research physicians coded all reported events 
independently according to the International Classification of Diseases, 10th 
edition (ICD-10, sudden cardiac death: I.46). In case of disagreement, 
consensus was sought.  Finally, a cardiologist, whose judgment was 
considered decisive, reviewed all events. 
ECG interpretation and measurements 
A 10 sec 12-lead resting ECG (on average 8-10 beats) was recorded with an 
ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sampling frequency 
of 500 Hz and stored digitally.  All ECGs were processed by the Modular ECG 
Analysis System (MEANS), which determines the QT-interval from the start 
of the QRS complex until the end of the T wave. The Bazett’s formula 
(QTc[b]=QT/sqrt(RR)) was used to correct for heart rate differences. 
Digitally stored ECGs from 6134 and 4415 participants who visited the 
research centre were available at the time of the first and second visit (86% 
vs. 70% of the study population), respectively.  
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The immediate last QTc value on record prior to the case of SCD was used as 
the measurement associated with death. QTc values were categorised into 
bins of 10 msec increments as shown in Table 1.  For calculating changes in 
QTc-interval the immediate two last consecutive values on record were used. 
Two analyses were performed using the differences in QTc (delta QTc). The 
first one was meant to explore the directionality of the two consecutive 
measurements: downward (negative delta) where ∆QTc<0, flat (zero delta) 
with ∆QTc=0, and upward (positive delta) where ∆ QTc>0.  The second 
analysis was based on a subsequent dichotomisation of delta QTc values into 
less than 10 msec and those equal or greater than 10 msec.  In all those cases 
in which measurements could not be obtained or were missing, the patient 
was excluded from this investigation.  
Statistical analysis 
The incidence rate of sudden cardiac death was determined by dividing the 
total number of sudden cardiac death cases by the total number of person-
years accumulated in the study population. 95% confidence intervals were 
calculated based on a Poisson distribution. 
Trend analysis of the incidence rates was then performed.  SCD rates for 
delta QTc of <10 msec and >10 msec were compared with negative, zero and 
positive changes between consecutive measurements. In addition, a 
sensitivity analysis was performed to assess parameter precision at different 
time lapses between death and last ECG measurement at 6, 12, 18, 24, 30 and 
36 months. 
Binomial proportions testing was performed to determine if the proportions 
of SCD cases with QTc values above and below the population median QTc 
value were significant using p < 0.05 as a statistical significance level. This 
consisted of comparing the ratios between the number of deaths associated 
with QTc-intervals that are below the median QTc value of the entire 
population versus the number of deaths associated with QTc-intervals that 
are above the population median QTc value. Furthermore, logistic regression 
calculations were done to determine if predictor variables or regression 
coefficients in this analysis, namely bins of QTc-intervals, delta QTc of <10 
msec or > 10msec, and delta QTc of < 0, =0 or >0, were correlated with the 
probability of occurrence of SCD.  A p-value < 0.05 was also chosen as 
threshold for statistical significance.  






Rate / 1000 PY 
Confidence 
Intervals 
1 <300 0 0.000 - 
2 300-309 0 0.000 - 
3 310-319 0 0.000 - 
4 320-329 0 0.000 - 
5 330-339 0 0.000 - 
6 340-349 0 0.000 - 
7 350-359 0 0.000 - 
8 360-369 3 0.013 0.0026 - 0.0369 
9 370-379 2 0.003 0.0004 - 0.0110 
10 380-389 5 0.003 0.0001 - 0.007 
11 390-399 12 0.003 0.0017 - 0.0057 
12 400-409 18 0.003 0.0016 - 0.0044 
13 410-419 21 0.002 0.0014 - 0.0035 
14 420-429 42 0.004 0.0027 - 0.0051 
15 430-439 36 0.004 0.0025 - 0.0049 
16 440-449 33 0.004 0.0029 - 0.0058 
17 450-459 38 0.007 0.0049 - 0.0095 
18 460-469 17 0.005 0.0031 - 0.0086 
19 470-479 16 0.009 0.0052 - 0.0147 
20 480-489 9 0.010 0.0044 - 0.0182 
21 490-499 10 0.016 0.0076 - 0.0890 
22 500-509 6 0.014 0.0052 - 0.0309 
23 510-519 4 0.014 0.0037 - 0.0348 
24 520-529 3 0.025 0.0051 - 0.0727 
25 530-539 1 0.009 0.0002 - 0.0485 
26 540-549 4 0.085 0.0231 - 0.2168 
27 550-559 1 0.064 0.0016 - 0.3549 
28 560-569 0 0.000 - 
29 >570 1 0.906 0.0057 - 1.259 
 
Table 1. QTc categories and the corresponding QTc values in increment bins of 10msec.  The incidence 
rates are shown for each category with its corresponding confidence intervals. 
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8.3 RESULTS 
Out of 6680 subjects with an ECG measurement, 282 cases of SCD were 
identified of which 147 cases were witnessed. Only 38 subjects were taking 
QTc-prolonging medications at the time of the last ECG measurement prior to 
death.  No clear pattern has emerged from exploring the sequences of ECG 
measurements over time, as shown in the top panel in Figure 1 for seven 
randomly selected subjects who experienced SCD. The median QTc value 
associated with all the QTc values included in the analysis is 434 msec.  
There were 162 SCD cases out of 3235 QTc measurements above the median 
value, 118 cases out of 3315 measurements below the median value and 2 
cases out of 91 measurements at the median value. Based on the binomial 
proportions test it was concluded that the differences between the two 
groups were statistically significant (p = 0.004574). The overall distributions 
of all QTc measurements associated with cases of SCD and non SCD show that 
the fatal event can occur at normal, borderline and prolonged values, as 
defined by the Committee for Proprietary Medicinal Products (Figure 1, 
middle and bottom panels). 19 
In contrast, incidence rates did increase with higher baseline QTc values (p < 
0.001) as shown in Table 1. This increase was consistently observed 
irrespective of the time elapsed between the last ECG measurement and 
death (Figure 2).  When delta QTc values are compared with regard to its 
direction of fluctuation, the trend over time is uncorrelated (p = 0.195).  In 
Figure 3, negative, zero and positive delta QTc values were compared for 6, 
12, 18, 24, 30, and 36 months between last ECG measurement and death. 
Remarkably, shown in Figure 4, the magnitude of the changes in QTc-
interval, < 10 msec or > 10 msec, was not correlated to incidence rates of SCD 
with results varying from 4.6 to 4.0 cases per 1000 person years respectively 
(p = 0.261).  ∆ QTc values were also compared for 6, 12, 18, 24, 30, and 36 
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Figure 1.  Four consecutive ECG measurements of seven randomly selected subjects prior to SCD (top 
panel).  The x-axis denotes the four measurements (visit) between 1990-2004. Density distribution of 
last ECG measurements before SCD (middle panels).  Density distribution of last ECG measurements of 
non SCD cases (bottom panels). The definition of “normal”, “borderline”, and “prolonged” QTc values are 
taken from the European regulatory guidelines. 19 
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Figure 2.  Top panel - Incidence rates of sudden cardiac death by increment bins of 10 msec QTc-
intervals (p < 0.00000235).  Bottom panels - Sensitivity analysis of incidence rates of sudden cardiac 
death.  Each sub-panel shows the time lapse between the last measurement and death.  N denotes the 
number of subjects included in the analysis. 
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Figure 3.  Incidence rates of sudden cardiac death by defining delta QTc as decreasing (negative delta), 
maintained (zero delta) and increasing (positive delta) (p = 0.195).  The x-axis shows the time lapse 
between the last measurement and death.  
 
Figure 4.  Incidence rates of sudden cardiac death by defining ∆QTc as < 10 msec and > 10 msec (p = 
0.261).  The x-axis shows the time lapse between the last measurement and death. 
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8.4 DISCUSSIONS 
A prolonged QT-interval has been considered an attractive non-invasive risk 
factor for SCD. In this study, we showed that the incidence rate of SCD is 
better correlated with high absolute baseline QTc-interval values.  A 
prolongation by > 10msec did not significantly affect the incidence rate of 
SCD given there were only 182 cases with two consecutive QTc 
measurements prior to death. 
Even though no consistent evidence has been demonstrated for increased 
risk of total or cardiovascular mortality or sudden death,  the results from 
this study do agree with previous epidemiological studies. Recently, Straus et 
al., found that prolonged QTc-intervals are associated with threefold 
increased risk of sudden cardiac death after adjustment for age, sex, body 
mass index, hypertension, cholesterol/HDL ratio, diabetes mellitus, 
myocardial infarction and heart failure in the same population used in this 
present study.17 In another study, a QTc-interval > 440 msec was found to 
double the risk of sudden cardiac death.15  Analogous conclusions have been 
drawn by the Amsterdam study and by Dekker et al.24 Furthermore, 
inferences can also be made from data showing that the relative risk for 
arrhythmic death is higher when resting heart rate is greater or equal to 84 
bpm25, and that TdP is rarely associated with QTc-intervals less than 500 
msec.26  
On the other hand, our findings contrast with the Framingham study11, which 
did not demonstrate an association of baseline QTc with sudden death. 
However, the population was considerably younger at time of enrolment 
(ages 30-65 years) and thus, the majority of baseline ECGs were recorded in 
patients probably before changes in risk become significant or cardiac 
disease is still subclinical. Other attempts to characterise the determinants of 
SCD have been less successful due to the limited number of SCD cases16  or 
because of issues with the sensitivity and specificity of the analysis27. 
Despite the lack of evidence corroborating the link between QT/QTc-interval 
prolongation and TdP, QT-interval has been used as a surrogate marker for 
cardiovascular safety risks.  When corrected for heart rate, the QT-interval 
read from an electrocardiogram is a direct marker of ventricular action 
potential duration and represent the time taken for the heart to return to its 
resting state following the preceding contraction that pumps blood around 
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the body.  Albeit imperfect, it is at present the best available surrogate maker 
for the risk of TdP, which can potentially lead to SCD.  From the sensitivity 
analysis performed in our study, SCD incidence rates were found to be 
independent from the time elapsed since last ECG measured and death.  This 
implies that using the absolute QTc values to determine the risk of SCD may 
be relatively more reliable. 28,29    
Most importantly, our findings appear to contradict the hypothesis 
underlying the current requirements by ICH topic E14 guideline on the 
evaluation of cardiovascular risk for non antiarrhythmic drugs, in which 
safety is defined by a threshold for an upper interval delta prolongation 
value of 10 msec.  From our analysis, the association between a delta 10 msec 
change in QTc and SCD is not statistically significant, nor reliable. Thus, two 
important concepts will need to be addressed in future revisions of the ICH 
E14 guideline: the threshold of 10 msec and the usage of delta QTc values. 
There are also challenges in interpreting the significance of mean changes 
(∆QT) from baseline without understanding inter-individual differences in 
drug exposure.30 For example, the mean increases in peak QTc-interval were 
9 and 22 msec following single oral doses of, respectively, 10 mg and 50 mg 
thioridazine31, whilst 15 msec and 17 msec increases relative to placebo 
were found with 400 mg and 800 mg of single oral doses of moxifloxacin. 32  
In this context, the assumption of a constant increase in the risk of pro-
arrhythmia does not seem to be substantiated by clinical data. In fact, 
pharmacokinetic-pharmacodynamic analysis reveals clear differences in the 
slope of the concentration-effect relationships of compounds showing QTc-
prolonging effects. 33  
Thus far, the risk of TdP as well as SCD has all pointed to an association with 
absolute QTc measurements. Based on our results, it appears that drug-
induced changes in QTc may not increase the cardiovascular risks unless the 
measured QTc value falls within a range of values with a higher risk. 34  
It should be noted that our estimates were not adjusted for other 
cardiovascular risk factors, such as age, gender, smoking status, body mass 
index, diabetes and cardiac-related comorbidities, and that we used the most 
recent regulatory guidelines to classify QTc prolongation.35  We have 
assumed random distribution in the measurement error and negligible 
confounding effect of drug-induced T-wave changes, which may complicate 
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the measurement of the QT-interval. Yet, it should be emphasised that the 
absolute risk of sudden cardiac death does show an increase with age. 36,37   
In summary, our findings corroborate an association between heart-rate 
corrected (QTc)-interval and the risk of sudden cardiac death (SCD).  Given 
the growing relevance of QTc prolongation in drug development, our results 
clearly raise questions about the rationale for the evaluation of the pro-
arrhythmic potential of novel compounds.  Whilst it may not be feasible to 
establish a cut-off range for QTc-intervals without taking into account 
additional factors contributing to an increase in the risk of SCD, it seems 
evident that clinically effective risk management policies should consider 
baseline QT/QTc-interval as a strong prognostic factor for pro-arrhythmias. 
We strongly recommend revisiting the current guidelines for the evaluation 
of cardiovascular safety.  The assumption of a comparable risk of TdP across 
the population for an increase in QTc-interval of >10 msec cannot be 
sustained.  
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ABSTRACT 
Aim: Correction for changes in heart rate is a fundamental step to the 
evaluation of QTc-interval prolongation. Yet, clinical trial simulations 
for thorough-QT (TQT) studies often rely on approximations to evaluate 
design factors such as group size. The aim of the investigation was to 
develop a model-based approach to describe the correlation between QT- 
and RR-intervals in healthy volunteers.  
Methods: A large pool of healthy volunteer ECG data has been used for 
model building and validation. The data was split into two subsets to 
allow for the external validation of the final model where analysis was 
performed using a nonlinear mixed effects approach. Model validation 
was carried out internally and externally. 
Results: A power function gave the best model performance. Age and 
gender were the only available covariates; gender was found to be 
significant both on slope [181 (sd. 13.5) for females and 166 (sd. 12.8) 
for males] and exponent [0.85 (sd. 0.13) for females; 0.74 (sd. 0.13) for  
males]. Inter-occasion variability on slope and exponent was also 
identified as a significant random effect. Distributions of simulated and 
real QT values were comparable. Parameter estimates were subsequently 
used as part of a TQT study simulation.  
Conclusions: The final model allows a reliable and realistic simulation 
of QT-interval profiles starting from a physiological set of RR values. In 
the context of clinical trial simulations, the availability of such a model 
represents a concrete improvement in the evaluation of drug-induced 
QTc-interval prolongation. 
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9.1 INTRODUCTION 
The QT-interval in the electrocardiogram (ECG) represents the total duration 
of depolarisation and repolarisation of the cardiac cycle. Drug-induced 
prolongation of ventricular repolarisation, also known as QT prolongation, is 
considered the best surrogate marker of risk for ventricular arrhythmia [1]. 
The assessment of a drug's effect on the QT-interval has therefore become 
mandatory during drug development [2, 3].  However, heart rate also affects 
the QT-interval. The shortening effect of heart rate on the QT-interval must 
be taken into consideration when evaluating possible drug-induced effects 
[4]. Correction for heart rate is necessary to provide a single intrinsic 
physiological value that can be compared between subjects and within the 
same subject under different conditions. In fact, the relationship between the 
QT-interval and heart rate can be modelled mathematically, yielding a 
corrected QT-interval (QTc) which enables discrimination between drug-
induced from heart rate-dependent effects.  
In the past few years, a considerable number of mathematical functions has 
been described that supposedly best characterise the heart rate-QT 
relationship [5-12]. Whilst the focus of those investigations has been on the 
accuracy and precision of the parameters describing the so-called 
physiological relationship, little attention has been paid to the use of such 
functions in clinical trial simulations to support the design of clinical 
protocols aimed at the evaluation of drug-induced effects on QT/QTc-
interval, and in particular of the thorough-QT (TQT) study [2].  The ability to 
decide if a new chemical entity (NCE) should be discontinued early in 
development depends on the implementation of a well-designed protocol, in 
which statistical power calculations take into account the non-random 
nature of variability in QT-interval.  Similar considerations also apply to 
study design when concentration-effect relationships are used as basis for 
the assessment of drug-induced effects.  
Recently, we have proposed the use of a Bayesian hierarchical model for the 
evaluation of QTc-interval prolongation using phase I data in lieu of a specific 
TQT study [13].  Effective implementation of this approach requires the use 
of clinical trial simulations (CTS) to ensure accurate assessment of drug-
induced effect size and to determine if a TQT study is actually necessary.  
Simulations are also essential to enable the characterisation of type I and II 
error rates.  Traditionally, however, re-sampling techniques from existing 
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data or empirical correlations have been used to evaluate drug effect and 
design factors such as group size.  
The availability of a method to generate realistic RR profiles according to 
typical protocol sampling schemes, which can be used as input into a model 
describing the QT-RR relationship, would be very useful.  In the present 
study, we aim to generate 24-hour RR profiles and develop a nonlinear 
mixed effects model to characterise QT-RR relationship in healthy subjects.  
To meet the aforementioned objectives, challenges must be overcome from 
both a physiological and a statistical perspective.  
Non-linear regression methods have been applied, which rely on a 
fundamental assumption that the predictor variable (RR-interval) is 
measured without error [14]. However, the fact is that both QT- and RR- 
intervals measured in electrocardiogram (ECG) are subject to not only 
measurement error, but also fluctuation that is caused by physiological and 
biological factors [15]. In addition, statistically, it has been shown that the 
relationship between the RR-interval (=1/heart rate) and the QT-interval is 
highly variable between individuals but stable over time within each 
individual, but none of investigations has looked closely at the variability 
associated with the sampling scheme [16].  In contrast to previous research, 
in which Bayesian hierarchical model was used to account for or exclude 
measurement error in the evaluation of QTc-interval prolongation [13], we 
have chosen to simulate data in which correlations and variance structure 
reflect the noise due to measurement and sampling procedures.  
9.2 METHODS  
Data 
The data for this study was derived from a large pool of healthy volunteer 
ECG data, totaling 776 subjects (339 males and 437 females), with mean age 
of 31.1 years (sd. 9.4).  Variables such as QT, QTc, RR, VR, QRS, PR, age, 
weight and gender were available.  From seven different studies, the 24-hour 
profiles of RR- and QT-intervals measured at discrete time points according 
to one of the seven protocols, were used in this analysis.  The mean QT value 
and the mean RR value from the combined dataset were 390.5 msec (sd. 
27.8) and 0.96 msec (sd. 0.15) respectively.   
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Generating RR-iIntervals 
Using the starting RR-interval values (RR0) from each of the 776 profiles, a 
vector of RR-intervals was created to sample from for a new hypothetical 
population at time 0.  Then the median RR0 was determined.  Using the 
median value, two distributions of RR differences were defined, one each for 
above and below the median.  We chose to split the values at the median 
because it was found that the two distributions statistically differ from each 
other whereas the distributions when the data is separated by bins of 
different sizes or quartiles were not significantly different. The definition of 
differences in RR values was defined according to the following formula: 
ΔRR1 = M1 – M2; ΔRR2 = M1 – M3; …, where 
M1 = first RR measurement, M2 = second RR measurement, etc. 
After the RR value for time 0 for each of the profile in the hypothetical 
population was sampled, the RR differences for the remaining profile were 
sampled from one of the two distributions described earlier, depending on 
the starting value.  Finally, a full 24-hour RR profile was back-calculated for 
each subject based on the differences sampled, according to a typical clinical 
trial sampling scheme as shown in Table 1.  Since the new RR profiles 
generated were sampled non-parametrically, physiological boundaries were 
used to prevent unrealistic values.   
 Baseline Dose Post-dose 
Time -1 -0.75 -0.5 -0.25 0 0.5 1 1.5 2 2.5 3 4 6 8 12 18 24 
PK x x     x         x  x x x x x x x x x x x x 
PD x     x        x  x x x x   x  x x  x 
Table 1.  Typical clinical trial sampling scheme 
Generating QT-intervals 
QT-intervals for each RR-interval generated according to the aforementioned 
steps were simulated according to the following relationship, 
 
QT = SLP * RR^EXP + INCPT, 
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between all the pairs of QT and RR values in the healthy subject data, where 
SLP is the slope parameter of the relationship, EXP is the exponential term 
quadratic function and INCPT is the parameter of the y-intercept.  The data 
was split into two subsets to allow for model building and external validation 
of the final model.  Model building was performed using nonlinear mixed 
effects approach as implemented in NONMEM VI (ICON Development 
Solutions, Ellicott City, MD, USA)  [17]. 
The criteria of model selection were based on changes in objective function 
(OFV; equal to -2 log likelihood) and goodness of-fit plots (GOF).  Gender, age 
and weight were tested as covariates on the parameters SLP, EXP and INCPT 
but only gender was found to have an impact on SLP and EXP.  In addition, 
visual predictive checks (VPC) and normalised prediction distribution error 
(NPDE) plots were used to judge model performance with regard to the 
predictions for a different subset of the data.    
Goodness-of-fit plots, including observed (OBS) versus individual prediction 
(IPRED), OBS versus population prediction (PRED), conditional weighted 
residuals (CWRES) [18] versus time and CWRES versus OBS were used for 
diagnostic purposes.  The NPDE method was used to determine whether 
1000 simulated QT values were interchangeable with the original data using 
graphical diagnostics [19].  NPDE was implemented with an add-on software 
package in R2.8 (The R project - http://www.r-project.org/) [20].   
9.3 RESULTS 
RR-intervals 
In general, all simulated values are visually compared to the real data by 
overlapping the distributions to determine if the simulated values resemble 
the original data.  The resulting distributions of RR differences are shown in 
Figures 1.  After the hypothetical profiles of an entire population were 
simulated, the distributions of actual RR values are displayed in Figures 2. 
Actual values, population and individual profiles, are also inspected visually 
to determine if the variability of RR profiles are consistent over time 
between real and simulated data.   Population comparisons are shown in 
Figure 3 and Figure 4 are individual profiles. 
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Figure 1.  Distribution of RR differences of the entire population (left), above the median (middle) and  
below the median (right).  The lighter colour in the histogram represents the portion of overlapped data 
between the observed and the simulated values. 
 
 
Figure 2.  Distribution of RR values of the entire population (left), above the median (middle), and below 
the median  (right).  The lighter colour in the histogram represents the portion of overlapped data 
between the observed and the simulated values. 
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Figure 3.  Distribution of RR values over time.  Top panels: all real data (left), above the median (middle)  
and below the median (right).  Bottom panels: all simulated data (left), above the median (middle) and 
below the median (right). 
 
Figure 4. Individual profiles of RR-intervals with  observed data (left) and  simulated data (right). 
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QT-intervals 
Among the different functions used in the evaluation of the QT-RR 
correlation [21], a power function yielded the best model performance. The 
final model parameters are shown in Table 2.  Gender was found to be a 
significant covariate both on slope and exponent. Inter-occasion variability 
on slope (SLP) and exponent (EXP) was also identified as a significant 
random effect.  Model diagnostics of the final model are shown in Figure 5, 
which provided the confidence that the model is able to well describe the 
data.  Figure 6 is the model evaluations of the external validations using a 
subset of the original data. 
 
 SLP EXP INCPT IOV Residual 
 female male IIV female male IIV    
Model  
estimate 181 166 0.0059 0.85 0.74 0.046 221 0.012 0.0004 
Bootstrap  
mean 180.2 165.3 0.0062 0.87 0.76 0.0459 222.3 0.013 0.0004 
CV % 12.3 13.7 29 13.7 13.1 17.4 10.1 38 5 
Table 2.  Final model estimates for the QT-RR correlation. 
 
Figure 5.  Right panel: goodness-of-fit plots  and left panel:  NPDE, for final QT-RR model evaluation. 
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Figure 6.  Right panel: goodness-of-fit plots and left panel:  NPDE,  for external validation of final QT-RR 
mode using an external dataset. 
 
QT values were simulated for the RR-intervals. Figure 7 shows the 
overlapping distributions between real and simulated QT data as well as the 
comparison between the individual profiles. 
 
 
Figure 7.  Overlapping distributions of real and simulated QT values (left), individual profiles of observed 
QT data (middle) and simulated profiles (right) of QT-intervals. The lighter colour in the histogram 
represents the portion of overlapped data between the observed and the simulated values. 
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9.4 DISCUSSIONS 
Realistic QT-intervals were obtained, from a novel modelling approach 
describing the QT-RR relationship.  Specifically, the developed model allowed 
for accurate simulation of QT-interval profiles starting form a physiological 
set of RR values.  In the context of clinical trial simulations, the availability of 
such a model offers considerable advantages as compared to re-sampling 
methodologies. The use of a model-base method allows one to generate an 
infinite number of realistic individual QT profiles, which can be used 
subsequently in conjunction with a PKPD model to assess the liability of a 
compound, including QTc-interval prolongation.  This approach also enables 
the prediction of potential drug effects on QTc-interval for patients who do 
not meet inclusion/exclusion criteria.  
Various models have been proposed to simulate beat-to-beat RR-interval [22, 
23]; however, they are not necessarily useful when RR measurements are 
needed for clinical trial simulations (CTS). To apply RR-intervals in CTS, 
measurements should be taken at discrete intervals according to the study 
protocol, yielding between-measurement variability which is not described 
by beat-to-beat variation. Our method represents a valuable tool for the 
optimisation of drug development processes, especially in studies such as 
TQT.   
Recently, Chen et al proposed a Bayesian hierarchical measurement error 
modelling approach to assess QT-interval correction and prolongation [14].  
The novel method not only takes into account the measurement errors in RR-
intervals, but it also provides a unified approach to QT-interval correction 
and prolongation evaluation in place of other methods to correcting QT-
interval for heart rate [24, 25].  This method would be useful when assessing 
drug-induced QTc prolongation of NCE, however, it would not be useful 
towards other clinical trial simulations that do not aim to determine pro-
arrhythmic propensity of compounds. 
Conversely, our newly proposed approach to non-parametric sampling of 
RR-intervals does not take into account any possible measurement errors 
stemming from the ECG recordings.  Furthermore, this approach assumes all 
RR-interval values fall within the same distribution which is not always the 
case when subjects are in different treatment arms or dose groups.  Thus the 
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pharmacological effect on RR-intervals of the compound under investigation 
must be well understood prior to using the non-parametric methodology.   
One advantage to using the approach presented here is that a fixed number 
of subjects with a number of observations can provide the basis for a large 
scale simulation.  Thus as long as the sampling intervals remain the same 
between observed data and sampled data, there would not be any bias in the 
new dataset.  By extension, this method also offers advantages over the 
traditional bootstrapping technique.  Chief of which is the fact that `new` 
subjects can be created with entirely different observations as opposed to a 
re-sampling approach where new sets of data are taken from the observed 
information using sampling with replacement so that it is not identical to the 
original set.   
Potential applications for this novel method to simulating discrete RR 
measurements include any investigations involving PR-intervals, ST-
intervals, QRS-intervals where changes in RR-intervals matter [26].  Other 
physiological research in which RR is the variable of interest, such as anti-
inflammatory pathways [27], respiratory functions [28, 29]  and 
cardiovascular safety [30] can also benefit from this approach.  Thus the 
usefulness of the technique discussed in the present study goes far beyond 
thorough-QT study and other clinical trial simulations.  
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ABSTRACT 
The aim of the study was to investigate if the previously proposed 
Bayesian approach to characterise the probability of drug-induced QTc-
interval prolongation can overcome the statistical issues associated with 
the recommended double-delta method for the analysis of thorough-QT 
studies.  A completely simulated trial population was created based on 
non-parametric RR samplings and its corresponding QT-intervals using 
hierarchical modelling technique.  Thirty-six different TQT studies were 
simulated with a hypothetically fixed drug-effect size, trial design and 
numbers of subjects,  To compare the two different approaches, 
sensitivity and specificity were calculated and tabulated for each method 
to capture false negative and false positive rates. In general, false 
positive trials were only detected with the double-delta method and lower 
specificity was observed with smaller sample size.  The results also 
showed the Bayesian approach is able to detect QTc-interval 
prolongation with higher accuracy and precision with different number 
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10.1 INTRODUCTION 
In 2005, the International Conference on Harmonisation (ICH) published a 
guidance, topic E14, for clinical evaluation of QT prolongation as a result of 
increasing concern for drug-induced proarrhythmic events [1].  Since QT-
interval prolongation has been considered a surrogate marker for risk of 
developing the potentially fatal tachyarrhythmia, torsade de pointes (TdP), 
the guidance advocated the use of thorough-QT (TQT) studies to evaluate the 
propensity of QT/QTc-interval prolongation caused by a new chemical entity 
(NCE).  TQT studies, as recommended, should be conducted early in clinical 
development to exclude compounds that produce a prolongation exceeding a 
threshold when comparing active to placebo treatment arms.  A study is only 
deemed negative when the upper limits of all the 1-sided 95% confidence 
intervals (CI) are below 10 milliseconds at every time point [2].  Conversely, 
a study is interpreted as positive if just one CI includes a prolongation of 10 
milliseconds or greater.   
Presently these studies must be powered for the statistical detection of QTc-
interval changes as small as 5 milliseconds.  Since this translates into a 
noticeable drug development burden, strategies need to be identified 
allowing the size and thus the cost of thorough-QT/QTc studies to be 
minimised.  Efforts have been made to investigate the influence of QT- and 
RR-interval data quality and the precision of heart rate correction on the 
sample sizes of thorough-QT/QTc studies [3].  Despite these concerns, 
research focus has been restricted to the investigation of correction factors 
and measurement techniques as determinants of precision and accuracy [3, 
4].  Instead, more recently, it has become clear that the choice of the data 
analysis method plays an equally or even more important role in the 
precision and accuracy of results. 
In recent research, the analysis of baseline values, study sensitivity with 
positive control arm and formulas to correct QT-intervals for heart rate, have 
been explored in detail as they have been determined to impact the precision 
and accuracy of results [5].  Baseline measurement, if not controlled and 
consistent across studies, could lead to significant misinterpretation of 
results as drug, placebo and active control are estimated relative to it [6].  In 
an analysis conducted by Sethuraman et al., it was determined that the 
choice of baseline approaches impacts the type I error and power for various 
study designs [7].  Furthermore, there is a high probability of concluding that 
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the TQT study is positive when the two groups differ considerably at baseline 
in a study with parallel design [8].  An equally important consideration is the 
use of a positive control.  The purpose of including a positive control arm is 
to demonstrate the study’s ability to detect a small effect on the QT-interval.  
In most studies, moxifloxacin has been selected as it supports the 
appropriateness of its use in TQT studies [9].  Finally, QT correction for heart 
rate has also been an important topic of discussion when interpreting TQT 
study results [10].  Since the Bazett’s and Fridericia’s formula from 1920, 
many new ways to correct QT for heart rate have been proposed such as a 
study-population-specific correction formula [11] and individual subject-
specific correction formula [12]. 
From a statistical perspective, the suggested method of analysis in the ICH 
guidance is the double-delta method where the time-matched mean QTc-
interval difference between active and placebo treatments, both adjusted for 
baseline, is taken [13].  Then an assessment of non-inferiority of the supra-
therapeutic dose to placebo is performed by the intersection-union test [14].  
Thus the statistical method used to calculate sample size on power 
depending on the covariance structure of the data needs to be chosen 
carefully [14-16].  Methods of ECG measurements, such as manual vs. 
automated [17], and statistical approaches used to analyse inter-and intra-
reader variability for ECG measurements also requires attention as the 
traditional Bland-Altman method [18-21] may not be applicable when more 
than two readers are involved [4]. Ultimately, the careful considerations in 
using various statistical methods in different aspects of a TQT study are to 
ensure a well balanced specificity and sensitivity of results. 
A comprehensive evaluation of type I and II error rates is highly desirable 
given the clinical and financial impact of inaccurate decisions regarding drug-
induced QTc interval prolongation. Moreover, alternative methodology 
should be considered in addition to standard hypothesis testing. Frequentist 
methods aimed at detecting a threshold or cut-off value for the effect size are 
not clinically as relevant as methods which enable characterisation of how 
changes in drug exposure correlate with changes in QTc-interval, particularly 
if such effects are observed primarily at supra-therapeutic levels.  
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Currently, evidence shows that the double-delta method produces high false-
positive rates [22].  These rates are also influenced by various study design 
factors, such as design type (i.e. crossover and parallel), sample size and 
number of baseline QT measurements taken [2].  Recently, we have shown 
the potential advantages of applying a Bayesian approach to characterise the 
probability of drug-induced QTc-interval prolongation and the underlying 
concentration-effect relationship [23].  Here we show the clinical and 
statistical implications of using a model-based approach to design and 
analyse drug-induced effects in a TQT study.  Using simulations with a range 
of parameter estimates defining as negative (< 5 msec), borderline (~ 
5msec) and positive (> 10 msec) drug effects, we assessed type I and II error 
rates for different population sizes and study designs using a hypothetical 
population of healthy subjects.  We expect to substantiate previous findings 
which suggest that the use of the double-delta method is inappropriate for 
the analysis of TQT studies. 
10.2 METHODS  
SIMULATION OF EXPERIMENTAL VARIABLES IN A HYPOTHETICAL POPULATION 
Assumptions 
The steps taken to generate a dataset for a hypothetical population were not 
done without certain assumptions.  For instance, we assumed that the 
random noise in the simulated data reflects the actual variability in 
measurements.  In manually read ECG data, there exist between-observer 
variability and potentially other sources of bias due to the algorithm used to 
harmonise the differences, while machine-read ECG values also include 
measurement errors.   
No demographic or other covariates were simulated for the hypothetical 
population because these were deemed as random factors and as such will 
not interfere with the drug-induced effect size estimation.  Furthermore, we 
made the assumption that there was no metabolite formation which could 
lead to delayed onset of effects.  Only the parent drug affected QT-intervals 
and not RR, thus only minor within-subject variability existed in the QT/RR 
relationship. 
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The maximum QTc-interval prolongation had been set to occur at the same 
time as the maximum concentration.  Therefore if the sampling frequency 
had been reduced, it can be assumed that the true drug-induced effect may 
be missed by any analytical  method.   
Data generation 
An overview to generate a dataset for a hypothetical population to compare 
the methods for analysing QTc-interval prolongation is shown in Figure 1.    
 
Figure 1.  Flow diagram describing the steps taken to generate a full dataset for a hypothetical 
population. 
Study population demographics 
The data for this study was derived from a large pool of healthy volunteer 
ECG data, totaling 776 subjects (339 males and 437 females), with mean age 
of 31.1 years (sd. 9.4).  Variables such as QT, QTc, RR, VR, QRS, PR, age, 
weight and gender were available.  From seven different studies, the 24-hour 
profiles of RR- and QT-intervals measured at discrete time points according 
to one of the seven protocols,  were used in this analysis.  The mean QT value 
and the mean RR value from the combined dataset are 390.5 msec (sd. 27.8) 
and 0.96 msec (sd. 0.15) respectively.   
Steps 1 and 2 - QT- and RR-intervals 
Using the starting RR-interval values (RR0) from each of the 776 profiles, a 
vector of RR-intervals was created to sample from for a new hypothetical 
population at time 0.  Then the median RR0 was determined.  Using the 
median value, two distributions of RR differences were defined, one each for 
above and below the median.  We chose to use to split the values at the 
median because it was found that the two distributions statically differ from 
each other whereas the distributions, when the data is separated by bins of 
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different sizes or quartiles, were not significantly different. The definition of 
differences in RR values was defined according to the following formula: 
ΔRR1 = M1 – M2; ΔRR2 = M1 – M3; …, where 
M1 = first RR measurement, M2 = second RR measurement, etc … 
After the RR value for time 0 for each of the profile in the hypothetical 
population was sampled, the RR differences for the remaining profile were 
sampled from one of the two distributions described earlier, depending on 
the starting value.  Finally, a full 24-hour RR profile was back-calculated for 
each subject based on the differences sampled, according to a typical clinical 
trial sampling scheme as shown in Table 1.  Since the new RR profiles 
generated were sampled non-parametrically, physiological boundaries were 
used to prevent unrealistic values.   
 Baseline Dose Post-dose 
Time -1 -0.75 -0.5 -0.25 0 0.5 1 1.5 2 2.5 3 4 6 8 12 18 24 
PK x x    x       x  x x x x x x x x x x x x 
PD x    x      x  x x x x   x  x x  x 
Table 1.  Sampling scheme for hypothetical trial 
QT-intervals for each RR-interval generated according to the aforementioned 
steps were simulated according to the following relationship, 
QT = SLP * RR^EXP + INCPT, 
between all the pairs of QT and RR values in the healthy subject data, where 
SLP is the slope parameter of the relationship, EXP is the exponential term 
quadratic function and INCPT is the parameter of the y-intercept.   
Step 3 - New chemical entity 
The pharmacokinetic model for the hypothetical compound in step 3 was 
assumed to be a one-compartment model with typical PK parameter 
estimates.  The mean population estimates used were 0.75 h-1 for 1st order 
absorption constant, Ka, 0.125 h-1 for clearance, CL, 100 L for central 
compartment volume for a hypothetical dose of 100 mg.  Each parameter 
was also fixed with a variability of 30%. The pharmacodynamic effects were 
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simulated according to the diagram in Figure 2 using a  model described in a 
previous publication [23] with the following relationship: 
 
QTc=SLOPE * CONC+QTc0+A * cos((2 * π/24) * (Ctime-phase))  
  
Equation 1 
The drug-effects (∆y) were fixed at 2 msec for a negative QTc prolongation 
study, 5 msec for a borderline outcome and 10 msec for a positive effect at 
the maximum concentration (Cmax).  A variability of 1 or 4 msec on top of 
the mean effect was added to test the sensitivity of the different 
methodologies.  The PD parameters used in the simulations were 6.75 msec 
for amplitude, 13 h for phase.  QTc0 was the actual mean of the QTc baseline 
values of the simulated population.  30% variability was also applied to all 
the parameters and a residual error of 5.3 was also included. 
 
Figure 2.  Diagram depicting the relationship between imposed maximum effects at maximum 
concentration (Cmax) which helps to define the slope values for the PK/PD relationship for the 
hypothetical compound and thus the resulting drug-induced QTc-interval values. 
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Step 4 - Positive control 
A positive control, such as moxifloxacin, is required to be assessed as part of 
the thorough-QT study to validate the assay sensitivity of each study [16].  
For step 4, the moxifloxacin data was extracted from a two-way crossway, 
placebo-controlled, single-blind trial aimed at evaluating the effect of 
repeated oral doses of lamotrigine on cardiac conduction (study 
SCA104648).  Only data from sessions with placebo and moxifloxacin 
(400mg), which was used as a positive control, were used for the purposes of 
this study.  137 subjects were included in model building of moxifloxacin.    
PHARMACOKINETIC MODELING 
The pharmacokinetic data was modeled first using nonlinear mixed effects 
approach as implemented in NONMEM VI (v 1.0; ICON Development 
Solutions, Ellicott City, MD) [27].  It was found that an oral administration 
two-compartment model best described the data with a combination of zero- 
and first order absorption processes.  Model selection was based on the 
likelihood ratio test, parameter point estimates, and their respective 
confidence intervals, as well as parameter correlations and goodness-of-fit 
plots.  Given that sample collection for drug concentration quantifications 
was carried out at time points different from those for ECG measurements, 
the purpose of the pharmacokinetic model was to allow imputation of drug 
concentrations at the time point of each ECG measurement so that pair-wise 
concentration-effect data would be available for pharmacodynamic (PD) 
modelling. 
PHARMACOKINETIC / PHARMACODYNAMIC MODELING AND SIMULATION 
Instead of applying traditional maximum likelihood methods to model QTc-
interval, a Bayesian adaption of a model was implemented using WinBUGS 
1.4 [28, 29] according to Equation 1.  The model was implemented in a 
hierarchical manner in which subject-specific levels (between-subject 
variability) were considered for all parameters.  In depth details of the model 
building and results were described in an earlier publication [23].  
Simulations for the hypothetical cohort were carried out according the final 
model with zero-order absorption value of 2.21 h-1, first-order absorption 
value of 0.629 h-1, 13.4 L/h for clearance, 122 L as the volume for central 
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compartment, 55.4 L for the peripheral compartment volume, 78.4 h-1 as the 
inter-compartmental clearance and 0.004 msec/ng/mL as the slope value for 
the PKPD relationship.   
STUDY DESIGN SCENARIOS 
Three different clinical study designs (crossover with full day baseline, 
crossover with 3 pre-dose baseline and parallel), number of subjects (16, 30, 
46, 60, 90 and 120) and effect sizes of the hypothetical compound (2, 5 and 
10 msec) were tested.  A total of 36 scenarios were created, Table 2 shows 
the details of permutation. 










































 Table 2.  Study designs for hypothetical trials 
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For each of the thirty-six scenarios, two levels of between subject-variability 
on the slope parameter were considered, namely, 1 and 4 msec.  Finally, one 
hundred trials were generated for each of the scenarios.  
DATASET SIMULATIONS AND RESULTS ANALYSIS 
Using R2.8 (The R project - http://www.r-project.org/) [30], the entire 
simulation exercise was implemented as stated above.  It was also used to 
control the execution and collection of results from other software, namely 
NONMEM and WinBUGS. After the fully completed datasets were generated, 
the software was used again to analyse the results according to the criteria 
described below.   
SENSITIVITY AND SPECIFICITY OF THE DOUBLE-DELTA METHOD AND 
HIERARCHICAL MODELLING APPROACH 
Each dataset was analysed for its propensity for QTc-interval prolongation 
by the double-delta method, as proposed in the ICH E14 guideline [1] and by 
the Bayesian hierarchical modelling approach [23] where all the parameters 
in the model were estimated.  All the results were tabulated and compared to 
the true drug-effects imposed.  For each combination of trial design and 







We defined false positive trials with drug effects of 2 or 5 msec where the 
resulting analysis indicates a QTc-interval prolongation of greater or equal to 
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10 msec.  On the other hand, false negatives were based on analysis done 
with drug-effects equal to 10 msec.  Should the final results from respective 
methods do not detect a prolongation of greater or equal to 10 msec, then the 
trial would be deemed a false negative.   
10.3 RESULTS 
With 36 permutations for design scenarios, 100 simulated trials each, and 
both 1 msec and 4 msec variability imposed on the slope value of the 
hypothetical drug in the PKPD relationship, a total of 7200 trials were 
simulated.  An example of the pharmacokinetic profiles of the new chemical 
entity is displayed in Figure 3. 
 
Figure 3.  An example of the pharmacokinetic profiles over time for the hypothetical compound used for 
the purpose of the simulations. 
4 msec variability on slope 
A tabulation of the final comparison for the sensitivity and specificity 
between the traditional double-delta method and the Bayesian method is 
shown in Table 3a.  The table shows the outcomes for the different trial 
designs tested, namely crossover studies with time-matched full day baseline 
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measurements (CRtm), crossover design with 3 pre-dose baseline 
measurements (CRbl) and parallel study design (PA), along with various 
numbers of subjects per trial.  The false negative and positive percentages 
over different number of subjects per trial design for each design are shown 
in Figure 4 for CRtm, CRbl and PA designs. 
 
Figure 4.  False negative and positive percentages over different number of subject per trial design 
(10msec, 5msec, 2msec) for the crossover time-matched full day baseline measurements (top panels), 
crossover 3 pre-dose baseline measurements (middle panels), and parallel study design scenario 
(bottom panels ).  Solid line denotes result from double delta method, Δ denotes a trial is positive when 
at least 99% of all BUGS simulations are positive, + denotes a trial is positive when at least 95% of all 
BUGS simulations are positive, × denotes a trial is positive when at least 90% of all BUGS simulations 
are positive. 
1 msec variability on slope 
When 1 msec variability was applied on the slope parameter for the PKPD 
relationship of the hypothetical compound, the trend of the results were 
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similar to the 4 msec variability.  The tabulation showing the results for 
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10.4 DISCUSSIONS 
In summary, the Bayesian approach has higher or equal specificity and 
sensitivity compared to the double-delta method in all trial designs.  False 
positive trials are only detected with the double-delta method where lower 
specificity is observed with smaller number of subjects per trial.  Lower 
specificity is also seen with full day baseline measurements as compared to 
only 3 pre-dose baseline measurements.  In addition, false negative trials are 
more frequently detected with parallel design.  Lower sensitivity is achieved 
with the double-delta method with lesser number of subjects per trial as 
expected.   
The results from this study highly suggest that the Bayesian approach should 
be considered when analysing the propensity of drug-induced QTc-interval 
prolongation when determining the proarrhythmic-genicity of new 
compounds in the future.  The novel approach not only has the ability to 
correctly identify the effect size at the therapeutic exposure range [24] due to 
its nature to describe the PKPD relationship of the compound [25, 26], but it 
is also sensitive enough to perform the analysis with smaller number of 
subjects and has the flexibility to accommodate different trial designs. 
Keeping in mind that the high cost of studies is mainly attributed to the 
requirement of large trials to satisfy the power needed to show an effect of a 
QT-interval prolongation of 5 msec, being able to achieve the same results 
with lower sample sizes would minimise the burden. In the present analysis, 
very specific conditions and properties in pharmacokinetic and 
pharmacodynamic have been placed in the hypothetical compound.  
However, the Bayesian approach is not limited to those specific conditions 
and can be used towards a variety of compounds, such as those where 
covariate effects alter the PK, compounds with concurrent effect on RR as 
well as on QT or other cardiovascular parameter. The same flexibility can be 
applied to manually-read or machine-read ECG measurements or any other 
algorithms, as well as other methods used to resolve between-observer 
variability in the observations, as those method are independent to the way 
ECG is read. 
Another advantage of the PKPD model is that it can handle multiplicity issues 
arising from having to establish non-inferiority at each time point.  The QTc 
prolongation is established continuously at the range of observable 
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concentration, rather than at each discrete measurement.  Conversely, to 
minimise the problem, investigators may choose to take measurements only 
at a bare minimum required number of time points when using the double-
delta approach.   
Ultimately, the newly proposed Bayesian method still depends on the 
placement of PK and PD samples taken for the study.  If the sampling 
schedule misses the maximum concentration that leads to the true maximum 
effect being absent from the data or Emax is unrecorded independently, then 
the analysis would not be able to capture the true proarrhythmic property of 
the compound.  However, should the nature of the PKPD relationship is 
known in advance, such as hysteresis, adjustments can be made to the 
Bayesian model to accommodate for the use of an effect compartment. 
In conclusion, we have conducted a simulation of a hypothetical population 
on a compound with imposed drug effects so that we can clearly compare the 
results of the drug-induced QTc-interval prolongation analysis using a 
previously published Bayesian approach with the double-delta method as 
proposed by the ICH E14 guideline.  The outcomes have shown that the 
Bayesian approach is able to detect the prolongation of QTc-interval with 
equal or better accuracy and precision at various effect sizes, using different 
number of subjects and with a variety of trial designs.  These encouraging 
facts are envisioned to provide an alternative to the current methodology 
used in TQT studies as well as a strategy to minimise the cost of drug 
development.   
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ABSTRACT 
The aim of the present study was to investigate if the first-time-
in-human (FTIH) trials can be modified and optimised to 
achieve the same information as thorough-QT (TQT) studies.  
Three different FTIH trial designs with various sample sizes 
were simulated and analysed using negative and positive 
hypothetical drug-effects.  First, a traditional dose escalation 
study design was simulated and analysed according to a 
standard protocol. Second, an additional dose of moxifloxacin 
was incorporated into the traditional study design where only 
PD measurements were sampled and historical PK information 
was used.  A similar scenario was created last where both PK 
and PD observations are simulated.  All scenarios performed, 
adequately captured the drug-induced QT-interval 
prolongation with the probabilities correctly indicating the 
likelihood of a change greater than or equal to 10 msec.  By 
modifying the traditional FTIH studies, we were able to gain 
valuable safety information early in development which can 
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11.1 INTRODUCTION 
Since 2005, the International Conference on Harmonisation (ICH) introduced 
the topic E14 guideline mandating the systematic evaluation of QT 
prolongation [2].   Regulatory agencies expect evidence on the propensity of 
a new chemical / biological entity to cause pro-arrhythmia, as determined by 
data arising from a thorough-QT (TQT) study.  Numerous arguments have 
been proposed to defend the need for a separate clinical trial to address this 
specific safety concern [3]. Among other factors, the requirement for 
manually read ECGs, a positive control treatment arm and time-matched 
sampling scheme have been used as arguments to exclude alternative 
options for evidence on cardiovascular safety (e.g. aggregated summary of 
safety or  meta-analysis).  
Oncoming evidence clearly show however, that the current 
recommendations for a TQT study appear to have been reached without 
careful evaluation of pharmacological, statistical and technical aspects 
underlying the assessment of drug-induced effect on cardiac repolarisation.  
From a pharmacological perspective, TQT studies neglect the underlying 
concentration-effect relationship, which ultimately determines the clinical 
relevance of drug-induced effects [1, 4].  Statistically, study design and 
sampling schemes overlook type I and II error rates, in particular when 
replicates or more frequent sampling are used [5, 6]. Furthermore, recent 
data suggest that despite the expenditure of 2-7 million US dollars, 
conclusions about the magnitude of drug effects are possibly biased [7].  
From a technical perspective, the introduction of manually read tracings has 
not eliminated all the concerns regarding measurement bias.  Surface ECG 
algorithms have intrinsic limitations which cannot be fully mitigated by 
manual reading procedures. More recently, the value of current regulations 
has been questioned even from a cost-effectiveness perspective [7, 8].   
Often opposition to the requirement for a mandatory TQT study is perceived 
as an attempt to evade the need to safeguard patients. For those less familiar 
with the evolution of the proposal that resulted in the current guidelines, it 
should be clear that from a clinical and scientific perspective, there is no 
dispute about the importance of obtaining accurate evidence of 
cardiovascular safety. Undoubtedly, what one must continue to question is 
how such evidence is generated, analysed and interpreted. 
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Given the statistical flaws, the scientific oversight, the ethical burden and 
financial consequences of study design implementation recommended by 
ICH E14, the current investigation assesses the feasibility of using first-time-
in-human (FTIH) studies as the basis for evidence synthesis to investigate 
the propensity for pro-arrhythmic effects.  FTIH studies are a mandatory step 
in the drug development process.  Traditionally, the studies are small, with 
single and multiple escalated doses, normally reaching supra-therapeutic 
levels in healthy subjects or in the target patient population.  The purpose of 
such escalating doses in a FTIH study is to characterise pharmacokinetics 
(ADME - absorption, distribution, metabolism, excretion properties), 
pharmacodynamics, safety and tolerability. In principle, the doses or dose 
range evaluated during escalation should enable the evaluation of the 
concentration-effect curve, providing evidence for drug effects not only at 
therapeutic level, but also supra-therapeutic levels. From a safety and 
tolerability perspective, pharmacodynamic measures are monitored 
frequently or continuously throughout the dosing interval in parallel to 
pharmacokinetic sampling. Specifically, 12-lead ECG or Holters are used for 
cardiovascular safety monitoring according to the common standards 
applied also for other phase I clinical trials [9].   
Recently, using a model-based approach, we have shown the advantages of 
using a Bayesian hierarchical model to quantify drug-induced effects on QTc-
interval [1].  Our approach also provides estimates of the probability of QTc 
prolongation versus a wide range of drug concentrations, providing 
immediate translation of the findings in terms of their clinical relevance. It 
should be noted that the drug-specific parameter in this model (slope) does 
not independently indicate whether there is a risk associated with the use of 
the compound. Rather, it provides an unambiguous description of the PKPD 
relationship, taking into account various sources of variability. We anticipate 
therefore that the use of an integrated hierarchical model for the assessment 
of the propensity for QTc-interval prolongation will be sufficiently robust to 
overcome some of the criticisms around the use of different study designs 
and the reliance on automated ECG measurements. 
We also challenge the requirement for the continuous assessment of 
individual sensitivity to QTc-interval prolongation. In fact, it has been 
demonstrated that other interventions or procedures such as food and liquid 
intake and exercise may all be used as proxy for sensitivity [10]. Yet, we do 
not exclude the possibility of including a benchmark or positive control arm 
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in a typical FTIH trial, if necessary.  The many historical studies with 
moxifloxacin [11] can be used in an integrated manner as benchmark or as 
priors during data analysis. 
11.2 METHODS  
SIMULATION OF EXPERIMENTAL VARIABLES IN A HYPOTHETICAL POPULATION 
Assumptions 
The steps taken to generate a dataset for a hypothetical population were not 
done without certain assumptions.  For instance, we assumed that the 
random noise in the simulated data reflects the actual variability in 
measurements.  In manually read ECG data, there exist between-observer 
variability and potentially other sources of bias due to algorithm used to 
harmonise the differences, while machine-read ECG values also includes 
measurement errors.  We have also assumed there are no systematic biases 
due to automated ECG readings that yield reliable measurements with 
constant variance throughout the simulation.  
No demographic or other covariates were simulated for the hypothetical 
population because these were deemed as random factors and as such will 
not interfere with the drug-induced effect size estimation.  Furthermore, we 
made the assumption that there was no metabolites formation which could 
lead to the delayed onset of effects.  The parent drug solely affected QT-
intervals and not on RR, thus only minor within-subject variability existed in 
the QT/RR relationship. 
Data generation 
An overview to generate a dataset for a hypothetical population to compare 
the methods for analysing QTc-interval prolongation is shown in Figure 1.    
Study population demographics 
The data for this study was derived from a large pool of healthy volunteer 
ECG data, totaling 776 subjects (339 males and 437 females), with mean age 
of 31.1 years (sd. 9.4).  Variables such as QT, QTc, RR, VR, QRS, PR, age, 
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weight and gender were available.  From seven different studies, the 24-hour 
profiles of RR- and QT-intervals measured at discrete time points according 
to one of the seven protocols, were used in this analysis.  The mean QT value 
and the mean RR value from the combined dataset are 390.5 msec (sd. 27.8) 





 Baseline Dose Post-dose 
Time -1 -0.75 -0.5 -0.25 0 0.5 1 1.5 2 2.5 3 4 6 8 12 18 24 
PK x x    x       x  x x x x x x x x x x x x 
PD x    x      x  x x x x   x  x x  x 
 
Figure 1.  Flow diagram describing the steps taken to generate a full dataset for a hypothetical 
population. * A closer examination on the relationship between imposed maximum effects at maximum 
concentration (Cmax) which helps to define the slope values for the PK/PD relationship for the 
hypothetical compound and thus the resulting drug-induced QTc-interval values. ** The typical 
sampling scheme for a clinical trial used in step 4. 
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Steps 1 and 2 - QT- and RR-intervals 
Using the starting RR-interval values (RR0) from each of the 776 profiles, a 
vector of RR-intervals was created to sample from for a new hypothetical 
population at time 0.  Then the median RR0 was determined.  Using the 
median value, two distributions of RR differences were defined, one each for 
above and below the median.  We chose to use to split the values at the 
median because it was found that the two distributions statically differ from 
each other whereas the distributions, when the data is separate by bins of 
different sizes or quartiles, were not significantly different. The definition of 
differences in RR values was defined according to the following formula: 
 
ΔRR1 = M1 – M2; ΔRR2 = M1 – M3; …, where 
M1 = first RR measurement, M2 = second RR measurement, etc … 
 
After the RR value for time 0 for each of the profile in the hypothetical 
population was sampled, the RR differences for the remaining profile were 
sampled from one of the two distributions described earlier, depending on 
the starting value.  Finally, a full 24-hour RR profile was back-calculated for 
each subject based on the differences sampled, according to a typical clinical 
trial sampling scheme as part of Figure 1.  Since the new RR profiles 
generated were sampled non-parametrically, physiological boundaries were 
used to prevent unrealistic values.   
QT-intervals for each RR-interval generated according to the aforementioned 
steps were simulated according to the following relationship, 
 
QT = SLP * RR^EXP + INCPT, 
 
between all the pairs of QT and RR values in the healthy subject data, where 
SLP is the slope parameter of the relationship, EXP is the exponential term 
quadratic function and INCPT is the parameter of the y-intercept.   
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Step 3 - New chemical entity 
The pharmacokinetic (PK) model for the hypothetical compound in step 3 
was assumed to be a one-compartment model with typical PK parameter 
estimates.  The mean population estimates used were 0.75 h-1 for 1st order 
absorption constant, Ka, 0.125 h-1 for clearance, CL, 100 L for central 
compartment volume for a hypothetical dose of 100 mg.  From the initial PK 
model, concentration values for doses of 5 mg, 10 mg, 25 mg, 50 mg, 250mg 
and 500 mg were simulated.  Each parameter was also fixed with a variability 
of 30%. The pharmacodynamic effects were simulated according to the 
sampling scheme shown as part of Figure 1 and the model described in a 
previous publication [1] with the following relationship: 
QTc=SLOPE * CONC+QTc0+A * cos((2 * π/24) * (Ctime-phase)) 
Equation 1 
The drug-effects (∆y) were fixed at 2 msec for a negative QTc prolongation 
study, 5 msec for a borderline outcome and 10 msec for a positive effect at 
the maximum concentration (Cmax).  A variability of 1 or 4 msec on top of 
the mean effect was added to test the sensitivity of the different 
methodologies.  The PD parameters used in the simulations were 6.75 msec 
for amplitude, 13 h for phase.  QTc0 was the actual mean of the QTc baseline 
values of the simulated population.  30% variability was also applied to all 
the parameters and a residual error of 5.3 was also included. 
Step 4 - Positive control 
For step 4, the moxifloxacin data was extracted from a two-way crossway, 
placebo-controlled, single-blind trial aimed at evaluating the effect of 
repeated oral doses of lamotrigine on cardiac conduction (study 
SCA104648).  Only data from sessions with placebo and moxifloxacin 
(400mg), which was used as a positive control, were used for the purposes of 
this study.  137 subjects were included in model building of moxifloxacin.    
PHARMACOKINETIC MODELLING 
The pharmacokinetic data was modelled first using nonlinear mixed effects 
approach as implemented in NONMEM VI (v 1.0; ICON Development 
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Solutions, Ellicott City, MD) [12].  It was found that an oral administration 
two-compartment model best described the data with a combination of zero- 
and first order absorption processes.  Model selection was based on the 
likelihood ratio test, parameter point estimates, and their respective 
confidence intervals, as well as parameter correlations and goodness-of-fit 
plots.  Given that sample collection for drug concentration quantifications 
was carried out at time points different from those for ECG measurements, 
the purpose of the pharmacokinetics model was to allow imputation of drug 
concentrations at the time point of each ECG measurement so that pair-wise 
concentration-effect data would be available for pharmacodynamic (PD) 
modelling. 
PHARMACOKINETIC / PHARMACODYNAMIC MODELLING AND SIMULATION 
Instead of applying traditional maximum likelihood methods to model QTc-
interval, a Bayesian adaption of a model was implemented using WinBUGS 
1.4 [13, 14] according to Equation 1.  The model was implemented in a 
hierarchical manner in which subject-specific levels (between-subject 
variability) were considered for all parameters.  In depth details of the model 
building and results were described in an earlier publication [1].  Simulations 
for the hypothetical cohort were carried out according the final model with 
zero-order absorption value of 2.21 h-1, first-order absorption value of 0.629 
h-1, 13.4 L/h for clearance, 122 L as the volume for central compartment, 
55.4 L for the peripheral compartment volume, 78.4 h-1 as the inter-
compartmental clearance and 0.004 msec/ng/mL as the slope value for the 
PKPD relationship.   
STUDY DESIGN SCENARIOS 
Three different FTIH trial designs, number of subjects (12, 18, 27) and drug-
effect sizes of the hypothetical compound were tested, as shown in Table 1.  
Randomisation schemes of each dose-escalation studies are depicted in 
Tables 2a-c. 
In total, 150 simulations were performed for each scenario.  The hypothetical 
compounds were assumed to have no effect (2 msec), or significant effect (10 
msec) on QTc-interval.  Doses of 5, 10, 25, 50, 100, 250 and 500 mg of 
hypothetical compounds were given in all scenarios. Pharmacokinetic (PK) 
266        First-Time-In-Human Studies 
and pharmacodynamic (PD) sampling schemes were simulated according to 
standard FTIH protocol.  Data analysis was performed in WinBUGS v 1.4.3, 
where the probabilities of QTc-interval prolongation were derived from the 
underlying QTc-interval versus concentration relationship [1]. 
  Scenario 1         (Typical FTIH) 
Scenario 2            
(Modified 1 FTIH) 
Scenario 3         
(Modified 2 FTIH) 
Trial Design 
- 5 sessions 
- Placebo-controlled 
trial 
- 4 consecutively 
escalating doses of 
hypothetical 
compound 
- 6 sessions 
- Placebo-controlled 
trial 
- 4 consecutively 
escalating doses of 
hypothetical 
compound 
- Single dose of 
moxifloxacin 
- 5 sessions 
- Placebo-controlled 
trial 
- 3 consecutively 
escalating doses of 
hypothetical 
compound 
- Single dose of 
moxifloxacin 
Sample Size  N = 12 N = 12 and 18 N = 18 and 27 
Randomisation 
Two cohorts: 
- Cohort 1: 5, 10, 25 
and 50 mg of active 
drug 
- Cohort 2: 50, 100, 
250 and 500 mg of 
active drug 
Two cohorts: 
- Cohort 1: 5, 10, 25, 
and 50 mg of active 
drug 
- Cohort 2: 50, 100, 
250 and 500 mg of 
active drug 
- All received 
moxifloxacin 
Three cohorts: 
- Cohort 1: 5, 10 and 
25 mg of active drug 
- Cohort 2: 25, 50 and 
100 mg of active drug 
- Cohort 3: 100, 250 
and 500 mg of active 
drug 




Trial was analysed 
with uninformative 
priors as well as using 
historical moxifloxacin 
parameter estimates 
as informative prior 
Only ECG were taken 
when moxifloxacin 
was administered.  
Historical population 
PK values were used 
for both cohorts. 
PK and ECG were 




Table 1.  Trial design specifications are described for each of the different FTIH studies. 
DATASET SIMULATIONS AND RESULTS ANALYSIS  
Using R2.8 (The R project - http://www.r-project.org/) [15], the entire 
simulation exercise was implemented as stated above.  It was also used to 
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control the execution and collection of results from other software, namely 
NONMEM and WinBUGS. After the fully completed datasets were generated, 
the software was used again to analyse the results according to the criteria 
described in the next section.   
SUBJ DAY 1 DAY 8 DAY 15 DAY 21 DAY 28 
1 PLACEBO D1 D2 D3 D4 
2 D1 D2 PLACEBO D3 D4 
3 D1 PLACEBO D2 D3 D4 
4 D1 D2 D3 D4 PLACEBO 
5 D1 D2 D3 PLACEBO D4 
6 D1 D2 PLACEBO D3 D4 
 
SUBJ DAY 1 DAY 8 DAY 15 DAY 21 DAY 28 DAY 35 
1 PLACEBO D1 D2 D3 D4 Moxi 
2 D1 D2 PLACEBO D3 D4 Moxi 
3 D1 PLACEBO D2 D3 D4 Moxi 
4 D1 D2 D3 D4 PLACEBO Moxi 
5 D1 D2 D3 PLACEBO D4 Moxi 
6 D1 D2 PLACEBO D3 D4 Moxi 
 
SUBJ DAY 1 DAY 8 DAY 15 DAY 21 DAY 28 
1 PLACEBO D1 D2 D3 Moxi 
2 D1 D2 PLACEBO D3 Moxi 
3 D1 PLACEBO D2 D3 Moxi 
4 D1 D2 PLACEBO D3 Moxi 
5 D1 PLACEBO D2 D3 Moxi 
6 D1 D2 D3 PLACEBO Moxi 
7 PLACEBO D1 D2 D3 Moxi 
8 D1 D2 D3 PLACEBO Moxi 
9 D1 D2 PLACEBO D3 Moxi 
 
Tables 2a-c.  Detailed randomisation scheme for each design: traditional FTIH (top), modified 1 FTIH 
(middle), and modified 2 FTIH (bottom). 
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SENSITIVITY AND SPECIFICITY OF THE DOUBLE-DELTA METHOD AND 
HIERARCHICAL MODELLING APPROACH 
Each dataset was analysed for its propensity for QTc-interval prolongation 
by the double-delta method, as proposed in the ICH E14 guideline [2] and by 
a Bayesian hierarchical modelling approach [1] where all the parameters in 
the model were estimated.  All the results were tabulated and compared to 
the true drug-effects imposed.  For each combination of trial design and 







We defined false positive trials with drug effects of 2 or 5 msec where the 
resulting analysis indicates a QTc-interval prolongation of greater or equal to 
10 msec.  On the other hand, false negatives were based on analysis done 
with drug-effects equal to 10 msec.  Should the final results from respective 
methods do not detect a prolongation of greater or equal to 10 msec, then the 
trial would be deemed a false negative.   
11.3 RESULTS 
The three different scenarios required a total 7200 FTIH datasets to be 
simulated.  The top panels of Figure 2 represent an example of the dose 
escalation PK and PD profiles of the hypothetical compound.  Moxifloxacin 
(positive control) profiles are shown in the bottom panels of Figures 2.   
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It was possible to accurately predict the risk of 10 msec QT prolongation 
using simulated FTIH data, with and without evidence from a positive control 
treatment arm.  Figures 3 and 4 present a selection of the most relevant 
findings.  The uncertainty in the relationship between QT-interval 
prolongation versus concentration and the probability of an increase of 10 
msec was larger with smaller population size in all cases.   
 
Figure 2. Typical PK (left), PD (right) profiles of the hypothetical compound (top panels), PK (left) and 
PD (right) profiles of moxifloxacin (lower panels) used in the simulated FTIH studies. 
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Figure 3. Relationship between QT prolongation (top panels) and probability of  >10 msec increase 
(bottom panels) vs. concentration for a positive compound with 18 or 27 subjects for each of the 
scenario simulated - typical FTIH design, modified design with moxifloxacin PD measurements and 
modified design with moxifloxacin PK and PD measurements.  The dotted vertical line in each of the 
graphs represent the concentration at which the hypothetical drug effects were confined to. The two 
dotted horizontal lines in the top panels indicate the positive drug effect of 10 msec QT prolongation and 
negative effect of 2 msec increase.  Each plot also contains the median, 5th and 95th percentile of the 
predicted QT prolongation as well as the probability of 10 msec increase.   
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Figure 4. Relationship between QT prolongation (top panels) and probability of  >10 msec increase 
(bottom panels) vs. concentration for a negative compound with 12 or 18 subjects for each of the 
scenario simulated - typical FTIH design, modified design with moxifloxacin PD measurements and 
modified design with moxifloxacin PK and PD measurements.  The dotted vertical line in each of the 
graphs represent the concentration at which the hypothetical drug effects were confined to. The two 
dotted horizontal lines in the top panels indicate the positive drug effect of 10 msec QT prolongation and 
negative effect of 2 msec increase.  Each plot also contains the median, 5th and 95th percentile of the 
predicted QT prolongation as well as the probability of 10 msec increase.   
Type I and type II error rates 
Finally, Tables 3a and b displays the specificity and sensitivity rates that are 
compared between the double delta method used in a traditional TQT and 
Bayesian approach suggested for the FTIH studies using the same sample 
sizes, namely 12, 18 and 27.  The trends are plotted in Figure 5. 
 
272        First-Time-In-Human Studies 
 
Figure 5.  False negative and positive rates for the Bayesian approach used in the FTIH studies with 
various study scenarios - typical FTIH design (top row), modified 1 design (second row), modified 2 
design (third row) and number of subjects.  Δ, + and x dash lines describe the results using different 
definitions of threshold of detection at 99%, 95% and 90% respectively. The last row contains false 
positive and negative rates using double delta method with the same  number of subjects. 
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4 msec variability on SLP CRbl 12 CRbl 18 CRbl 27 
DD 
Specificity 0.96 0.915 0.96 
Sensitivity 1 1 1 
 












 (P >= 99%) 
Specificity 0.95 0.87 0.87 0.91 0.68 0.92 
Sensitivity 1 1 1 1 1 1 
BUGS 
 (P >= 95%) 
Specificity 0.97 0.94 0.95 0.97 0.85 0.98 
Sensitivity 1 1 1 1 1 1 
BUGS 
 (P >= 90%) 
Specificity 0.98 0.97 0.97 0.98 0.93 0.99 
Sensitivity 1 1 0.97 1 1 0.99 
 
Table 3.  Specificity and sensitivity tabulation results the FTIH simulations with 4 msec variability 
applied to the slope parameter for the double-delta method (top) and the Bayesian approach (bottom).  
Results are shown for detection thresholds at 99%, 95% and 90%. 
11.4 DISCUSSIONS 
Our study has demonstrated that FTIH studies can be used to assess the 
probability of drug-induced QTc prolongation. In contrast to current belief 
regarding the requirement for statistical power of a study to detect 5 msec of 
prolongation, the false-positive rates in the newly proposed FTIH studies are 
in general lower than what is observed in a typical TQT study.  Moreover, the 
current execution of TQT studies does not necessarily guarantee accuracy 
and precision of the effect size which does not satisfy the intention of 
conducting a stand-alone study dedicated to detect any proarrhythmic 
property of new compounds.  An advantage to using the Bayesian PKPD 
approach to analyse the proarrhythmic property is its ability to describe the 
prolongation effect over the therapeutic range or specific dose levels.  Since 
FTIH trial is a mandatory step in the drug development process, to increase 
the number of ECG measurements taken to provide a larger PD sample size 
will provide an initial assessment of the compound’s safety profile.  This can 
in turn support the strategic decision to proceed or not with development. 
In our study, we did not find a difference in the outcomes with and without 
the inclusion of a positive-control arm.  Given that benchmark moxifloxacin 
data may not explicitly reflect individual sensitivity to the effects of a NCE in 
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this instance, a comprehensive assessment of the propensity for QTc-interval 
prolongation may be achieved by further integration with preclinical 
findings, from in vitro experiments and in vivo studies.  This further call for 
the need to generate safety data in an integrated manner, in which drug 
exposure and potential biomarkers are analysed using a model-based 
approach to ensure the results are translatable and comparable.  However, 
there is still no consensus among regulatory authorities whether preclinical 
results can predict the risk of QTc prolongation in humans and guide the 
early clinical QTc assessment strategy [9, 16-18], as evident from the ICH 
S7A and S7B guidance [19, 20].   
The Bayesian approach is limited to improving the analytical aspect to detect 
QTc-interval prolongation of a compound and thus only used to assess the 
propensity of proarrhythmic properties.  It does not, however, solve other 
issues in TQT studies of practical or statistical nature with ECG 
measurements.  Figure 6 summarises the potential areas of concern where 
significant impact can be made to the observed QT-interval data.  These 
include the algorithm used for ECG recordings, the technique selected to 
correct measurement bias, the nature of the disease that influence ECG 
values, and various other covariates that can impact the recordings. 
In general, most forms of ECG measurements (manual, automated, computer-
assisted (CA)) are able to demonstrate assay sensitivity of moxifloxacin in 
healthy volunteers.  However the measurement variability differs greatly 
with manual and CA measurements at 5-28% greater than that associated 
with automated methods [21].  Much research is currently performed to 
address the precision of QT measurements including the use of automated 
readings.  Efforts are also being made to address statistical issues [22, 23], 
identifying sources of variability [24], new algorithms [25-30] as well as the 
issues of reproducibility [31-33].   
In 2001, the US Food and Drug Administration (FDA) even requires digital 
ECGs from TQT be submitted into its Warehouse and encourages other 
recordings as part of new drug application (NDA) dossiers for review and 
approval purposes [34].   Beyond its official use, the Warehouse also 
provides a great opportunity for pharmaceutical companies and academia to 
conduct research.  It is an asset that can be used to study new biomarkers of 
proarrhythmia, correlate them with clinical and laboratory cardiac safety 
outcomes, improving the diagnosis and treatment of cardiovascular diseases 
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[34], determine the underlying physiological variation, and use as prior 




Figure 4.  Summary of the potential areas of concern where significant impact can be made to the 
observed QT-interval data, including the algorithm used for ECG recordings, the technique selected to 
correct measurement bias, the nature of the disease that influence ECG values, and various other 
covariates that can impact the recordings [35]. 
 
There are occasions when traditional TQT studies cannot be conducted in 
special populations such as testing anti-cancer therapies in patients [36].  
Due to the fact that our mechanistic PKPD approach can detect prolongation 
at any observable concentration range, and does not necessarily require the 
inclusion of a positive control arm, it can be applied to any trial populations 
where only therapeutic doses can be applied.  Our results showed that 
evidence for the drug concentration-QTc prolongation relationship can be 
accurately derived from FTIH studies, which provides safety information 
regarding the compound early in the clinical development process.  In the 
Bayesian analysis approach, biological and mechanism-based elements are 
differentiated thus making the model translatable.  Furthermore, we have 
demonstrated that PKPD relationships can eliminate statistical flaws 
associated with the double-delta method, but most importantly decrease 
type I and II error rates in the traditional approach.  Thus by extension, the 
results clearly challenged the need and relevance of a TQT study. 
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12.1 REGULATORY FRAMEWORK AND CHALLENGES IN THE 
TRANSLATION OF PRODROMIC EFFECTS INTO RISK. 
Different intrinsic and extrinsic factors, including genetic susceptibility, are 
known to prolong QT/QTc-interval in humans. Although QT-interval 
prolongation is not necessarily harmful, it is currently deemed a biomarker 
for ventricular tachyarrhythmias, such as torsades de pointes (TdP) and a 
risk or prognostic factor for sudden cardiac death [1, 2].  Of particular 
concern to regulatory authorities is the evidence of QTc-interval 
prolongation for non-antiarrhythmic drugs [3, 4]. Despite continuous efforts 
in characterising the potential dromotropic effects of new molecules, QTc-
interval prolongation has become the second most common reason for post-
marketing drug withdrawal. Furthermore, the number of non-antiarrhythmic 
drugs that carry what has been termed a “QT-liability” continues to increase. 
Given the implications of what has become the most recent 
“pharmacoepidemic”, it is essential to predict the potential for QTc-interval 
prolongation and to accurately assess its clinical relevance as early as 
possible to prevent regulatory actions such as denial of approval, delays and 
severe restrictions on the use of the product [5]. 
In addition to the development of experimental protocols for the assessment 
of in vitro and in vivo cardiovascular safety in preclinical species, a guideline 
(topic E14) by the International Conference on Harmonisation (ICH) has 
been used as basis for the clinical evaluation of the proarrhythmic propensity 
in new compounds [6].  Similar guidelines (S7A and S7B) were also 
developed for the preclinical studies [7, 8].  In the E14 document, a dedicated 
trial is recommended to formally dismiss the evidence of a safety signal. The 
so-called thorough-QT (TQT) study is designed and powered to detect a 5 
msec increase and includes a one-sided confidence interval that is less than 
10 msec to be deemed negative.  While the introduction of appropriate 
monitoring and evaluation is well intended, the recommendations made are 
far from perfect (Figure 1).  
In this thesis we have attempted to highlight three major flaws in the current 
approach, which can undermine the evaluation and development of suitable 
molecules for the treatment of important unmet medical needs. The first 
aspect refers to assumptions underlying the translation of 
pharmacological effects from experimental protocols or clinically 
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controlled trials to real-life conditions. The impact of varying 
experimental settings and procedures seems to be overlooked, leading to 
important gaps in the understanding of how pharmacological properties 
translate into risk in a strictly quantitative manner.  The second aspect 
pertains to the conceptual definition and biological implications of the 
differences between association and causation. The choice for the use of 
QT-interval as a biomarker or proxy for the risk of pro-arrhythmias without 
accounting for the underlying pharmacokinetic-pharmacodynamic 
relationships blurs the assessment of causality. Basic signal detection 
principles appear to be missing in research protocols, including the lack of 
relative operating curves, consistency of the data and quantitative strength 
of the association, taking into account the construct validity. The third and 
possibly most important aspect from a drug development perspective is the 
lack of a framework that enables effective evidence synthesis for the 
assessment of risk and benefit-risk ratio. The focus on evidence generation 
without data integration, including systematic incorporation of prior 
knowledge leads to less than optimal experimental protocols and inaccurate 
decision criteria. Consequently, wrong recommendations are likely to arise 
with regard to the termination of a compound in development. Most 
importantly, current approaches prevent any comprehensive assessment of 
what the expected risk is in the target population and how mitigation 
measures might perform in real life conditions. 
In drug development, the ideal situation for the prediction of drug-induced 
QTc prolongation would be if in vitro experiments showed strong predictive 
value of the clinical outcome both from a qualitative (QTc prolongator or not) 
and quantitative (the amount of prolongation per concentration unit) 
perspective.  A qualitative correlation (trying to avoid false positive and false 
negative results) has been proposed by different authors [9, 10], but has 
been based on an empirical classification of findings. However, one of the 
main issues with these qualitative approaches is that the compounds with a 
small QTc prolonging effect are hard to place and that quantitative 
approaches that facilitate the integration of evidence obtained during the 
different stages of development and therapeutic use of drugs are lacking. 
Although our work has focused on the translation of in vivo data, the 
availability of predictive measures which take in vitro properties into 
account remains highly desirable. The possibility to make inferences from in 
vitro measures would imply the generation of less complex experimental 
data and decision making at an earlier stage of development. Consequently, 
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this could represent an opportunity for less attrition post candidate 
selection.  
 
Figure 1: Clinical trials and in particular the TQT trial design yields estimates of 
drug effects on a restricted subset of the population.  The expectation that such a 
study will generate accurate evidence of the true safety profile of a new chemical 
entity in the overall population (with different demographic characteristics, 
comorbidities and concomitant medication usage) is questionable, especially if one 
takes into account the lack of assessment of concentration-effect relationship in the 
analysis of a TQT study.   
Instead, we have focused on the subsequent phase of drug development, for 
which no hurdles should exist with regard to the translational value of data 
being generated in vivo, in particular in early clinical development, during 
which pharmacokinetics and intensive cardiovascular monitoring are 
already common practice. Most importantly, we attempted to identify the 
translational gaps caused by the differences associated with the controlled 
conditions used in randomised clinical trials and in particular with regard to 
the effects of inclusion and exclusion criteria. The premise for this work was 
that risks are inherent to all drug interventions and as such, decisions about 
developability and therapeutic use should rely on quantitative assessment of 
the risk it poses to the target population. Rather than relying on assumptions 
about the construct validity and generalisability of experimental protocols, 
we deem more appropriately to rely on inferences about risk by taking into 
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account the impact of potential differences between experimental protocols 
and real-life conditions.  
Another important point arising in the work proposed here is that evidence 
synthesis can be by far more powerful than evidence generation, as it 
encompasses prior and existing knowledge. In fact, in conjunction with 
appropriate clinical and scientific rationale and suitable statistical 
methodology, evidence synthesis by inferential methods can provide a much 
more reliable basis for decision making, taking into account practical and 
ethical constraints associated with the generation of safety data in humans.  
This issue is particularly relevant for low frequency events as well as when 
risk results from long term exposure.  
Given the aforementioned systematic flaws, the high costs associated with 
conducting a TQT trial and the need to accurately determine the implications 
of prodromic effects (if any), it is paramount to explore novel strategies and 
consider implementation of new processes for the evaluation of 
cardiovascular safety of non-antiarrhythmic drugs. Most importantly, 
regulation should reflect scientific understanding. This is clearly not the case 
for ICH E14, which still relies on scientific and regulatory context that 
prevailed more than a decade ago, when quantitative pharmacology concepts 
and pharmacometrics as clinical sciences were evolving. It is imperative that 
novel, robust methodologies are considered in regulatory decision making 
and that guidance documents and policies reflect such advancements. By and 
large, inferential methods by modelling and simulation are under-utilised in 
safety assessment. Despite the wealth of data generated throughout clinical 
development and the evidence from historical data of compounds showing 
similar pharmacological properties, little has been done to ensure that prior 
knowledge is used in a systematic manner all the way from early clinical 
trials to post-market safety surveillance.  
As shown throughout this thesis, a new paradigm is proposed for safety 
assessment in which evidence synthesis is favoured, making evidence 
generation a confirmatory step in the continuum between hypothesis and 
scientific understanding or knowledge. In this context, inferential methods 
are central to evidence synthesis and translation of safety findings into 
hazard or risk. The essence and contribution of our research is the possibility 
to introduce and incorporate pharmacological concepts into 
pharmacoepidemiology, bridging the gap between drug development, and 
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health care and therapeutics.  An immediate implication of our approach 
is the shift from association to causation as the basis for the evaluation 
of safety signals (Figure 2).    
 
Figure 2. Inferential methods are essential to establish causality during signal 
detection. The inclusion of concentration-effect relationships into pharmaco-
epidemiological research can provide more accurate, quantitative estimates of 
drug-induced effects.  Different experimental and non-experimental conditions can 
be evaluated by inference. An important advantage of evaluating risk by inferential 
methods using modelling and simulation is the possibility to discriminate between 
drug and systems or patient specific properties. 
Based on the premises outlined above, this thesis has provided the basis for 
reducing attrition during the screening of compounds and improving the 
efficiency of experimental protocols for the evaluation of drug-induced 
prodromic effects. In Chapter 1, we have presented an overview of the 
approaches and techniques currently used for candidate selection and 
progression of a compound into late clinical development. A critical review is 
made of the predictive value of the experimental protocols, highlighting the 
requirements for translation of findings both in terms of experimental 
procedures as well as in terms of data analysis methodology. In particular it 
addresses the choices for model parameterisation when making use of 
inferential methods. This underpins the objectives and the intent of the 
investigation presented in Chapter 2. The use of hierarchical modelling forms 
the basis for effective translation of drug-induced effects into risk in real-life 
conditions. Our work reveals not only the importance of alternative 
methodology to quantify QT/QTc-interval prolongation as a maker of 
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cardiovascular safety, but also provides insight into the technical 
requirements for model parameterisation. A benchmark for the analysis and 
interpretation of risk during the evaluation of cardiovascular safety was then 
evaluated which accounts for the underlying concentration-effect 
relationship. Subsequently, focus is given to the importance of a bridging 
strategy, which we have named simply as Not-In-Trial Simulations (NITS). 
The use of NITS is proposed as basis for decision making and risk 
management. Lastly, different protocol optimisation scenarios are 
considered for prospective evaluation of novel compounds where one or 
more of the aforementioned issues are dealt with.  Conceptually, our work 
also included a comprehensive assessment of the specificity and sensitivity 
of the currently accepted threshold value (i.e., QT-interval prolongation > 10 
msec) for defining the clinical relevance of prodromic effects. The predictive 
value of efforts in early pre-clinical or clinical development relies on the 
receiver operating characteristics (ROC) of the experimental variables or 
parameters of interest [11].  Even though we do not present a formal ROC 
analysis of QTc-interval prolongation, our efforts were aimed at 
demonstrating that flaws exist in assumptions underlying current policies 
and guidelines.  
12. 2 BAYESIAN HIERARCHICAL MODELLING 
After a general introduction, we have explored the technical requirements 
for model parameterisation and defined a new benchmark for the analysis 
and interpretation of risk during the evaluation of cardiovascular safety. In 
Chapter 3, it was shown how a Bayesian hierarchical model can be used to 
describe the relationship between drug concentration and QTc-interval 
prolongation for d,l-sotalol, moxifloxacin and grepafloxacin.  The use of an 
integrated modelling approach had also allowed explicit dissection of the 
drug-induced QTc prolongation, discriminating it from other factors such as 
variation due to heart rate and circadian rhythm.  The drug-specific 
parameter in the model, slope, did not independently indicate whether risks 
associated with the use of the compound existed, nor did it indicate if the 
development of the drug should be stopped.  Rather, it provided an 
unambiguous description of the PKPD relationship, taking into account 
various sources of variability which enabled a clear interpretation of risk.  
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From a drug development perspective, this approach is highly relevant, as it 
allows prospective evaluation of compounds. Given the distinction between 
drug- and system-specific parameters, drug effects can be characterised even 
if hysteresis occurs, as in the case of indirect mechanisms or metabolite-
induced QTc-interval prolongation. The proposed Bayesian analysis provides 
clearly interpretable clinical measurements which may help the decision 
process throughout the development of new compounds. In fact, the 
posterior (predictive) distribution can be used directly to translate liability 
to QTc-interval prolongation across varying doses or concentration ranges.   
The possibility of extrapolating the effect size across different dose ranges 
and estimating the associated risk can greatly enhance the decision making 
process for the regulators, clinicians and drug developers.  Furthermore in 
the investigation the probability associated with an increase in QTc-interval 
>10 msec was provided, given a range of concentrations. This threshold can 
easily be changed to higher or lower values to accommodate other types of 
assessments, rendering the model useful for different types of analysis or 
scenarios, including the comparison of drug effects across species. Most 
importantly, the results show that accurate judgement of the risk and 
liability associated with a novel chemical or biological entity cannot be 
performed without distinguishing drug-specific parameters from system-
specific parameters. 
12. 3 TRANSLATIONAL PHARMACOLOGY 
12. 3. 1 FROM PRECLINICAL EXPERIMENTAL PROTOCOLS TO CLINICAL 
STUDIES 
The ability of the in vitro models to quantitatively predict drug effects at 
therapeutic concentrations remains often limited based on available 
methodology.  On the other hand, the developability criteria applied during 
the preclinical evaluation of novel molecules supposedly reflects 
torsadogenicity without further evidence of the concentration or exposure 
range at which drug effects occur. The danger is under-estimation of the rate 
of false positive results, which lead to termination of perfectly efficacious 
compounds.  In fact, the ICH S7B suggests that in vivo assessment of the drug 
effects on QT-interval duration, performed in addition to a hERG channel 
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assay, should form the minimal basis for the evaluation of pro-arrhythmic 
risk.  However, the utility of non-clinical assays remains questionable. In 
order to establish in vitro-in vivo correlations, non clinical studies must be 
calibrated against clinical data. The use of concentration-effect relationships 
as benchmark for translational research across species has not been applied 
before, as proposed in this thesis.  In Chapter 4 the same Bayesian 
hierarchical model developed previously to describe QT-interval 
prolongation in clinical studies was applied to preclinical data to describe the 
relationship between drug concentration and QTc-interval prolongation for 
cisapride, d,l-sotalol and moxifloxacin in conscious dogs, establishing their 
correlation with the pharmacological effects in healthy subjects at 
comparable exposure ranges.  Based to the explicit distinction between drug-
specific and system-specific parameters, a model-based analysis of 
pharmacokinetic and QT-interval data in dogs allowed inferences about the 
probability of drug-induced QTc prolongation in humans.  The drug-specific 
parameter in the model (slope) did not independently indicate whether there 
was risk associated with the use of the compounds, nor did it indicate if their 
development should be stopped.  Rather, it provided an unambiguous 
description of the PKPD relationship, taking into account various sources of 
variability. 
Within the drug development framework, our approach appears to overcome 
one of the main limitations of earlier PKPD modelling efforts in preclinical 
research, i.e., it offers the opportunity to distinguish drug-induced effects in a 
generic manner, enabling the use of the model for prospective evaluation of 
novel compounds.  Models should be used as a tool for predictive purposes 
rather than only focusing on model parameter estimation. In contrast to 
recent examples of model-based analysis of QTc-interval prolongation [12-
15], we were able to correlate preclinical and human effects in a direct, 
quantitative manner. Based on the evidence obtained from the evaluation of 
paradigm compounds, it appears that one of the most important factors for 
accurate translation of preclinical findings to the effect in humans is the 
ability to evaluate drug effects across a clinically relevant exposure range.  
Inferences from extremely high dose levels, often used in toxicology 
experiments may lead to biased conclusions about the magnitude of the 
effect on QT-interval and its clinical implication in humans.  In addition, our 
investigation showed some critical shortcomings in current experimental 
protocols which prevent effective use of model-based approaches in early 
drug development.   
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12. 3. 2 FROM CONTROLLED CLINICAL TRIALS TO TREATMENT OUTCOME IN 
REAL-LIFE CONDITIONS 
We have shown that translational efforts are required not only during the 
progression of a compound from preclinical to clinical phases of 
development. It is also critical to understand the safety profile of a drug in 
the overall target population, as during Phase IIb, III and IV.  In Chapters 5, 6 
and 7 focus is given to the characterisation of the differences between the 
expected magnitude of drug-induced QTc prolongation and the overall 
increase in QTc-interval in real-life conditions. In addition, we highlight some 
important practical and ethical hurdles associated with the generation of 
safety data, particularly when safety concerns regard low frequency or rare 
events. Such information can only be derived from epidemiological studies, 
which are planned and performed only after drug approval.  In Chapter 5, we 
have shown that population selection and inclusion/exclusion criteria 
applied to clinical protocols in early drug development may lead to 
significant differences between drug-induced and overall treatment effect 
size in the target population. Thus far, the evidence of pro-arrhythmia 
associated with QTc prolongation in real life patients has been primarily 
linked to drug-induced effects, disregarding the contribution of other 
important intrinsic and extrinsic determinants of response. Thanks to the 
use of a model-based approach it was possible to make inferences about the 
effects of d,l-sotalol in patients and evaluate in an integrated manner how 
different covariates and sources of variability contribute to the observed QTc 
values in real life patients. Our findings revealed that the distribution of 
observed QTc values in the real life cohort cannot be explained by the effects 
of d,l-sotalol alone. Other causal factors are present, which significantly affect 
the observed QTc values. In fact, the binary logistic regressions performed on 
our data revealed that diabetes, heart failure, arrhythmia, hypertension and 
myocardial infarction are indeed risk factors for QTc prolongation in this 
population. In addition to comorbidities, we have also identified statistically 
significant effects of concomitant medication, both of which contribute to 
upper tail of the distribution of observed QTc values.  
This chapter illustrated how both clinical trial and epidemiological data can 
be used in an integrated manner for the purpose of signal detection and 
improved risk management. By applying pharmacokinetic-
pharmacodynamic modelling concepts to epidemiological data, it was 
demonstrated that assessment of the concentration-effect relationships in 
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healthy subjects has limited value unless one can account for the effect of 
influential covariates in the target population.  By extension, these findings 
clearly raised questions about the validity of TQT trials as the state-of-the-art 
approach for determining the risk of pro-arrhythmia or TdP.  Indirectly, it 
also revealed the shortcomings of the double-delta method currently 
suggested for the TQT studies.  The use of time-matched differences between 
active and placebo arms do not reflect the potential QTc prolongation in real-
life conditions.  Another advantage associated with the use of a PKPD model 
was that even if the pharmacokinetics are evaluated at supra-therapeutic 
levels, drug exposure can be extrapolated to reflect drug concentrations 
across therapeutic doses, so that accurate inferences can be made of the 
clinical relevance of the effects  on QT-interval.   
Our approach also revealed a flaw in the assumption that findings about drug 
effects in a clinical trial may be generalisable to the target population under 
real-life conditions. The requirements for the evaluation of drug-related QTc-
interval prolongation are presented in Chapter 6, where we have reconciled 
the differences found between clinical trial population and real patients and 
assessed the contribution of different factors by simulation methods.  The 
concept of Not-In-Trial Simulation is introduced under the assumption that, 
QTc-interval (real life population) = age-dependent baseline QTc values + 
drug-induced fluctuation in QTc + effects of concomitant medications and co-
morbidity conditions. We also anticipate the importance of such an approach 
to assess the characteristics of high-risk population subgroups by 
introducing such patients into simulation scenarios.   This approach can 
provide more accurate estimates of cardiovascular risk and enable mitigation 
measures, preventing potential withdrawals due to unexpected 
cardiovascular safety findings.  
This investigation also shed light onto important methodological aspects 
associated with the assessment of causality, enabling further understanding 
of the potential differences or mismatch in the safety profile of drugs pre and 
post-launch. Firstly, present safety trial designs are highly efficacy-oriented.  
Secondly, the number of patients exposed to the drug in the preapproval 
phase is not large enough to detect a relatively rare but potentially fatal risk.  
Thirdly, many subgroups of patients most of whom show higher risk of TdP 
are usually excluded from clinical trials. These subgroups included: females; 
the elderly, those with predisposing cardiac or non-cardiac diseases 
associated with diminished repolarisation reserve (and therefore greater 
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susceptibility to prolongation of the QT-interval); those with 
pharmacogenetic defects of drug metabolising enzymes or pharmacological 
targets such as potassium channel polymorphism; those susceptible to 
bradycardia or electrolyte imbalance; or those receiving drugs with a 
potential for pharmacokinetic or pharmacodynamic interactions.  
Furthermore, our results revealed the effect of age on baseline QTc-interval, 
a correlation which plays an important role in the observed QTc values in the 
target patient population, irrespective of treatment.   
To assess the robustness of the inferences derived from Not-In-Trial 
Simulations, a new paradigm compound, cisapride, was evaluated in Chapter 
7. Rather than limiting pharmacovigilance research to “retrospective” meta-
analytical approaches on empirical data from long term safety  (i.e., from 
clinical practice as well as from randomised clinical trial), we showed once 
more that model-based approaches enable  “prospective” evidence synthesis. 
Using hierarchical models, it is possible to integrate fixed effects (drug-
related and disease related factors) as well random effects (including 
parameter and model uncertainties). Model parameters can subsequently be 
used to explore relevant scenarios.  QTc measurements in cisapride users 
were accurately described, especially the extremely high values.   
The aforementioned results were considered as part of an external validation 
procedure for the generalisation of the concept of Not-In-Trial Simulation as 
a framework for signal detection and risk management in clinical 
development. Predictions of QTc values in real life were accurate for two 
compounds with very different mechanisms of action and therapeutic use.  
Two major determinants of response were proven to be drug-independent, 
namely the effect of age and comorbidities on baseline values of QTc-interval.   
Although the work was limited to QTc-interval prolongation, we anticipate 
that the concept could be applied for any adverse event. It can also be used to 
discriminate confounding factors, in particular when drug-drug interactions 
or drug-disease interactions occur which are compound-specific and may not 
have been identified yet. 
From a methodological point of view, this framework offers advantages 
compared to meta-analysis where the resulting model is primarily 
descriptive of a large, pooled dataset. Based on Not-In-Trial Simulation 
scenarios, investigators will have the opportunity to explore hypothetical 
populations and test different doses which are not confined to the observed 
296        Conclusions and Perspectives 
data.  The main limitation to our approach at this point of development is the 
absence of random effects in drug exposure, which is inferred from the 
prescribed dosing regimens.  The inclusion of random effects (between-
subject variability) would further improve the assessment and predictability 
of the exposure-effect relationship in real-life conditions.  Further work and 
different experimental protocols in pharmacovigilance studies will be 
required to better explain the role of pharmacokinetic variability. 
12. 3. 3 PROGNOSTIC VALUE OF QTC-INTERVAL PROLONGATION AS 
BIOMARKER OF RISK  
The primary interest and intention in investigating the QT/QTc prolongation 
of new compounds were to reduce the prevalence of drug-induced 
arrhythmias or torsade de pointes (TdP) by non anti-arrhythmic drugs.  By 
extension, the rationale was aimed at minimising the occurrence of sudden 
cardiac death (SCD) due to the putative association between prolonged QTc-
interval, arrhythmias (TdP) and SCD. Yet, there were no consistent data 
demonstrating the link between QTc-interval prolongation and SCD.  
Therefore in Chapter 8, we undertook comprehensive evaluation of the 
prognostic value of QTc-interval prolongation using 182 cases of SCD in the 
Rotterdam Study cohort. In this study, we showed that the incidence rate of 
SCD is better correlated with high absolute baseline QTc-interval values.  A 
prolongation by > 10msec did not significantly affect the incidence rate of 
SCD. These findings were in agreement with data showing that the relative 
risk for arrhythmic death is higher when resting heart rate is greater than or 
equal to 84 bpm, and that TdP is rarely associated with QTc-intervals less 
than 500 msec.  
These results raise further questions about the implications of the use of QT-
interval prolongation as a surrogate for cardiovascular safety risk. In fact, 
from the sensitivity analysis performed in our study, SCD incidence was 
found to be independent from the changes from baseline or time elapsed 
since last ECG measured and death. This implied that using the absolute QTc 
values to determine the risk of SCD may be relatively more reliable.   Most 
importantly, our findings contradicted the hypothesis underlying the current 
requirements by ICH topic E14 guideline on the evaluation of cardiovascular 
risk for non antiarrhythmic drugs, in which safety is defined by a threshold 
for an upper interval delta prolongation value of 10 msec.  The association 
between delta 10 msec change in QTc and SCD was not found to be 
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statistically significant. We envisage therefore that two important concepts 
will need to be addressed in future revisions of the ICH E14 guideline: the 
rationale for a threshold of 10 msec and the use of changes from baseline 
(delta QTc values) to define risk or liability. Based on our results, it can be 
concluded that drug-induced changes in QTc may not increase the 
cardiovascular risk unless the underlying baseline QTc values are high.  
Whilst it might not be feasible to establish a cut-off range for QTc-intervals 
without taking into account additional factors contributing to an increase in 
the risk of SCD, it seemed evident that clinically effective risk management 
policies should consider baseline QT-interval as a strong prognostic factor 
for pro-arrhythmias. The assumption of a comparable risk of TdP across the 
population for an increase in QTc-interval of greater than or equal to 10 msec 
could not be sustained. 
12. 4 THE ROLE OF CLINICAL TRIAL SIMULATIONS IN PROTOCOL 
OPTIMISATION 
12. 4.1 GENERATING RR VALUES AND QT-INTERVALS 
The assessment of a drug's effect on the QT-interval must be corrected for 
changes in heart rate, as it also affects the QT-interval. The shortening effect 
of heart rate on the QT-interval must be taken into consideration when 
evaluating possible drug-induced effects. In fact, the relationship between 
the QT-interval and heart rate can be modelled mathematically, yielding a 
corrected QT-interval (QTc) which enables discrimination between drug-
induced from heart rate-dependent effects.  
Effective implementation of clinical trial simulations (CTS) for the 
assessment of drug-induced QT-interval prolongation requires therefore 
individual heart rate profiles.  In contrast to re-sampling techniques from 
existing data, in Chapter 9, we developed a model describing the relationship 
between QT and RR over 24 hours. Our approach enabled generation of 
realistic RR profiles according to typical protocol sampling schemes, which 
can be used as input into a model describing the QT-RR relationship.  Using 
the newly proposed method to generate QT/RR values, measurements were 
taken at discrete intervals according a study protocol, yielding between-
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measurement variability which would not be described by beat-to-beat 
variation or by other previous approaches available in the published 
literature. By contrast, we have chosen to simulate data in which correlations 
and variance structure reflect the noise due to measurement and sampling 
procedures. This novel approach was essential for the evaluation and 
optimisation of the clinical protocols discussed in Chapters 10 and 11, where 
hypothetical populations were simulated to explore type I and II error rates 
using different study designs and methods of analysis.   
12. 4. 2 CONCENTRATION-EFFECT RELATIONSHIPS VERSUS DOUBLE-DELTA 
METHOD 
In Chapter 10, TQT study protocols were simulated with varying number of 
subjects and putative drug-induced QT effects. Different statistical designs, 
including crossover with full day time-matched baseline, crossover with 
three pre-dose baseline measurements and parallel designs were considered 
for the purpose of this investigation.  It was demonstrated that the use of a 
Bayesian hierarchical model has higher or equal specificity and sensitivity 
compared to the double-delta method.  Results strongly suggested that 
concentration-effect relationships should be considered when analysing the 
propensity of drug-induced QTc-interval prolongation as opposed to the 
currently recommended double-delta method.  Most importantly, the 
proposed approach does not only enable accurate estimation of the effect 
size across the therapeutic exposure range, but it is also more sensitive to 
detect a safety signal. Conclusive results can be obtained about the liability 
for QT prolonging effects with a significantly smaller number of subjects. 
Keeping in mind that the high cost of TQT studies have mainly been 
attributed to the trial size required, this represents a major opportunity to 
address ethical, statistical and financial considerations associated with the 
assessment of a QT-interval prolongation of 5 msec.  Another advantage of 
the use of a model-based approach is the possibility to handle multiplicity 
issues arising from having to establish non-inferiority at each time point. 
Instead, drug induced effects are established as a continuous function across 
the range of observable concentration, rather than at each discrete sampling 
time.  Thus, these encouraging results gave rise to an alternative to the 
current methodology used in TQT studies as well as a strategy to minimise 
the cost of a such a trial.  
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Given the considerable increase in the sensitivity of a model-based approach 
to detect drug-induced QTc-interval prolongation, in Chapter 11 we have also 
explored the possibility of using the first-time-in-human (FTIH) study as 
basis for the assessment of QT liability. In conjunction with evidence of the 
concentration-effect relationship and the corresponding probability of an 
increase in QTc-interval in pre-clinical species, it can be envisaged that 
accurate decisions can be made about the relevance of QT prolonging effects. 
In addition, such an integrated approach overcomes the flaws in the current 
execution of TQT studies, which does not necessarily guarantee the accuracy 
and precision of the effect size.  Another advantage to using the proposed 
Bayesian modelling approach to analyse the proarrhythmic properties of a 
compound is the possibility to describe its QT-prolonging effect over the 
therapeutic range. Since FTIH studies represent a mandatory step in clinical 
development, minor adaptations are required to ensure appropriate 
sampling schemes are used to collect ECG signal. This could in turn support 
the strategic decision to proceed or not with development. Furthermore, the 
results of the analysis demonstrated that accurate estimates of effect size of 
QT prolongation can be obtained without the inclusion of a positive-control 
arm. Yet, we do not exclude the possibility of including historical studies with 
moxifloxacin as parameter priors or benchmark during data analysis.   
12. 5 RECOMMENDATIONS  
Clear shortcomings from various aspects of the ICH E14 guideline have been 
identified and alternative methods and recommendations have been 
proposed in this thesis.  First, a Bayesian model describing the underlying 
concentration-QTc prolongation relationship was introduced to describe the 
actual drug-induced effects over a relevant concentration range. This method 
should be used instead of the statistically-based double-delta method.  This 
implies that a supra-therapeutic dose is not necessary but even if used, the 
therapeutic effect can easily be derived using the hierarchical model. 
Furthermore, the use of a Bayesian approach also showed superior accuracy 
and precision in predicting actual QTc prolongation over the entire time 
course of observations, not just at specific time points.  Another advantage to 
using the model-based approach is its ability to describe data across 
compounds as well as between different species.  Beyond predictions, the 
availability of posterior distributions enables the assessment of the 
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probability for any pre-defined increase in QTc-interval.  By utilising the 
same model in the analysis of a FTIH trial with enriched ECG monitoring, it is 
possible to determine the proarrhythmic propensity of compounds without 
embarking on a TQT study, which implies go/no-go decisions can be made 
earlier in the drug development cycle.   
12. 6 PERSPECTIVES 
The results presented in this thesis highlight the need for a new paradigm for 
the assessment of cardiovascular safety, in which evidence generation does 
not prevail over the role of evidence synthesis, which is by far more 
encompassing and informative. We also reiterate the importance of revisiting 
current guidelines, in particular the ICH E14 document, which shows 
inconsistency with oncoming evidence from scientific research.   
Clinical researchers, health care providers, regulatory authorities and policy 
makers have to realise the implications of experimental design to the 
generation of evidence under controlled conditions, as in the case of 
randomised clinical trials. Differences in the patient population during drug 
evaluation (pre-launch) and clinical use (post-launch) cannot be overlooked. 
There is a clear contribution of intrinsic and extrinsic factors or covariates 
determining treatment outcome, which alter, counteract or mitigate drug-
related effects. Hence, the crucial question from regulatory perspective is 
“How efficient and reliable are the pre-approval clinical trials in identifying 
the clinical risk of TdP, given differences in patient population enrolled, 
background noise arising from spontaneous intra-individual variability in 
QTc-interval and the relatively low frequency of the clinically significant 
drug-induced effect?” [16]. 
As suggested by the title of this thesis, there is a gap in the translation of 
safety findings from clinical trials to real-life conditions which must be 
accounted for in risk management. During clinical development one needs 
therefore to focus on evidence synthesis and ensure accurate assessment of 
the underlying pharmacokinetic-pharmacodynamic relationships. Modelling 
and simulation are essential tools to close this gap.  We envisage that further 
advancements in the prediction of cardiovascular safety can be obtained by 
expanding the concepts of Not-In-Trial Simulation to multiple endpoints as 
well as by incorporating mechanistic models to the pharmacometric 
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framework proposed in this thesis. Given the increasing availability of 
pharmacovigilance cohorts, access to data will not be the limiting step any 
longer. In fact, the translational concepts developed here may be applied to a 
wider range of outcomes, enabling drug developers, clinical researchers and 
regulators to bridge the gap between controlled clinical trial and real life 
conditions. In any case, the ability to discriminate between drug- and system-
specific parameters will remain critical for the success of a model-based 
approach. 
An additional concept has emerged from our research, which can provide the 
basis for further integration of clinical and pharmaco-epidemiological data. 
The concept of Not-In-Trial Simulations (NITS) has been introduced as 
inferential tool to evaluate the implications of strict inclusion / exclusion 
criteria imposed on the study population, and the relatively short duration of 
trials. These constraints make it impossible to detect infrequent or rare 
safety signals until the drug has been on the market for a longer period of 
time.  The ability to anticipate such signals prior to launch offers the 
opportunity to explore and implement mitigation measures.   
The idea behind NITS is to include the physiologically-relevant factors along 
with drug-induced effects and explore the contribution from real-life 
scenarios such as comorbidities and concomitant medications.  This work is 
only possible with combining pharmacological and epidemiological concepts 
and data.  In his publication, Black highlighted “the false conflict between 
those who advocate randomised trials in all situations and those who believe 
observational data provide sufficient evidence needs to be replaced with 
mutual recognition of the complementary roles of the two approaches.” [17]  
Others have also advocated the synergistic potential for using both kinds of 
data to aid decision making. 
Regulatory and clinical efforts regarding the effective use of drugs presently 
rely on the concept of positive benefit-risk ratio and as such depend 
primarily on the availability of oncoming evidence from clinical or 
observational trials [18-21]. These are often defined by Phase IV long term 
safety trials or more recently by progressive licensing proposal, which 
ultimately imposes the burden on patients and drug developers, with the 
caveat of the having the evidence after the facts.  Thus far, alternative 
methods to formalise prospective trials have been limited to “retrospective” 
meta-analytical approaches on data arising from empirical data, i.e., from 
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clinical practice as well as from randomised clinical trials.  It is imperative 
that more efforts are put into how to devise forward-looking strategies. 
The Bayesian approach is limited to improving the analytical aspect to detect 
QTc-interval prolongation of a compound and thus is only used to assess the 
propensity of proarrhythmic properties.  It does not, however, solve other 
issues in TQT studies of practical or statistical nature with ECG 
measurements.  Figure 3 summarises the potential areas of concern where 
significant impact can be made to the observed QT-interval data.  These 
include the algorithm used for ECG recordings, the technique selected to 
correct measurement bias, the nature of the disease that influence ECG 
values, and various other covariates that can impact the recordings. 
 
 
Figure 3.  Various factors that affect QT-interval measurements. A combination of 
contributors should be taken into considerations when assessing QT/QTc-interval 
prolongation including intrinsic and extrinsic characteristics [22].   
Much research is currently performed to address the precision of QT 
measurements including the use of automated readings.  Efforts are also 
being made to address statistical issues, identifying sources of variability, 
new algorithms as well as the issues of reproducibility.  In 2001, FDA 
established a digital ECG Warehouse to store ECG recordings received from 
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submission.  Beyond its official use, the Warehouse also provides a great 
opportunity for pharmaceutical companies and academia to conduct 
research.  It is an asset that can be used to study new biomarkers of 
proarrhythmia, correlate them with clinical and laboratory cardiac safety 
outcomes, improving the diagnosis and treatment of cardiovascular diseases, 
determine the underlying physiological variation, and use as prior 
distributions for future Bayesian PKPD analysis for QTc-interval 
prolongation. 
Ultimately, we must "mind the gap" between controlled clinical trials and 
real-life conditions.  Time has come to address these issued by quantifying, 
predicting, interpreting and eventually mitigating these inherent differences.  
It cannot be stressed enough that a modelling and simulation-based strategy 
for risk assessment and management can now be developed. 
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Mind The Gap:  De voorspelling van 
cardiovasculaire veiligheid tijdens de 
ontwikkeling van nieuwe geneesmiddelen – 
Samenvatting, conclusies en vooruitblik 
13.1 HET REGULATOIR KADER EN DE VERTALING VAN DE PRO-
ARITMISCHE ACTIVITEIT VAN GENEESMIDDELEN NAAR RISICO 
Verscheidene intrinsieke en extrinsieke factoren, waaronder genetische 
predispositie, kunnen het zogenoemde QT (of QTc)-interval in een 
electrocardiogram verlengen. Hoewel QT verlenging niet gevaarlijk hoeft te 
zijn, wordt het in verband gebracht met hartritmestoornissen  en plotselinge 
hartdood [1, 2].  Aanwijzingen dat een geneesmiddel het QTc interval kan 
verlegen is in het algemeen een reden tot zorg voor regelgevende 
autoriteiten [3, 4]. Ondanks inspanningen om het effect van geneesmiddelen 
op de hartgeleiding in een vroeg stadium van ontwikkeling te identificeren, is 
QTc verlenging de op-één-na meest voorkomende reden om een 
geneesmiddel uit de handel te nemen.  Verder bljkt het aantal 
geneesmiddelen die beschouwd worden een risicovol QT profiel te tonen 
geleidelijk toe te nemen. 
Deze recente “farmacoepidemie” in ogenschouw nemend, is het van belang 
het QT-verlengingspotentiaal te voorspellen en de klinische relevantie ervan 
zo vroeg mogelijk vast te stellen, zodat wijgering of vertraging van de 
geneesmiddelregistratie en beperkingen in het gebruik van het geneesmiddel 
vermeden kunnen worden [5]. 
Naast de ontwikkeling van onderzoeksprotocollen voor het vaststellen van 
cardiovasculaire veiligheid in dierproeven worden in het klinisch onderzoek 
de zogenoemde E14 richtlijnen toegepast, welke zijn opgesteld door de 
International Conference on Harmonisation (ICH) [6].  Gelijksoortige 
richtlijnen (nummers S7A en S7B) zijn ook ontwikkeld voor onderzoek in 
dieren [7, 8].  De E14 richtlijnen bevelen een aparte studie aan die de 
cardiovasculaire veiligheid moet aantonen.  Deze zogenoemde grondige QT 
studie (thorough QT, TQT) is zodanig ontworpen dat een eventuele QT 
verlenging van 5 milliseconden aangetoond kan worden. Indien het 
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bijbehorende éénzijdige betrouwbaarheidsinterval de 10 milliseconden niet 
overschrijdt, wordt dit geïnterpreteerd als  een gebrek aan bewijs voor een 
risicovolle QT verlenging.  Alhoewel de aanbevolen invoering van risico-
evaluatie goed bedoeld is, zijn de aanbevelingen allesbehalve perfect.  
Dit proefschrift belicht drie belangrijke tekortkomingen in de huidige 
aanpak, welke de evaluatie en ontwikkeling van geneesmiddelen 
ondermijnen en daardoor de vermindering van de bestaande medische 
behoefte belemmeren. De eerste tekortkoming betreft de aannames die ten 
grondslag liggen aan de vertaling van farmacologische effecten in 
experimenten en klinische studies naar die in de medische praktijk.  De 
uitwerkingen van experimentele factoren en processen wordt over het hoofd 
gezien, wat leidt tot een onvolledig begrip van de betekenis van 
farmacologische eigenschappen en het vertaling ervan naar kwantificeerbare 
risico’s.  De tweede tekortkoming heeft te maken met het verschil tussen 
associatie en causaliteit en de biologische implicaties hiervan. De keuze 
voor het QT interval als maat voor het risico op hartritmestoornissen zonder 
hierbij de relatie tussen geneesmiddelblootstelling en farmacologisch effect 
te betrekken bemoeilijkt het vaststellen van een causaal verband tussen 
eerstgenoemden. Eenvoudige principes van signaaldetectie, inclusief 
discrimatiedrempel zoals aangegeven door ROC curves en begripsvaliditeit 
worden veronachtzaamd in onderzoeksprotocollen.  De derde tekortkoming 
is het ontbreken van een methode om afzonderlijke aanwijzingen van 
de risico’s  en baten  van de behandeling samen te smeden tot één 
waarde ofwel “evidence synthesis”. De nadruk op het genereren van 
aanwijzingen zonder deze vervolgens te integreren leidt tot suboptimale 
protocollen en onjuiste beslissingscriteria. Dit heeft tot gevolg dat de 
ontwikkeling van een geneesmiddel onterecht beeïndigd kan worden. De 
huidige methodes staan een integratieve benadering zelfs niet toe: noch van 
het te verwachten risico,  noch van de effectiviteit van maatregelen om het 
risico te verminderen.   
Idealiter zouden experimenten in celpreparaten reeds een goede 
voorspelling verschaffen van de te verwachten klinische effecten, zowel 
vanuit het kwalitatieve perspectief (de voorspelling luidt: ofwel QT interval 
verlenging vindt plaats ofwel het vindt niet plaats) als vanuit het 
kwantitatieve (een voorspelling van de QT verlenging per eenheid 
verandering van de geneesmiddelconcentratie).  Verschillende auteurs 
hebben methodes voorgesteld om een kwalitatieve voorspellende relatie te 
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identificeren [9, 10]. Deze relaties zijn echter gebaseerd op een empirisch 
gemaakt onderscheid tussen diverse bevindingen. Het probleem hierbij is dat 
de classificatie van geneesmiddelen met een klein QT verlengingseffect 
moeilijk is. Verder ontbreken er kwantitatieve benaderingen, die de 
integratie nastreven van de resultaten die verkregen worden in de diverse 
stadia van geneesmiddelontwikkeling.  
Hoewel het werk in dit proefschrift de voorspelling van QT effecten met 
gebruikmaking  van in vivo (uit levende organismen) verkregen informatie 
behelst, blijft ook de ontwikkeling van voorspellende methoden met behulp 
van in vitro (c.q. afkomstig uit experimenten met celpreparaten) gegevens 
van groot belang. De mogelijkheid tot voorspelling met op basis van in vitro 
verkregen maatstaven zou het vervolgproces van experimenten en 
beslissingen al in een vroeg stadium kunnen vereenvoudigen. Dit betekent 
een mogelijke beperking van het aantal afgewezen kandidaat-moleculen.  
De nadruk ligt in dit werk echter op het in vivo stadium van 
geneesmiddelontwikkeling. Barrières voor de vertaling van 
onderzoeksgegevens verkregen in dit stadium naar de late klinische en 
praktijksituaties zijn overbrugbaar, zeker wanneer het gegevens uit vroeg-
klinische studies betreft: hier immers worden de geneesmiddelblootstelling 
en cardiovasculaire signalen altijd uitvoerig gemeten.   De belangrijkste 
doelstelling van dit proefschrift is daarom de identificatie van ontbrekende 
factoren in de genoemde vertaalslag. Deze factoren zijn het gevolg van 
verschillen in de gecontroleerde omstandigheden waarin studies worden 
uitgevoerd, met name de verschillen in de toegepaste inclusie- en 
exclusiecriteria. Aan dit werk ligt de vaststelling ten grondlag dat aan de 
medische behandeling met geneesmiddelen altijd risico’s verbonden zijn. 
Beslissingen aangaande de geschiktheid van een molecuul voor verdere 
ontwikkeling tot geneesmiddel alsmede het therapeutisch gebruik van het 
ontwikkelde geneesmiddel moeten daarom gebaseerd zijn op een 
kwantitatieve bepaling van het risico in de patientendoelgroep. In plaats van 
te vertrouwen op de veronderstelde algemene geldigheid en 
extrapoleerbaarheid van individuele onderzoeksprotocollen, is het beter om 
uit te gaan van risicoanalyses waarin de verschillen tussen experiment en 
praktijk in acht genomen worden.  
Een belangrijke bevinding die naar voren komt uit dit werk is dat het 
samenvoegen van bestaande resultaten  doeltreffender kan zijn dan het 
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genereren van nieuwe gegevens. Wanneer deze synthese plaatsvindt met de 
juiste klinische en wetenschappelijke intentie en met toepassing van 
geschikte statistische methoden, kan zij een betere basis vormen voor 
besluitvorming. Tegelijkertijd respecteert zij praktische en ethische 
bezwaren die verbonden zijn aan het onderzoek van geneesmiddelveiligheid 
in de mens. Dit is speciaal van belang wanneer het gaat om 
veiligheidssignalen die met een lage frequentie voorkomen of wanneer het 
risiko gedurende of  na chronische behandeling ontstaat.  
De genoemde tekortkomingen, de hoge kosten verbonden aan het uitvoeren 
van een TQT studie en de noodzaak om de klinische betekenis van vroege 
veiligheidssignalen op een nauwkeurige mannier  in te kunnen schatten 
vormen tezamen een pleidooi voor het beproeven van nieuwe strategieen 
voor de evaluatie van de cardiovasculaire veiligheid van geneesmiddelen. 
Bovendien is het essentieel dat de regelgeving op dit gebied een afspiegeling 
wordt van de wetenschappelijke kennis. Dit is evident niet het geval voor de 
ICH E14 richtlijnen, welke nog gestoeld zijn op de wetenschappelijke en 
regelgevingsgeest zoals die meer dan tien jaar geleden heerste. In die tijd 
waren de kwantitatieve farmacologie en farmacometrie als klinische 
disciplines nog in ontwikkeling. Nieuwe, robuuste methodes zouden in 
overweging moeten worden genomen en in de regelgeving opgenomen. 
Richtlijnen en regelgevingsbeleid zouden voortschrijdende inzichten moeten 
belichamen. Inferentiemethoden gebaseerd op modellen en simulaties 
blijven in veiligheidsbepalingen nog ondergebruikt. De grote hoeveelheid 
data die gegenereerd wordt tijdens de klinische ontwikkelingsfase en de 
beschikbaarheid van gegevens over geneesmiddelmoleculen met 
vergelijkbare farmacologische eigenschappen worden niet systematisch – 
vanaf de vroege klinische studies tot aan de veiligheidsbewakking na 
toelating – ingezet.    
De in dit proefschrift voorgestelde nieuwe denkwijze stelt “evidence 
synthesis” centraal en beschouwt het genereren van nieuwe informatie als 
een bevestigingsstap in het proces dat leidt van hypothese naar kennis. 
Statistische methodes vormen de gereedschappen voor deze synthese, die in 
meer specifieke zin de vertaling van veiligheidssignalen naar risico‘s behelst. 
Het hier beschreven onderzoek introduceert bovendien farmacologische 
concepten in een epidemiologische context en verkleint daarmee het 
onderscheid tussen geneesmiddelontwikkeling en gezondheidszorg.  
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Een direct gevolg van de hier gekozen benadering is een accentverschuiving 
in de analyse van veiligheidssignalen, van associatie naar causaliteit.    
Gestoeld op bovenstaande principes geeft dit proefschrift een aanzet tot 1) 
het terugdringen van het aantal afgewezen kandidaat-moleculen gedurende 
het screeningsonderzoek en 2 ) de ontwikkeling van betere 
onderzoeksprotocollen voor het vaststellen de het pro-arrhythmische effect 
van nieuwe geneesmiddelen. Hoofdstuk 1 verschaft inzicht in het huidige 
proces van de selectie en ontwikkeling van kandidaat-moleculen. De 
voorspellende waarde van onderzoeksprotocollen wordt aan een kritische 
blik onderworpen en de voorwaarden voor de vertaling van bevindingen 
worden beschouwd in relatie tot de experimentele procedures en data-
analysemethodes waaruit zij voortkomen. Bij de data analyse wordt speciaal 
gelet op de keuze van parameterisering. Deze wordt nader onderzocht in 
hoofdstuk 2. Het gebruik van zogenaamde hierarchische modellen vormt 
een geschikte basis voor de vertaling van geneesmiddeleffecten naar 
praktische risico’s. In dat opzicht onderstreept dit werk niet alleen het 
belang van alternatieve methodologie voor het kwantificeren van QT (of 
QTc) intervalverlenging, maar beschrijft het ook de eisen voor de 
parameterisatie van de hiervoor gebruikte modellen. Vervolgens werd een 
dergelijk model dat het verband tussen geneesmiddelconcentratie en effect 
beschrijft geëvalueerd. In de daaropvolgende stap lag de nadruk op de 
waarde van een strategie voor de overbrugging  van de resultaten uit 
clinische studies naar de doel patiëntenpopulatie in de medische praktijk. 
Deze strategie kreeg de benaming Not-in-Trial Simulaties (NITS). NITS 
verdient aanbeveling als methode voor besluitvorming en 
risicomanagement. Tenslotte werd de waarde onderzocht van enkele 
aanpassingen in de standaard onderzoeksprotocollen voor de screening van 
kandidaat-moleculen. Ons onderzoek ging ook in op de specificiteit en 
sensitiviteit van een standaard gehanteerde drempelwaarde voor QT 
verlenging (nl. 10 milliseconden). Voor waarden boven deze drempel wordt 
aangenomen dat er een klinisch relevant cardiovasculair risico bestaat. In 
principe kan men ervan uit gaan, dat de voorspellende waarde van resultaten 
uit vroege ontwikkelingsfases vastgesteld kunnen worden uit de 
zogenaamde receiver operating characteristic (ROC) curves [11].  Hoewel 
een formele ROC analyse buiten beschouwing bleef, werden enkele 
tekortkomingen in de aannames van gerelateerd beleid en richtlijnen 
aangetoond.  
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13. 2   BAYESIAANSE HIERARCHISCHE MODELLEN 
In hoofdstuk 3 werd getoond hoe met een Bayesiaans hierarchisch model 
het verband tussen geneesmiddelconcentratie en de verlenging van het QTc 
interval beschreven kan worden. Deze toepassing werd gedemonstreerd aan 
de hand van drie referentiegeneesmiddelen d,l-sotalol, moxifloxacine en 
grepafloxacine.  Het gebruik van een geïntegreerde modelmatige benadering 
stelde ons in staat het effect van het geneesmiddel op de QTc verlenging 
onafhankelijk van andere factoren te karakteriseren. De parameter die dit 
effect kwantificeert is echter geen onafhankelijke maat van het risico dat 
verbonden kan worden aan de verdere ontwikkeling van het molecuul of aan 
het uiteindelijke gebruik van het geneesmiddel. De waarde van deze 
parameter is daarentegen een directe afspiegeling van het verband tussen 
farmacokinetiek en farmacodynamiek die, samen met andere bronnen van 
variabiliteit, het effect bepaalt.  
Daarnaast maakt deze benadering de prospectieve evaluatie van 
kandidaatgeneesmiddelen mogelijk. Omdat geneesmiddel-specifieke effecten 
worden gescheiden van de zogenoemde systeem-specifieke effecten kunnen 
zij ook onder gecompliceerde omstandigheden vastgesteld worden, 
bijvoorbeeld wanneer het effect op het QT-interval vertraagd optreedt of 
door een metaboliet wordt veroorzaakt. De voorgestelde Bayesiaanse 
analyse levert klinisch interpreteerbare effectmaten op die van nut kunnen 
zijn bij besluitvorming in diverse stadia van de ontwikkeling van een 
farmacon. De uit deze analysemethode voortvloeiende a-posteriori-verdeling 
kan direct gebruikt worden voor de vertaling van QTc intervalverlenging 
naar risico over een reeks van doseringen of concentraties.   
De bovengenoemde eigenschappen kunnen relevant zijn in het kader van 
regelgeving, klinische geneeskunde en geneesmiddelonderzoek. In dit 
onderzoek werd deze methode gebruikt om voor een bepaalde blootstelling 
of concentratiebereik de waarschijnlijkheid van een QTc verlenging >10 
milliseconden te bepalen. Deze drempelwaarde kan aangepast worden al 
naar gelang het te onderzoeken scenario, welk bijvoorbeeld de vergelijking 
van effecten tussen diersoorten kan betreffen. De essentie van dit deel van 
het onderzoek is dat een nauwkeurige bepaling van het risico verbonden aan 
een nieuw kandidaat-molecuul niet mogelijk is zonder geneesmiddel- en 
systeem-specifieke parameters van elkaar te onderscheiden. 
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13. 3 TRANSLATIONELE FARMACOLOGIE 
13. 3. 1 VAN PREKLINISCHE ONDERZOEKSPROTOCOLLEN NAAR KLINISCHE 
STUDIES 
De huidige in vitro experimenten zijn beperkt in hun vermogen om de 
effecten van therapeutische geneesmiddelconcentraties kwantitatief te 
voorspellen. De beslissingscriteria die gehanteerd worden bij de 
ontwikkeling van een kandidaat-molecuul zijn gebaseerd op een kwalitatieve 
inschatting van het risico op hartritme-stoornissen zonder dat daarin de 
mate van blootstelling aan de stof meegenomen wordt. Deze tekortkoming 
kan een relatief hoog percentage vals-positieve uitkomsten tot gevolg 
hebben. De consequentie hiervan is dat effectieve farmaca verloren gaan 
voor verdere ontwikkeling. Richtlijn ICH S7B komt in dit bezwaar tegemoet 
aangezien het stelt dat, om tot een risico-inschatting te komen, naast in vitro 
experimenten ook het geneesmiddeleffect op QT interval in vivo moet 
worden bepaald.  Niettemin blijft de bruikbaarheid van deze niet-klinische 
tests onduidelijk. In principe, dienen de uitkomstmaten voor niet-klinische 
studies geijkt te worden tegen klinische data. Het gebruik van concentratie-
effect relaties als maatstaf hierbij is een nog niet eerder beproefde methode. 
Het eerder beschreven en op klinische data getoetste Bayesiaanse 
hierarchische model werd in hoofdstuk 4 toegepast voor de beschrijving 
van de relatie tussen geneesmiddelconcentratie en QT verlenging na 
toediening van cisapride, d,l-sotalol en moxifloxacine aan honden. De 
resultaten van de klinische data analyse en die in honden werden vervolgens 
aan elkaar gecorreleerd.  Doordat het model onderscheid maakt tussen 
geneesmiddel-specifieke en systeem- (c.q. organisme-)specifieke parameters 
kon op basis van de analyse in honden een uitspraak gedaan worden over de 
te verwachten geneesmiddel-geïnduceerde QT verlenging in mensen. De 
geneesmiddelspecifieke parameter in het model is niet op zichzelf indicatief 
voor het klinische risico geassocieerd met het gebruik daarvan of het 
stopzetten van de ontwikkeling van het desbetreffende molecuul. Deze 
parameter beschrijft uitsluitend de relatie tussen geneesmiddelconcentratie 
en farmacologisch effect (in dit geval een veiligheidssignaal).  
De door ons voorgestelde benadering lijkt een van de belangrijkste 
beperkingen van eerdere pogingen tot een modelmatige aanpak te 
overwinnen. Deze nieuwe benadering is in staat geneesmiddeleffecten te 
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identificeren en is daarom geschikt voor de prospectieve evaluatie van 
geneesmiddelen in de ontwikkelingsfase.    In tegenstelling tot recente 
voorbeelden van het gebruik van PKPD modellen voor de analyse van QTc 
interval verlenging [12-15], was ons model in staat preklinisch en klinisch 
geobserveerde  effecten aan elkaar te correleren. Bovendien laat de data 
analyse voor de genoemde referentiegeneesmiddelen zien dat de 
beschikbaarheid van individuele farmacokinetische informatie 
(blootstellingswaarden) in een therapeutische orde van grootte een van de 
belangrijkste voorwaarden is voor de nauwkeurige vertaling van 
preklinische effecten naar de mens.   Vertalingen op basis van zeer hoge 
doseringen zoals gebruikelijk bij toxicologie experimenten kunnen leiden tot 
inaccurate voorspellingen van de grootte van het te verwachten QT effect.  
13. 3. 2 VAN GECONTROLEERDE KLINISCHE STUDIES NAAR DE 
MEDISCHE praktijk 
 
De bevindingen gepresenteerd in dit proefschrift tonen aan dat de 
vertaalslag niet alleen noodzakelijk is bij de overgang van de preklinische 
naar de vroege klinische fase van de ontwikkeling van een  nieuw molecuul, 
maar ook wanneer een geneesmiddel toegediend wordt aan de 
patientenpopulatie tijdens fase II, III en zelfs na registratie (fase IV). De 
doelstelling in hoofdstukken 5, 6 en 7 was een analyse van de verschillen 
tussen de verwachte en de in de medische praktijk waargenomen QTc 
effecten van geneesmiddelen. Verder belichtten deze hoofdstukken een 
aantal ethische en praktische vraagstukken met betrekking tot het vergaren 
van geneesmiddelveiligheidsdata, met name wanneer dit infrequent 
voorkomende nevenwerkingen betreft. Dergelijke informatie kan enkel 
gewonnen worden uit epidemiologische studies, welke uitsluitend na 
registratie van een geneesmiddel plaatsvinden. Hoofdstuk 5 toont aan dat 
de criteria die gehanteerd worden bij de selectie van proefpersonen en 
patienten in klinische studies een verklaring kunnen vormen voor het 
verschil dat bestaat tussen de bevindingen uit gecontroleerde studies en de 
relatieve bijdrage van een geneesmiddel aan het waargenomen effect in de 
doelgroep. Meestal worden met QTc verlenging gepaard gaande storingen in 
het hartritme van een patient toegeschreven aan het geneesmiddel zonder 
rekening te houden met andere intrinsieke en extrinsieke factoren die aan 
het effect kunnen bijdragen. Dankzij het model beschreven in dit proefschrift 
kon het geneesmiddelspecifieke QTc-verlengingseffect van d,l-sotalol in 
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patienten beschreven worden op een manier die de bijdrage van 
verschillende bronnen van variabiliteit in acht neemt. De resultaten tonen 
aan dat de waargenomen QTc waarden in deze populatie niet enkel door het 
effect van het geneesmiddel verklaard kunnen worden. Een logistische 
regressie analyse op de patientendata liet zien dat de aanwezigheid van of 
een geschiedenis van diabetes, hartfalen, hoge bloeddruk en hartinfarct 
risicofactoren zijn voor QTc verlenging. Verder werd een statistisch 
significant effect gevonden voor comedicatie en comorbiditeiten  die een 
belangrijke rol spelen op de hartgeleiding en waardoor er een grotere kans 
bestaat op verhoogde QTc waarden in de data. 
In dit hoofdstuk werd gedemonstreerd hoe klinische en epidemiologische 
data op een geintegreerde manier gebruikt kunnen worden voor de detectie 
van veiligheidssignalen en voor de verbetering van risicobeheersing van 
geneesmiddelen. De toepassing van farmacokinetische-farmacodynamische 
concepten op epidemiologische data liet zien dat de concentratie-effect 
relatie in proefpersonen (gezonde vrijwilligers), die betrokken worden 
tijdens de vroege fase van klinische ontwikkeling, van beperkte waarde is 
aangezien de invloed van factoren die van belang zijn in de doel 
patientenpopulatie niet meegenomen worden in de analyse. Deze 
bevindingen extrapolerend naar het domein van TQT studies, kan men 
vraagtekens zetten bij de validiteit van dit soort studies die de huidige 
standaard vormen voor de vaststelling van het effect van geneesmiddelen op 
het hartritme. Indirect wijzen deze bevindingen ook op de tekortkomingen 
van de zogenaamde double-delta methode voor de analyse van gegevens uit 
TQT studies. Het gebruik van tijdsgewijs berekende verschillen tussen de 
behandeling met geneesmiddel en placebo levert resultaten op die niet 
representatief zijn voor de mogelijk in de praktijk te verwachten 
geneesmiddel-geïnduceerde QTc verlengingen.  Een ander voordeel van het 
farmacokinetisch-farmacodynamische model is dat zelfs wanneer 
farmacokinetische parameters bepaald zijn op basis van subtherapeutische 
geneesmiddelconcentraties, de effecten van blootstelling aan therapeutische 
concentraties toch voorspeld kunnen worden.  Zodoende kunnen uitspraken 
gedaan worden over de verwachte QTc effecten van klinische relevante 
doseringen. 
Onze benadering heeft ook een onvolkomenheid aan het licht gebracht met 
betrekking tot de aanname dat bevindingen in een klinische studie 
extrapoleerbaar zijn naar de doel patientenpopulatie in de geneeskundige 
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praktijk. De voorwaarden voor de evaluatie van geneesmiddelgerelateerde 
QTc interval verlenging zijn het onderwerp van hoofdstuk 6. Hier werden de 
gevonden verschillen tussen populaties in klinische studies en die in de 
praktijk overbrugd en werd het aandeel van een aantal factoren in het QTc 
effect ingeschat met behulp van simulatiemethodes.  De zogenaamde Not-In-
Trial Simulatie (NITS) methode opereert onder de aanname dat het QTc 
interval in de algemene doel populatie  een optelsom is van het 
leeftijdseffect, het geneesmiddeleffect en de effecten van comedicatie en 
comorbiditeit. Verwacht wordt dat deze methode ook van belang kan zijn 
voor de inschatting van het QTc effect in risicopopulaties. Dit vereist dat 
patienten behorend tot deze subpopulaties opgenomen worden in 
simulatiescenarios.  Deze benadering kan nauwkeurigere schattingen 
leveren met betrekking tot het cardiovasculaire risico en kan oplossingen 
aanreiken om risico’s te vermijden. Zodoende kan een mogelijke 
terugtrekking van een geneesmiddelregistratie voorkomen worden.  
Dit onderzoek belichtte ook methodologische aspecten die verschillen 
kunnen verklaren in de detectie van veiligheidsignalen zoals die wordt 
vastgesteld voor en na de toelating van een geneesmiddel tot de markt.  Ten 
eerste is de opzet van veiligheidsstudies sterk gericht op effectiviteit, wat 
invloed heeft op de gemeten effecten. Ten tweede is het totale aantal 
patienten dat gedurende klinische studies aan het geneesmiddel wordt 
blootgesteld niet groot genoeg om een relatief weinig voorkomend maar 
mogelijk fataal risico op te sporen. Ten derde worden veel subpopulaties met 
een hoger risico op hartritmestoornis geweerd uit klinische studies. Onder 
deze subpopulaties kunnen vallen: vrouwen, ouderen, personen die door 
erfelijkheid of leefpatroon belast zijn met een risico op hart- of andere 
ziekten geassocieerd met een verminderde repolarisatiereserve (en 
daardoor meer geneigd zijn QTc interval verlenging te vertonen), personen 
met een genetische polymorfisme of defect, waardoor de activiteit van 
geneesmiddel-metaboliserende enzymen of  de aangrijpingspunten een 
ionkanaal aanzienlijk veranderd zijn; personen met een sterkere neiging tot 
het ontwikkelen van een abnormaal trage hartslag (bradycardie), of 
elektrolytische onbalans, of gebruikers van geneesmiddelen waarvan bekend 
is dat ze farmacokinetische of farmacodynamische interacties kunnen 
vertonen.  Verder toonden de in dit proefschrift vermelde resultaten een 
effect van leeftijd op het onder normale omstandigheden gemeten QTc 
interval. Deze correlatie verklaart voor een belangrijk deel de waargenomen 
QTc waarden in de patienten doelgroep, ongeacht van de behandeling.   
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Om de robuustheid van de bevindingen afgeleid uit de Not-in-Trial simulaties 
te testen werden data van cisapride als voorbeeld van een tweede 
geneesmiddel met QTc-verlengingseffect geanalyseerd in hoofdstuk 7. In 
plaats van farmacovigilantieonderzoek te beperken tot meta-analyses van 
bestaande data (zowel uit gerandomiseerde klinische studies als uit de 
medische praktijk) laat dit onderzoek zien dat een modelmatige aanpak ook 
prospectieve “evidence synthesis” mogelijk maakt. Het gebruik van 
hierarchische modellen stelt ons in staat vaste factoren (effecten van het 
geneesmiddel of het ziekteproces) en stochastische factoren (variabele 
effecten, onzekerheden in het model) te integreren. Parameters uit het model 
worden vervolgens gebruikt om nieuwe scenarios te onderzoeken die 
klinische relevant kunnen zijn. De QTc metingen in patienten die cisapride 
toegediend kregen, werden nauwkeurig gekarakteriseerd, in het bijzonder 
de zeer hoge waarden.   
De voorgaande resultaten moeten beschouwd worden als een externe 
validatie voor het concept van Not-in-Trial Simulatie als een algemene 
methode voor signaaldetectie en risicobeheersing in de klinische fase van 
geneesmiddelontwikkeling. De QTc waarden waargenomen in de praktijk 
voor twee geneesmiddelen met verschillende werkingsmechanismen en 
therapeutische toepassingen konden correct voorspeld worden. Van twee 
belangrijke factoren die de bepalend zijn voor het effect werd vastgesteld dat 
ze onafhankelijk zijn van het toegediende geneesmiddel. Deze factoren zijn 
leeftijd en comorbiditeit. Hoewel de toepassing van het Not-in-Trial 
Simulatie concept hier beperkt bleef tot QTc interval verlenging, wordt 
verwacht dat het ingezet kan worden voor elk neveneffect. Het kan ook 
gebruikt worden om onderscheid te maken tussen factoren wanneer deze 
interactie vertonen: met name wanneer het een interactie tussen twee 
geneesmiddelen of tussen een geneesmiddel en het ziekteproces betreft en 
de interactie specifiek is voor een bepaald geneesmiddel.  
De Not-in-Trial Simulatie methode biedt voordelen ten opzichte van 
zogenaamde meta-analyses van bestande studies, voor welke het 
resulterende model vooral een grote, samengestelde data set beschrijft. Met 
behulp van de simulatiemethode kunnen onderzoekers hypothetische 
populaties verkennen en verschillende doseringen testen die niet beperkt 
zijn tot de experimentele data.  
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De voornaamste beperking van de hier voorgestelde methode is het 
ontbreken van stochastische variabiliteit op het effect van 
geneesmiddelblootstelling. De inclusie van een dergelijke variabiliteit (welke 
verschillen tussen patienten verklaart) zou de bepaling en de 
voorspelbaarheid van de relatie tussen blootstelling en effect verbeteren. 
Meer onderzoek op basis van nieuwe onderzoeksprotocollen is nodig om de 
rol van farmacokinetische variabiliteit in farmacovigilantie studies beter te 
verklaren. 
13. 3. 3 DE VOORSPELLENDE WAARDE VAN QTC INTERVAL VERLENGING 
VOOR CARDIOVASCULAIR RISICO  
Het primaire doel van dit onderzoek naar het QT/QTc-verlengingseffect van 
nieuwe moleculen was het verminderen van voorvallen van 
geneesmiddelgeïnduceerd hartritmestoornissen (met uitzondering van 
geneesmiddelen die een gewenst therapeutisch effect hebben op het 
hartritme). Een doelstelling in het verlengde hiervan was gericht op het 
verminderen van gevallen van plotselinge hartdood. Dit doel was gebaseerd 
op het veronderstelde verband tussen verlenging van het QTc interval, 
hartritmestoornis en plotselinge hartdood. Echter, gegevens die dit verband 
aantonen waren niet bechikbaar. Daarom werd in hoofstuk 8 een 
omvangrijke evaluatie uitgevoerd waarin de voorspellende waarde van QT 
interval verlenging onderzocht werd in 182 gevallen van plotselinge 
hartdood (data afkomstig van het Rotterdam Study Cohort). Hier werd 
vastgesteld dat de mate van optreden van plotselinge hartdood beter 
gecorreleerd is aan een hoge absolute waarde van het QTc interval dan aan 
QTc verschillen.  Een verlenging van meer dan 10 milliseconden ten opzichte 
van de basiswaarde was niet van statistisch belang. Deze bevindingen zijn in 
overeenstemming met resultaten die laten zien dat het relatieve risico op een 
levensbedreigende hartritmestoornis hoger is bij een hartslag van meer dan 
84 slagen per minuut en dat deze stoornissen zelden voorkomen bij een QTc 
interval korter dan 500 milliseconden.  
De hier getoonde resultaten doen twijfel rijzen over het gebruik van QT 
interval verlenging als maat voor het cardiovasculaire veiligheidsrisico. In 
feit werd in een analyse van de incidentie van plotselinge hartdood in deze 
populatie geen correlatie gevonden met de veranderingen in het QT interval 
of de tijd tussen het laatst opgenomen electrocardiogram en overlijden.  Dit 
betekent dat het gebruik van absolute QTc waarden voor de bepaling van het 
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risico op plotselinge hartdood betrouwbaarder zou kunnen zijn. Deze 
bevindingen weerspreken de hypothese die aan de basis staat van de 
richtlijnen in ICH E14 over de evaluatie van het cardiovasculaire risico van 
geneesmiddelen. In deze richtlijnen is het veiligheidsrisico gedefinieerd aan 
de hand van een drempelwaarde voor verlengingen van 10 milliseconden. 
Het verband tussen het verschil van 10 milliseconden in QTc en plotselinge 
hartdood werd echter niet statistisch significant bevonden. Wij voorzien 
daarom aanpassingen aan twee belangrijke concepten in toekomstige 
revisies van de ICH E14 richtlijnen: de reden voor de keuze van een 
drempelwaarde van 10 milliseconden en het gebruik van veranderingen van 
basislijnwaarden van QTc om risico’s te bepalen. Uitgaande van onze 
bevindingen kan geconcludeerd worden dat veranderingen in QTc 
veroorzaakt door geneesmiddelen het cardiovasculaire risico niet 
noodzakelijkerwijs verhogen tenzij de QTc basislijnwaarde hoog is.  
Hoewel het onmogelijk is een vaste drempelwaarde voor QTc interval op te 
stellen zonder hierin verdere factoren te betrekken die bijdragen aan het 
risico op plotselinge hartdood, moet een effectief beleid voor 
risicobeheersing basislijn-QTc waarden meenemen als een belangrijke 
voorspellende factor voor hartritmestoornissen. De aanname dat een 
toename van het QTc interval met meer dan 10 milliseconden het risico op 
hartritmestoornissen binnen een populatie in gelijke mate verhoogt kon niet 
worden gerechtvaardigd. 
13. 4 DE ROL VAN SIMULATIES IN DE OPTIMALISATIE VAN 
PROTOCOLLEN VOOR KLINISCHE STUDIES. 
13. 4.1  SIMULATIE VAN RR WAARDEN EN QT INTERVALLEN 
Omdat de hartslagfrequentie mede de duur van het QT interval bepaalt, moet 
bij de bepaling van het geneesmiddeleffect op het QT interval voor hartslag 
gecorrigeerd worden. Het wiskundige verband tussen QT interval en 
hartfrequentie dient in het model voor QT bepaling opgenomen te worden. 
Door gebruik te maken van het gecorrigeerde QT interval (QTc) kan 
geneesmiddelgeïnduceerde effecten onderscheiden worden van de effecten 
door verschillen in hartfrequentie.  
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Voor een effectieve toepassing van simulaties als methode voor de 
bepalingen van QT verlenging is de beschikbaarheid van individuele 
hartfrequenties over de tijd noodzakelijk.  In tegenstelling tot methoden die 
ruwe data hanteren om verbanden tussen variabelen af te spiegelen (de zgn. 
“resampling” methoden), werd in hoofdstuk 9 het verband tussen QT 
interval en hartfrequentie (RR) over een periode van 24 uur expliciet 
beschreven met een model. Deze benadering stelt de onderzoeker in staat 
realistische hartfrequentiereeksen te genereren die vervolgens gebruikt 
worden als invoerdata voor het model dat het verband tussen QT en RR 
beschrijft.  Aan de hand van de nieuwe methode werden QT en RR metingen 
gesimuleerd voor discrete tijdspunten, zoals vaak uitvoerd in een klinisch 
protocol. De variantiestructuur en de correlaties in de gesimuleerde data zijn 
een afspiegeling van de ruis op de data tengevolge van meet- en 
staalnameprocedures. Deze nieuwe benadering was essentieel voor de 
evaluatie en optimalisatie van de klinische protocollen in hoofdstukken 10 
en 11. In deze evaluatie werden variaties in studieopzet en analysemethode 
onderzocht op de eruit voortvloeiende statistische type I en II fouten.   
13. 4. 2 CONCENTRATIE-EFFECT RELATIES VERSUS DE “DOUBLE-DELTA” 
METHODE 
In hoofdstuk 10 werden grondige QT (TQT) studies gesimuleerd onder de 
aanname van verschillende populatiegroottes en geneesmiddelgeïnduceerde 
QT effecten. Ook de studieopzet werd gevarieerd: een gekruiste studie met 
referentiewaarden voor alle kloktijden (staalnames), een gekruiste studie 
met drie referentiewaarden en parallelle studies werden bestudeerd.  De 
resultaten toonden aan dat een Bayesiaans hierarchisch model 
geneesmiddelgeïnduceerde QT effecten met een gelijke of hogere specificiteit 
en sensitiviteit onderscheidt dan de double-delta methode. Deze bevindingen 
pleiten voor het gebruik van concentratie-effectrelaties in plaats van de 
double-delta methode voor de analyse van QTc interval verlenging. 
Zodoende kunnen aanwijzingen voor of tegen een QT verlengend effect 
vergaard worden met een significant kleiner aantal studiedeelnemers. 
Aangezien de hoge kosten van TQT studies voornamelijk toegeschreven 
worden aan de vereiste studiegrootte, biedt dit resultaat een reden om 
ethische, statistische en financiele aspecten van de bepaling van QT 
verlengingen opnieuw te beschouwen.  Een ander voordeel van het gebruik 
van een modelmatige benadering is de mogelijkheid om op een andere 
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manier met het multipliciteitsprobleem om te gaan (multipliciteit onstaat 
wanneer een effect meerdere keren op verschillende momenten in de loop 
van de studie vastgesteld moet worden). Het geneesmiddelgeïnduceerde 
effect wordt beschreven als een continue functie van de 
geneesmiddelconcentratie in plaats van het op een aantal discrete tijden te 
schatten. Deze bemoedigende resultaten vormen de bouwstenen voor zowel 
een alternatief voor de huidige analysemethode voor TQT studies, als een 
strategie om de kosten van dergelijke studies te reduceren.  
Gezien de aanzienlijke winst in sensitiviteit die te boeken valt met een 
modelmatige benadering voor de bepaling van QT interval verlenging, werd 
in hoofdstuk 11 de mogelijkheid onderzocht om het QT verlengingsrisico 
gedurende de standaard uitgevoerde “first-in-human” (FTIH) studie te 
bepalen. Men kan ervan uit gaan dat het risico op een QT verlengend effect 
correct ingeschat kan worden wanneer de resultaten van een dergelijke 
bepaling beschouwd worden in samenhang met aanwijzingen voor een 
concentratie-effectrelatie en de daaraan verwante kans op QTc interval 
verlenging in preklinische diermodellen.  Een ander voordeel van de aanpak 
op basis van modellen is de mogelijkheid om het QT verlengende effect van 
een geneesmiddel over het gehele therapeutische concentratiebereik te 
karakteriseren. FTIH studies vormen een verplicht en vastomschreven 
onderdeel van het klinische ontwikkelingpad. Slechts geringe aanpassingen 
aan het schema van metingen zijn noodzakelijk om ECG bepalingen geschikt 
te maken voor een modelmatige analyse van  het geneesmidel effect op het 
QTc interval.  
Daarnaast lieten de analyseresultaten zien dat nauwkeurige schattingen van 
de grootte van het QT verlengende effect gemaakt konden worden zonder 
gebruik te maken van  een positieve controlearm. Het nut of relevantie van 
bestaande gegevens van een referentiegeneesmidel (ofwel positieve 
controle) in de vorm van een a priori schatting wordt hiermee echter 
geenszins ontkend.  
13. 5  AANBEVELINGEN  
Dit proefschrift belicht de gebreken van verscheidene aspecten van de ICH 
E14 richtlijn. Verder draagt het alternatieven aan en doet het aanbevelingen 
ter verbetering. In de eerste plaats werd een Bayesiaans model 
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geïntroduceerd dat het verband beschrijft tussen geneesmiddelconcentratie 
en QTc interval verlenging. Met dit model kunnen geneesmiddelafhankelijke 
effecten over een relevant concentratiebereik voorspeld worden. Deze 
methode verdient de voorkeur boven de puur empirische double-delta 
methode. Bovendien blijkt het gebruik van doseringen hoger dan de 
therapeutische niet noodzakelijk te zijn, maar ook indien deze wel toegepast 
worden, kan het effect van een dosis in het therapeutische bereik eenvoudig 
herleid worden met het hierarchische model. Verder werd aangetoond dat de 
Bayesiaanse benadering QTc verlengingen over een tijdscontinuum 
nauwkeuriger en preciezer voorspelt. Een ander voordeel van een op 
modelmatige aanpak is de mogelijkheid om QTc effecten te beschrijven en te 
vergelijken voor een spectrum van farmaca en organismen. De aan deze 
methode inherente beschikbaarheid van a posteriori 
waarschijnlijkheidsverdelingen stelt de onderzoeker in staat de kans op een 
vooraf gedefinieerde verlenging van het QTc interval te bepalen. Door 
hetzelfde model opnieuw toe te passen voor de analyse van data verkregen 
uit een FTIH studie met enkele aanpassingen met betrekking tot de ECG 
opnames, kan de kans dat een farmacon het hartritme beinvloedt vastgesteld 
worden zonder dat hiervoor een aparte TQT studie uitgevoerd hoeft te 
worden. Dit houdt in dat besluiten om de ontwikkeling van een geneesmiddel 
al dan niet voort te zetten eerder genomen kunnen worden.   
13. 6  VOORUITBLIK 
De resultaten gepresenteerd in dit proefschrift onderstrepen de behoefte aan 
een nieuwe denkwijze bij de vaststelling van de cardiovasculaire veiligheid 
van geneesmiddelen. In deze denkwijze is de “evidence synthesis” niet langer 
ondergeschikt aan het genereren van nieuwe gegevens. De resultaten 
bevestigen verder de noodzaak om de huidige richtlijnen te herzien. Met 
name de inhoud van het ICH E14 document blijkt niet in overeenstemming 
met recente wetenschappelijke inzichten.   
Het is van belang dat klinisch onderzoekers, medici in de gezondheidszorg en 
regel- en wetgevende autoriteiten inzien dat de opzet van een 
geneesmiddelstudie van invloed is op de gegevens die de studie voortbrengt. 
Verschillen tussen de onderzoekspopulatie bestudeerd tijdens de 
ontwikkelingsfase en de patientenpopulatie in de medische praktijk mogen 
niet genegeerd worden. Intrinsieke en extrinsieke factoren of covariaten 
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dragen bij aan de tot standkoming van het behandelingsresultaat. De 
farmacologische effecten van het geneesmiddel worden door deze factoren 
geantagoneerd, tenietgedaan of anderszins gemodificeerd. Binnen het 
regelgevende kader zou de vraag moeten rijzen hoe efficient en betrouwbaar 
klinische studies zijn in het vaststellen van het risico op levensbedreigende 
hartritmestoornissen, gezien de verschillen tussen populaties, de intrinsieke 
ruis op de data en het relatief infrequent voorkomen van significante 
geneesmiddelgerelateerde effecten [16]. 
Zoals de titel van dit proefschrift suggereert bestaat er een kloof in de 
vertaling van veiligheidssignalen in klinische studies naar de medische 
praktijk, welke overbrugd moet worden als onderdeel van de 
risicobeheersing gedurende de ontwikkeling van een nieuw molecuul. 
Daarom is het belangrijk tijdens de klinische ontwikkeling de aandacht te 
vestigen op het concept van “evidence synthesis” en ervoor te zorgen dat het 
verband tussen farmacokinetiek en farmacodynamiek bekend is. De 
beschikbaarheid van op modellen gebaseerde analyse- en simulatiemethodes 
vormen de essentiele gereedschappen om deze kloof te dichten. Wij 
verwachten dat vooruitgang geboekt kan worden in de voorspelling van 
cardiovasculaire geneesmiddelveiligheid door de toepassing van het concept 
van Not-in-Trial simulaties uit te breiden naar meerdere eindpunten en door 
mechanistische modellen te combineren met de voorgestelde Bayesiaanse 
hierarchische benadering. Gezien de toenemende beschikbaarheid van data 
over geneesmiddelveiligheid afkomstig uit observationele studies  zal de 
toegang tot informatie niet langer de beperkende factor zijn in de 
overbrugging van eerdergenoemde kloof. Onafhankelijk van de data blijft het 
verder van kritiek belang dat in de modelmatige benadering onderscheid 
gemaakt kan worden tussen geneesmiddelspecifieke en systeemspecifieke 
parameters. 
Het concept van de Not-in-Trial simulaties, ontwikkeld in dit proefschrift, 
kan een verdere basis bieden voor de integratie van klinische en farmaco-
epidemiologische data. Het werd in eerste instantie geïntroduceerd als een 
instrument om de uitwerking te bepalen van de strikte inclusie- en 
exclusiecriteria die opgesteld worden voor klinische studie-populaties, 
alsook om de invloed van de relatief korte duur van klinische studies na te 
gaan. Deze beperkingen dragen ertoe bij dat infrequent of zeldzaam 
voorkomende veiligheidssignalen pas lange tijd nadat het geneesmiddel op 
de markt beschikbaar komt gedetecteerd worden.  De mogelijkheid om 
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dergelijke signalen al vóór de registratie te anticiperen biedt de mogelijkheid 
om risicoverminderende maatregelen te onderzoeken en implementeren.   
Het idee achter Not-in-Trial simulaties is om relevante fysiologische 
parameters en geneesmiddel-specifieke parameters te combineren in een 
model en vervolgens de invloed van andere factoren zoals comborbiditeit en 
comedicatie op de parameterwaarden te bepalen. In één van zijn publicaties 
benadrukte Black “ dat het onterechte conflict tussen diegenen die onder alle 
omstandigheden voor gerandomiseerde studies pleiten en diegenen die 
geloven dat observationele data afdoende zijn, plaats moet worden gemaakt 
voor wederzijds begrip voor de complementaire rol van de twee 
benaderingen.” [17].  
Regelgevers en klinisch onderzoekers vertrouwen bij de evaluatie van een 
geneesmiddel onder meer op een positieve waarde van de ratio tussen 
therapeutische waarde en het desbetreffende risico. Hierbij zijn zij 
afhankelijk van data die gegenereerd wordt in klinische of observationele 
studies [18-21]. In de praktijk zijn dit vaak langdurige klinische fase IV 
studies of, recentelijk, observaties gemaakt in het kader van een 
voorwaardelijke registratieverstrekking (“progressive licensing”). Deze 
oplossing legt de last uiteindelijk bij patienten en 
geneesmiddelontwikkelaars, met het risico dat bewijs van onveiligheid pas 
verkregen wordt nadat een nevenwerking is opgetreden in de medische 
praktijk. Tot dusver zijn pogingen om alternatieven te ontwikkelen voor 
formele prospectieve studies beperkt gebleven tot “retrospectieve” meta-
analyses van bestaande data uit de klinische praktijk alsook uit 
gerandomiseeerde klinische trials. Het is essentieel dat meer onderzoek 
gedaan wordt naar de ontwikkeling van voorspellende methoden en 
vooruitblikkende strategieen. 
De kracht van de Bayesiaanse benadering is beperkt tot de analytische 
capaciteit om QTc interval verlenging op te sporen en helpt daarom enkel bij 
de bepaling van de arythmogeniciteit. Zij biedt echter geen oplossing voor de 
praktische of statistische problemen met betrekking tot de verwerking van 
ECG metingen. Mogelijke onderwerpen waarin vooruitgang geboekt kan 
worden zijn het algoritme voor het aflezen van ECG bepalingen, de techniek 
voor de correctie van meetonnauwkeurigheden,   de invloed van de aard van 
comorbiditeit op de ECG waarden en verscheidene andere covariaten die hun 
weerslag hebben op deze metingen. 
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Er wordt veel onderzoek verricht om de precisie van QT metingen te 
verbeteren. Onder de onderzochte methoden valt het gebruik van 
geautomatiseerde afleestechnieken. Verder wordt getracht statistische 
problemen te verhelpen door oorzaken van variabiliteit te achterhalen, 
nieuwe algoritmes te ontwikkelen en de reproduceerbaarheid van 
bepalingen te vergroten. In 2001 ontwikkelde de FDA het digitale ECG 
Warehouse voor de opslag van ECG metingen die aangeleverd worden ten 
behoeve van registratieverzoeken.   Naast zijn primaire functie van 
opslagfaciliteit vormt het Warehouse een geschikte bron voor onderzoek 
door universiteiten en bedrijven.  Het is een waardevol instrument dat 
gebruikt kan worden om nieuwe biomarkers voor hartritmestoornissen te 
bestuderen, deze te correleren aan klinische en biochemische maatstaven 
voor cardiovasculaire veiligheid, om hiermee de diagnose en behandeling 
van cardiovasculaire aandoeningen te verbeteren. Verder biedt het de 
mogelijkheid variabiliteit in fysiologische variabelen te bepalen en deze te 
gebruiken om a priori verdelingen op te stellen voor toekomstige 
Bayesiaanse analyses van QTc interval verlengingen op basis van 
farmacokinetische-farmacodynamische relaties. 
Geneesmiddelonderzoekers moeten “oppassen voor de kloof” tussen 
gecontroleerde klinische trials en de geneeskundige praktijk. De tijd is rijp 
om deze problematiek aan te pakken door de verschillen te kwantificeren, te 
voorspellen, te interpreteren en uiteindelijk te overbruggen. Het kan niet 
genoeg benadrukt worden dat het nu mogelijk is een op modellen en 
simulaties gebaseerde benadering voor risicobeheersing te ontwikkelen. 
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3.  The use of model parameterisation discriminating drug- and  
system-specific properties eliminates the bias arising from the  
current regulatory guidelines.  This thesis 
4. The integration of pharmacological concepts with pharmaco-
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5. The concept of Not-In-Trial Simulations defies the hurdles  
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(Rubart M. & Zipes D.P., JCI 2005;115(9):1–11) 
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10. The forecast is that complex, mixed-effects, mechanistic PD 
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